Outcome of pregnancy in women after pulmonary autograft valve replacement for congenital aortic valve disease. by Yap, S.C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/52389
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Congenital Aortic Stenosis in Adults 
 
Update on clinical outcome, diagnostic methods and pregnancy 
 
 
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colofon 
 
Yap, SC 
Congenital aortic stenosis in adults - Update on clinical outcome, diagnostic methods and pregnancy. 
 
ISBN: 978-90-8559-330-0 
 
© Copyright 2007 S.C.Yap 
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or 
transmitted in any form or by any means, electronical, mechanical, photocopying, recording, or 
otherwise, without prior written permission of the holder of the copyright. Several chapters of this 
thesis are based on published papers, which are reproduced with permission of the co-authors and 
the publishers. Copyright of these papers remains with the publishers. 
 
Cover: Véro Crickx, Sirene ontwerpers, Rotterdam, The Netherlands 
Lay-out: S.C.Yap 
Printed by Optima Grafische Communicatie, Rotterdam, The Netherlands 
 
Financial support by the Netherlands Heart Foundation for the publication of this thesis is gratefully 
acknowledged.  
 3 
 
 
 
 
Congenital Aortic Stenosis in Adults 
Update on clinical outcome, diagnostic methods and pregnancy 
 
 
 
Congenitale aortastenose in volwassenen 
Nieuwe inzichten in klinische uitkomsten, diagnostische methoden en 
zwangerschap 
 
 
Proefschrift 
 
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de 
rector magnificus 
 
Prof.dr. S.W.J. Lamberts 
 
en volgens besluit van het College voor Promoties. 
 
De openbare verdediging zal plaatsvinden op 
woensdag 19 december 2007 om 9.45 uur 
 
door 
 
Sing-Chien Yap 
geboren te ’s-Hertogenbosch 
 
 
 
 4 
Promotiecommissie 
 
Promotor:   Prof.dr. M.L. Simoons 
 
Copromotor:  Dr. J.W. Roos-Hesselink 
 
Overige leden: Prof.dr. A.J.J.C. Bogers 
Prof.dr. B.M.J. Mulder 
   Prof.dr. W.A. Helbing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
 
 
Chapter 1.  General introduction       9 
 
Part 1. Clinical outcome of congenital aortic stenosis 
 
Chapter 2.  Aortic stenosis at young adult age     18 
  Expert Rev Cardiovasc Ther 2005;3:1087-98 
 
Chapter 3 Congenital aortic stenosis in adults: rate of progression and   42 
predictors of clinical outcome 
Int J Cardiol 2007 Feb 7; [Epub ahead of print] 
 
Chapter 4 When to intervene in aortic ectasia     56 
Focused review. Braunwald’s Heart Disease: A textbook of  
cardiovascular medicine 
 
Chapter 5 Outcome of implantable cardioverter defibrillators in adults with 66 
congenital heart disease: a multi-centre study 
  Eur Heart J 2007;28:1854-61 
 
Part 2. Diagnostic methods for congenital aortic stenosis 
 
Chapter 6 Steepened aortoseptal angle may be a risk factor for discrete  86 
subaortic stenosis in adult patients 
  Int J Cardiol 2007 April 13; [Epub ahead of print] 
 
Chapter 7 Abnormal aortic elastic properties in adults with congenital   92 
valvular aortic stenosis 
Int J Cardiol 2007 Aug 7; [Epub ahead of print] 
 
Chapter 8 Rapid and accurate measurement of LV mass by RT3DE  104 
in patients with concentric LV hypertrophy: comparison to CMR 
 Eur J Echocard 2007 Jun 29; [Epub ahead of print] 
 
Chapter 9 A simplified continuity equation approach to the quantification of  118 
stenotic bicuspid aortic valves using velocity-encoded CMR 
 J Cardiovasc Magn Reson 2007 (in press) 
Contents 
 6 
Part 3. Pregnancy and congenital aortic stenosis 
 
Chapter 10 Complications during pregnancy in women with congenital heart 136 
disease: a literature review 
 JACC 2007;49:2303-11 
 
Chapter 11 Risk of complications during pregnancy in women with congenital  154 
aortic stenosis 
Int J Cardiol 2007 May 3; [Epub ahead of print] 
 
Chapter 12 Outcome of pregnancy in women after pulmonary autograft valve  168 
replacement for congenital aortic valve disease 
 J Heart Valve Dis 2007;16:398-403 
 
Chapter 13 Percutaneous triple-valve balloon valvuloplasty in a pregnant  180 
woman using intracardiac echocardiography: case report 
J Heart Valve Dis 2006;15:459-64 
 
Chapter 14 General discussion, conclusions and future directions   193 
 
Chapter 15 Samenvatting        207 
 
Chapter 16 Dankwoord         215 
 
List of publications        218 
 
Curriculum vitae        221 
 
 
 
 7 
 
 
1 
 
 
Congenital aortic stenosis in adults 
 
General introduction 
 
 
 
 
 
 
 
 
 
 
 
C 
H 
A 
P 
T 
E 
R 
Chapter 1 
 8 
 
General introduction 
 9 
INTRODUCTION 
 
Congenital aortic stenosis (AS) encompass a series of stenotic lesions starting in the 
anatomic left ventricular outflow tract (LVOT) and stretches toward the ascending 
aorta. Obstruction may be subvalvar, valvar, or supravalvar. All of these lesions 
impose an increased afterload on the left ventricle (LV), which can result in LV 
hypertrophy, dilatation and eventually heart failure, when left untreated. Congenital 
valvar AS is usually the result of a stenotic bicuspid aortic valve (BAV).1,2 Variants 
range from a nearly trileaflet bicommissural valve with mild cusp inequality to a 
unicuspid unicommissural valve. Recently, BAV has been the focus of much 
research as it identifies patients at risk of development of stenosis and regurgitation, 
and in addition predisposes patients to ascending aorta dilatation and dissection. 
BAV is the most common congenital malformations and has a prevalence of 1-2% in 
the general population.3,4 It results from fusion of one of the commissures (usually 
present as a raphe),5 resulting in two rather than three valve leaflets. No clear 
etiology has been defined for BAV, and no specific gene has been identified. Recent 
findings support the suggestion that all anomalies of the left ventricular outflow tract 
obstruction spectrum are developmentally related and multiple genes have been 
implicated. Experimental evidence suggests that the expression of endothelial nitric 
oxide synthase (eNOS) may have an influence on aortic valve anatomy and 
aneurysmal dilatation of the aorta.6,7 Mutations in the signaling and transcriptional 
regulator NOTCH1 gene result in developmental aortic valve abnormalities and 
severe valve calcification in affected families.8 Ubiquitin fusion degradation 1-like 
gene is another potential candidate, which is highly expressed in the cardiac outflow 
tract during embryogenesis and is downregulated in patients with BAV.9 Furthermore, 
familial clustering of BAV and other left ventricular outflow tract obstructions has 
been described.10,11 
 
 
PROGNOSIS AND TREATMENT 
 
Patients with congenital AS with severe symptoms in infancy and childhood have a 
poor prognosis without intervention.12 Sudden cardiac death may occur, especially in 
the setting of physical acitivity and exertion.13 Even after surgical valvotomy the 
incidence of sudden death is still 0.4% per year.14 A bicuspid valve may function 
normally throughout a lifetime, but usually is associated with the development of 
either progressive stenosis or regurgitation.15,16 BAV accounts for approximately 50% 
of all aortic valve replacements of isolated AS in adults.1 The main indication for 
aortic valve replacement is the presence of symptoms (i.e., angina, syncope, 
congestive heart failure) as this is associated with a worse outcome (i.e., overall 
cardiac mortality and sudden cardiac death).17-19 Ballloon valvotomy may be an 
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attractive option in children, adolescents and young adults who have pliable, 
noncalcified valves with fusion of the commissures, at the cost of restenosis or 
regurgitation.20,21 The Ross procedure (pulmonary autograft) is the treatment of 
choice in the pediatric population due to its growth potential, but the high reoperation 
rate and progressive autograft dilatation renders it unsuitable in adults.22 
 
 
AORTIC DILATATION 
 
There is a high incidence of aortic disease in patients with congenital aortic valve 
malformations suggesting a causal relationship between these two conditions. 
Controversy exists regarding the etiology of aortic dilatation in BAV patients. Once 
thought to be the consequence of post-stenotic dilatation, evidence is accumulating 
that intrinsic aortic medial weakness should be regarded as the underlying cause of 
aortic dilatation. Several findings support this hypothesis. Approximately 50% of 
patients with normally functioning BAV have an aortic dilatation, thus independent of 
the presence of stenosis or regurgitation.23-26 Also after aortic valve replacement 
aortic dilatation may occur. Furthermore, the histology of the ascending aortic wall is 
similar to that of the Marfan syndrome.27 Medial disease is present, as are varying 
degrees of abnormalities of the smooth muscle, extracellular matrix, elastin, and 
collagen.27-29 Dilatation of the aorta may be the result of the disruption of the 
extracellular matrix by upregulation of matrix metalloproteinase-2 that is triggered by 
an inherent deficiency of fibrillin-1.28,30-32 Furthermore, premature smooth muscle cell 
apoptosis leads to upregulation of matrix metalloproteinase-2.33,34 
 
 
PREGNANCY 
 
Cardiovascular physiology changes profoundly during pregnancy. Cardiac output 
increases 30-50% due to increases in both stroke volume and heart rate.35,36 During 
labour, cardiac output increases further due to pain and uterine contractions.37,38 
 The haemodynamic impact of AS is aggravated by the physiological changes 
during pregnancy. Pregnancy in AS patients has been the focus of some reports 
because of concern for development of heart failure and mortality during pregnancy. 
39,40
 The review of Lao et al. published in 1993 demonstrated seven deaths among 
65 women, resulting in a maternal mortality rate of 11% 41. Earlier diagnosis and 
treatment of patients with severe stenosis (e.g. balloon aortic valvotomy) has resulted 
in more women with congenital AS reaching childbearing age in relatively good 
condition. Recent pregnancy reports in AS patients are encouraging, showing a 
favorable pregnancy outcome with low maternal mortality.42-44  
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AIMS AND OUTLINE OF THE THESIS 
 
The aim of the present thesis is to present an update on clinical outcome, diagnostic 
methods and pregnancy in adults with congenital AS. It will not address congenital 
AS in the pediatric population.  
 In part 1 (chapters 2-5) of this thesis, I will present an overview of the current 
management of patients with congenital aortic stenosis with regard to timing of 
surgical or percutaneous intervention, aortic dilatation, exercise, pregnancy, and 
potential medical treatment.46 Secondly, we investigated the natural history of a 
cohort of patients with congenital aortic stenosis, with special emphasis on the rate of 
stenosis progression and its determinants.47 Furthermore, a discussion is presented 
regarding the optimal timing of prophylactic aortic replacement in dilated aorta, which 
is a common finding in BAV patients. Finally, as patients with AS are at increased 
risk of sudden cardiac death, the outcome of ICD therapy in patients with CHD is 
presented.48 
 In part 2 (chapters 6-9), we investigated the use of diagnostic techniques and 
innovative approaches in patients with congenital AS. A cohort of patients with 
congenital valvar AS was investigated using different imaging modalities (i.e., M-
mode, 2D-, 3D-echocardiography, and cardiac magnetic resonance). The aortic 
stiffness could be investigated using M-mode echocardiography. Furthermore, real-
time 3D-echocardiography was compared with M-mode and 2D-echocardiography in 
determining LV mass. The role of velocity-encoded cardiac magnetic resonance in 
determining aortic valve area using a modified continuity equation was established. 
Finally, we investigated  the aortoseptal angle in adults with discrete subaortic 
stenosis (DSS) compared to controls using 2D-echocardiography, in testing the  
hypothesis that altered flow patterns are a substrate for development of DSS.49 
In part 3 (chapters 10-13), the risk of pregnancy in women with congenital 
aortic stenosis is evaluated. Chapter 10 provides a general overview of complications 
encountered during pregnancy in women with congenital heart disease. Chapter 11 
and 12 investigate pregnancy in women with congenital aortic stenosis without 
previous aortic valve replacement and with pulmonary autograft valve replacement, 
respectively.50 These studies are part of the ZAHARA study, investigating pregnancy 
in congenital heart disease. For the selection of women in their fertile ages we used 
the Dutch CONCOR registry (CONgenital CORvitia; www.concor.net), which is a 
registry of all adult patients with CHD in the Netherlands.51 Chapter 13 presents a 
case report demonstrating the value of intracardiac echocardiography during 
percutaneous intervention in a pregnant woman thereby reducing radiation exposure 
to the foetus.52 
Finally, a general discussion is presented, including conclusions and 
recommendations for future research and clinical practice.  
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SUMMARY 
 
Aortic stenosis at young adult age is usually the result of a stenotic bicuspid aortic 
valve, which is the most common cardiac congenital anomaly. In clinical practice, 
exercise and pregnancy are important topics. Furthermore, the timing of intervention 
is under debate, as little information is available on the natural history and outcome 
after aortic valve replacement in these young adults. In older patients, there is a trend 
towards earlier intervention. With the increased knowledge of the pathophysiology of 
aortic stenosis, studies have focused on the dilatation of the ascending aorta with risk 
of dissection. Recently, it has been suggested that pharmacological treatment of 
aortic stenosis could be beneficial for these young adults. 
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Aortic stenosis (AS) at young adult age is usually the result of a stenotic bicuspid 
aortic valve (BAV), which is the most common cardiac congenital anomaly, occurring 
in approximately 1% of the general population.1,2 Aortic valve replacement is 
currently the only definitive treatment for AS. Despite a better understanding of the 
pathophysiology of the calcification of BAV, there is currently no accepted 
pharmacological therapy to prevent disease progression. However, recent studies 
have demonstrated promising results for directing pharmacologic treatment 
modalities. This review will summarize the current knowledge regarding the 
management of AS at young adult age, with special emphasis on exercise, 
pregnancy and timing of intervention. New pharmacological treatment modalities will 
also be discussed. 
 
Figure 1. Stenotic bicuspid valve. The mar-
gins of one of the cusps have a V-shaped con-
figuration, with the apex of the V pointing to-
ward a raphe. Reprinted with permission.4 
 
 
 
 
 
 
 
 
 
 
 
NATURAL HISTORY 
 
The most common fate of a congenital BAV is gradual development of a progressive 
calcific stenosis, as demonstrated by autopsy studies.1,3 Other important 
complications of BAV are aortic regurgitation, infective endocarditis and aortic 
complications, such as dilatation, dissection and rupture. AS associated with 
congenital aortic valve malformation is age dependent; the fewer the number of 
cusps, the younger stenosis develops (Figure 1 and 2).4 Sclerosis of BAV usually 
begins in the second decade of life, and aortic valve calcium is noted from the fourth 
decade.5 Several factors that are associated with coronary artery disease also seem 
to be related to the presence and progression of AS. A case-controlled study by 
Chan and colleagues demonstrated that the atherosclerotic risk factors of total 
cholesterol and systemic hypertension were associated with stenosis in patients with 
BAV.6 Progression of cusp sclerosis was faster in patients with anteroposteriorly 
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located cusps than in those with right-left-located cusps, and was faster in those with 
eccentric than symmetric cusps.5 The incidence of AS increases progressively with 
age, and approximately 73% of patients with BAV over age 70 years of age have 
AS.3 
 
Figure 2. Calcified tricuspid aortic valve. 
Reprinted with permission.4 
 
 
 
 
 
 
 
 
 
Little information exists on the natural history of young adults with AS; most studies 
describe the natural history of children or the elderly. The natural history of elderly 
patients with AS consists of a period with well-compensated, and thus asymptomatic, 
stenosis, which may be stable for a period of years, followed by a short symptomatic 
period that, without intervention, rapidly leads to death.7 The average survival of older 
patients with AS developing symptoms was 2-5 years (5 years after angina, 3 years 
after syncope and 2 years after congestive heart failure).8 With the onset of 
symptoms, the occurrence of sudden death increases by 15-20%. Sudden death in 
elderly asymptomatic patients with severe AS appears to be very rare, with a rate of 
less than 1% per year.9,10 As the development of symptoms is associated with poor 
survival, this is a generally accepted strong indication for aortic valve replacement. 
After aortic valve replacement, life expectancy is reduced in patients with a 
stenotic BAV compared with the general population. A prospective study at the 
authors’ center showed that survival in young adults with AS (mean age at operation 
44 years, range 18-54 years) 11 years after aortic valve replacement was 86% 
(Figure 3) [Unpublished data]. Data from this study shows that a 44-year-old male in 
the general population has a 95% chance of survival after 11 years.11 However, age-
corrected long-term survival after aortic valve replacement is nearly normalized in 
older patients undergoing surgery due to calcific AS.12 It is not clear why patients with 
stenotic BAV in particular have a reduced life expectancy after valve replacement. 
This may be related to factors other than valvular problems. Severe left ventricular 
(LV) hypertrophy may remain present after valve surgery, with the risk of 
arrhythmias, heart failure and death, or these patients remain at risk for aortic 
dissection, as a result of the dilated ascending aorta. 
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Figure 3. Cumulative survival after aortic valve replacement in 94 young adult patients with aortic 
stenosis (solid lines with 95% confidence interval) compared with the survival of a 44-year old man in 
the general population (stippled line). [Unplublished data]. 
 
 
TIMING AND CHOICE OF INTERVENTION 
 
Management depends on age at presentation, severity of obstruction, presence of 
symptoms, presence or absence of associated lesions and previous interventions. In 
general, patients with mild-to-moderate AS and normal LV dimensions and function 
should have medical follow-up with regular checks monitoring the onset of 
symptoms, changes in exercise tolerance and echocardiography. In case of 
moderate-to-severe calcification and peak aortic jet velocity of more than 4 m/s, 
patients should be re-evaluated every 6 months. Serial echocardiographic 
assessment should include aortic gradient and valve area, the diameter of the 
ascending aorta measured at several levels, LV dimensions, wall thickness and LV 
function. As patients with AS are at high-risk for infective endocarditis, antibiotic 
prophylaxis for nonsterile interventions is strongly recommended. 
The current American Collge of Cardiology/American Heart Association 
(ACC/AHA) guidelines indicate cardiac catheterization and possible balloon 
valvuloplasty for children and young adults with severe gradients (Doppler peak 
gradients >70-80 mmHg), those who develop LV repolarization or ischemic changes 
on the electrocardiogram (ECG) at rest or with exercise, and those with symptoms.13 
Patients with less severe gradients (Doppler peak gradient between 50 and70 
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mmHg) who are interested in participating in vigorous sports or those contemplating 
pregnancy are also commonly referred for balloon valvuloplasty. When balloon aortic 
valvuloplasty is ineffective or significant aortic regurgitation is present, valve 
replacement is the first choice treatment.  
The indications for aortic valve replacement of the calcified stenotic BAV in 
young adults are not described separately and thus the guidelines for degenerative 
senile calcified stenosis of a tricuspid valve should be used.13 Aortic valve 
replacement is indicated for symptomatic patients with severe AS. Valve surgery is 
also advised in patients who have severe AS and severe LV dysfunction or an 
abnormal exercise test. Furthermore, moderate-to-severe valvular calcification, a 
peak echo aortic velocity greater than 4.0 m/s and a rapid increase in the aortic 
velocity on serial studies (>0.3 m/s per year) have all been shown to predict patients 
at increased risk for developing symptoms or needing aortic valve replacement.10,14,15 
The timing and choice of intervention in young adults is difficult. Aortic valve 
replacement is certainly indicated when symptoms develop. More liberal approaches 
can be chosen if the valve is suitable for balloon valvuloplasty.  It is not clear whether 
aortic valve replacement should take place earlier in selected asymptomatic patients 
with severe AS, as detailed information on the natural history of young adult patients 
and predictors of outcome are lacking. It is possible that biochemical markers will 
become available for risk stratification. Recent studies have demonstrated that in 
patients with AS, plasma levels of natriuretic peptides (e.g., brain natriuretic peptide 
[BNP] and N-terminal pro-B-type [Nt-proBNP]) are related to severity of stenosis,16 
symptomatic status17 and predict symptom-free survival and postoperative 
outcome.18 Thus, natriuretic peptides may improve our ability to select mildly 
symptomatic or asymptomatic patients who will benefit from early elective surgery. 
When the decision has been made to intervene, one should consider the best 
treatment modality. In children, the treatment of choice has become balloon 
valvuloplasty, which has largely replaced surgical valvotomy. Balloon valvuloplasty is 
associated with good long-term outcome in children, adolescents, and young 
adults.19 In adults with calcified AS, first choice treatment is aortic valve replacement. 
In young adults with non-calcified valves, it is not clear which treatment modality is 
the best. One small retrospective study of patients with congenital AS aged 17-40 
years (mean age 23 years) treated with balloon valvuloplasty reported no deaths. 
However, 50% required a reintervention at a mean follow-up of 3.1 years.20 There is 
too little data to provide a guideline for the age at which age balloon dilatation is less 
effective. Severe calcification is a likely contraindication. For patients requiring aortic 
valve replacement, the surgical options include replacement with a mechanical valve, 
an allograft, homograft or pulmonary autograft (Ross procedure). When considering 
the optimal type of valve for aortic valve replacement, several factors are important. 
These include patient age, life expectancy, coexisting medical problems, lifestyle, 
and cardiologist and patient preference. The main advantage of mechanical valves is 
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their durability. Disadvantages are thromboembolism, need for anticoagulation 
therapy, hemorrhage, imperfect hemodynamic performance, increased risk of 
endocarditis and a high sound level. Tissue valves solve some of these problems, 
but have a finite durability and the risk of endocarditis, although slightly less than that 
for mechanical valves, is still significant. Young adult patients wishing to participate in 
body-contact sports, and female patients contemplating pregnancy are candidates for 
a bioprosthesis or homograft, to prevent complications of anticoagulation therapy. 
Implantation of a bioprosthesis or homograft at young adult age does imply 
reoperation(s). Bioprosthetic heart valves have an increased rate of structural 
deterioration for patients younger than 60 years of age.21 Furthermore, deterioration 
of bioprosthetic heart valves during pregnancy has been reported in several studies, 
but this could reflect the deterioration of tissue valves in young individuals.22 There is 
still much controversy concerning the use of the Ross procedure in adult patients 
with BAV. These patients have more severe degenerative changes in the media of 
the ascending aorta and main pulmonary artery than patients with tricuspid aortic 
valve disease (discussed hereafter), and are therefore at a higher risk for 
postoperative dilatation of the aortic autograft.23 However, reported series showed an 
absence of high risk for autograft dilatation in patients with BAV.24 The Ross 
procedure is recommended in children due to growth possibilities. 
 
 
INFECTIVE ENDOCARDITIS 
 
All patients with BAV are at risk for infective endocarditis, which is a serious 
complication. It usually presents in the fourth and fifth decades of life, requiring major 
surgery in most cases. In the series of Lamas and colleagues, BAV accounted for 
12% of the 408 cases of native valve endocarditis.25 Overall mortality was 14%, and 
surgical mortality was 9%. Of importance is that in many cases of endocarditis 
related to BAV, patients were unaware of the structural valve disease, preventing 
adequate antibiotic prophylaxis. With the virtual disappearance of rheumatic fever in 
the developed world, BAV is likely to become the most important intrinsic cardiac 
predisposition for infective endocarditis. Patients with BAV require antibiotic 
prophylaxis, and attention should be paid to fever and malaise. 
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AORTIC DILATATION AND DISSECTION 
 
BAV is associated with aortic root dilatation, presumably secondary to abnormalities 
within the media of the aorta. Histologic examination of the dilated aorta showed 
cystic medial necrosis.26 This is characterized by degeneration and fragmentation of 
elastic fibers, loss of smooth muscle cells, an increase in collagenous fibers and 
replacement of the degenerated tissue with interstitial collections of basophilic-
staining ground substance.23,27,28 Marfan syndrome is the prototypic disease in which 
cystic medial necrosis is described. In the past, the dilatation of the aorta was 
attributed to poststenotic turbulence. Arguments against this theory are that 
ascending aortic turbulence generated by discrete congenital subvalvular AS is 
accompanied by no more than moderate aortic dilatation,29 and that the acquired AS 
of trileaflet aortic valves is accompanied by normal media and no more than 
moderate dilatation.27 The ascending aorta in patients with BAV can be dilated 
whether the valve is stenotic, incompetent, or functionally normal.30-32 In fact, 
approximately 50% of patients with a mean age of 18 years with a normally 
functioning BAV have echocardiographic evidence of aortic dilatation.30 Even after 
aortic valve replacement, patients with BAV show progressive dilatation of the 
proximal ascending aorta.33 These findings suggest that, in addition to hemodynamic 
alterations due to a stenotic BAV, there is a structural weakness of the aortic wall 
secondary to a degenerative process. Several underlying mechanisms have been 
proposed including excessive apoptosis, deficient fibrillin-1 content and increased 
matrix metalloproteinases.28,34 
A significant number of patients with BAV have aortic root dilatation (50-
60%).30-32,35 This is presumed to be a precursor of aortic rupture and dissection, 
which are both potentially fatal events. BAV is found in 8% of individuals who have 
suffered from aortic dissection, and approximately 5% of patients with BAV will 
develop aortic dissection during lifetime.1-3 The risk of dissection in patients with BAV 
is not associated with the degree of stenosis.36 Aortic aneurysm may involve the 
sinuses but often extends into the sinotubular junction and the ascending aorta, with 
the greatest degree of dilatation in the ascending aorta.32,35 Aortic dilatation is often 
accompanied by aortic regurgitation. Progression of aortic dilatation may increase the 
degree of regurgitation and, vice versa, increased stroke volume due to the higher 
degree of aortic regurgitation may increase the hemodynamic stress imposed on the 
ascending aorta. A retrospective study in the authors’ center of 82 young adults 
(mean age 18 years) with congenital AS showed a mean progression of the 
ascending aorta diameter of 0.9 mm per year [Unpublished data]. Ferencik and 
colleagues observed the same high rate of progression.35 These findings warrant 
close follow-up of the ascending aorta in young adult patients with BAV.  
At present, surgical replacement of the ascending aorta with tricuspid aortic 
valves is recommended when the diameter exceeds 5.5-6.0 cm. In patients with 
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Marfan syndrome replacement of the ascending aorta is recommended when the 
diameter exceeds 5.0 cm. Given the fact that the aorta of patients with BAV have 
similarities to the aorta of Marfan patients, with respect to an increased risk of 
dissection and rupture, some authors have suggested that the aorta be replaced 
earlier. Patients with moderate aortic dilatation (4.5 to 5.0 cm) had reduced long-term 
survival compared with patients with no or only mild aortic dilatation (<4.5 cm).37 As 
previously mentioned, aortic valve replacement does not prevent aortic dilatation in 
patients with BAV. These findings provide evidence to support a more aggressive 
approach to ascending aorta replacement in patients with BAV. 
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Figure 4. Classification of sports.41 This classification is based on peak static and dynamic 
components achieved during competition. From Mitchell JH, Haskell W, Snell P, Van Camp SP. Task 
Force 8: Classification of sports. JACC 2005;45:1362-7. MVC: Maximal voluntary contraction.  
*Danger of bodily collision. †Increased risk if syncope occurs. 
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EXERCISE 
 
The recommendations regarding exercise are mainly based on the occurrence of 
sudden death, which is the most compelling concern for patients with AS. AS is 
responsible for 2.6% of sudden death in young athletes.38 It has been suggested that 
between 20 and 80% of sudden deaths in patients with severe AS have been found 
to occur during exercise.39 Although peak exercise is undesirable in these patients, 
there is little knowledge regarding the influence of chronic exercise on ventricular 
function and the effects for the patients. The guidelines of the 36th Bethesda 
Conference, (NO, USA), recommend that asymptomatic patients with mild AS (mean 
gradient ≤20 mmHg) can participate in all competitive sports (Box 1).40 Patients with 
moderate AS should avoid competitive sports that involve high dynamic and static 
muscular demands (Figure 4).41 Other forms of exercise can be performed safely, but 
it is recommended to evaluate such patients with an exercise test to ascertain the 
recommended level of physical activity. Patients with moderate AS interested in 
participating in vigorous sports are recommended balloon valvuloplasty. The 
guidelines recommend that patients who have severe AS (Doppler mean aortic valve 
pressure gradient ≥ 40 mm Hg) should not participate in competitive sports and 
should limit their activity to relatively low levels. 
Exercise testing provides an objective measure of exercise capacity of 
patients with AS. Severe AS has traditionally been regarded as a contraindication to 
exercise testing, and even asymptomatic moderate stenosis are regarded as a 
relative contraindication.42 However, exercise testing is safe in asymptomatic patients 
with AS when using the modified Bruce exercise test, and testing is discontinued if 
symptoms, hypotension or significant ST-depression develop.14,43,44 Furthermore, 
Das and colleagues demonstrated that in asymptomatic physically active patients 
younger than 70 years of age, limiting symptoms on exercise testing indicate a very 
high likelihood (79%) of symptom development within 12 months.44 The difference in 
prognosis between asymptomatic and symptomatic AS is great, and an objective 
measure for its distinction is clinically relevant. The authors believe that exercise 
testing can be of value in the risk stratification of asymptomatic patients with severe 
AS. 
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Box 1. Recommendations of the 36th Bethesda Conference (2005).40 
Aortic stenosis (AS): 
- Athletes with mild AS can participate in all competitive sports, but should undergo serial 
evaluations of AS severity on at least an annual basis. 
- Athletes with moderate AS can engage in low-intensity competitive sports (class IA). Selected 
athletes may participate in low and moderate static or low and moderate dynamic competitive 
sports (classes IA, IB, and IIA) if exercise tolerance testing to at least the level of activity 
achieved in competition demonstrates satisfactory exercise capacity without symptoms, ST-
segment depression or ventricular tachycardias (VT), and with a normal blood pressure 
response. Those athletes with supraventricular tachyarrhythmias or multiple or complex VT at 
rest or with exercise -can participate only in low-intensity competitive sports (class IA). 
- Patients with severe AS or symptomatic patients with moderate AS should not engage in any 
competitive sports. 
Bicuspid aortic valves with aortic root dilatation: 
- Patients with BAV with no aortic root dilatation (<40 mm) and no significant AS or aortic 
regurgitation may participate in all competitive sports. 
- Patients with BAV and dilated aortic roots between 40 and 45 mm may participate in low and 
moderate static or low and moderate dynamic competitive sports (classes IA, IB, IIA, and IIB), 
but should avoid any sports in these categories that involve the potential for bodily collision or 
trauma. 
- Patients with BAV and dilated aortic roots greater than 45 mm can participate in only low-
intensity competitive sports (class IA). 
 
 
PREGNANCY 
 
Women with AS whose contemplating pregnancy should be counselled regarding the 
potential maternal and fetal risks of pregnancy, and expected long-term maternal 
morbidity and survival as well as the risk of congenital malformations in the offspring. 
During pregnancy, normal physiological changes, such as an increase in stroke 
volume and a fall in peripheral resistance are largely responsible for the increase in 
the gradient across the aortic valve. There is a 50% increase in circulating blood 
volume during pregnancy that is accompanied by an increase in cardiac output that 
usually peaks between the midportion of the second and third trimester. The clinical 
consequences of the increased aortic gradient depend on the degree of pre-existing 
LV hypertrophy and LV systolic function. Furthermore, as aortic dilatation is 
commonly associated with BAV and hormonal influences have an impact on 
connective tissue in the aorta wall, pregnant women with AS are also at increased 
risk for aortic dissection, typically in the third trimester and early postpartum period. 
Older series dealing with severe AS cite a 17% rate of maternal mortality.45 
According to the ACC/AHA guidelines, women with severe AS (mean pressure 
gradient >50 mm Hg) or symptoms should be advised against pregnancy until the 
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stenosis is relieved.13 Recent studies are more encouraging.46-48 Silverside and 
colleagues reported no maternal death during pregnancy in women with congenital 
AS, of whom 59% had severe AS (AVA ≤1 cm2 or peak gradient ≥64 mm Hg). 
However, women with severe AS had more cardiac complications (pulmonary edema 
and arrhythmias) during pregnancy compared to women with mild-to-moderate AS. 
Fetal outcome remains compromized; 10% of pregnancies were associated with 
adverse fetal events.48 This may be mediated by an inadequate placental perfusion, 
which results in fetal growth retardation or premature labour. 
In general, pregnant women with mild-to-moderate AS (Doppler peak gradient 
before pregnancy <70 mm Hg) without complaints usually tolerate pregnancy well. 
When heart failure develops or syncope occurs during pregnancy, balloon 
valvuloplasty or valve replacement can be considered. Balloon valvuloplasty is 
possible in noncalcified valves with only low complication risks from radiation 
exposure when transesophageal echocardiography is used for guidance during the 
procedure. Several studies on balloon valvuloplasty for severe AS during pregnancy 
suggest favourable outcomes for both mother and fetus.49,50 The use of balloon 
valvuloplasty in pregnancy is useful as a palliative procedure, allowing deferral of 
valve replacement until after birth. Valve replacement with the need for 
cardiopulmonary bypass carries a higher risk for the fetus, with fetal wastage of up to 
20%.51 
 
Anticoagulation  
In women already treated with a mechanical prosthesis, there is a significant risk of 
maternal mortality during pregnancy estimated at 1-4%, with the main cause of death 
being related to valve thrombosis.52 Pregnancy involves a state of hypercoagulability 
caused by hormone-induced increased levels of various clotting factors and 
increased blood viscosity. Thromboembolic prophylaxis of women with mechanical 
heart valves during pregnancy is best achieved with oral anticoagulants, but this is 
associated with an increased risk of embryopathy (6.4%), particularly when used 
between the 6th and 9th weeks of pregnancy.53 Unfractionated heparin does not cross 
the placenta and substitution of the oral anticoagulants with unfractionated heparin in 
the first trimester (between 6 and 12 weeks’ gestation) reduces the risk of 
embryopathy. However, it is less effective and carries an increased risk of 
thromboembolic complications for the mother (9.2% vs. 3.9% for oral anticoagulants). 
Furthermore, long-term use of unfractionated heparin is associated with 
osteoporosis, alopecia and heparin-induced thrombocytopenia. Low-molecular 
weight heparins may be attractive because they are easier to use and have fewer 
side effects than unfractionated heparin. However, no randomized trials are reported 
documenting the benefits of low-molecular weight heparin in pregnant patients with a 
mechanical valve, and some case reports of trombosed prosthetic aortic valves 
under low-molecular-weight heparin have been reported in pregnant women.54 
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Patients with a mechanical valve in the aortic position should be considered at low 
risk for valve thrombosis as compared with patients with a mechanical valve in the 
mitral position.22 In the authors’ opinion, oral anticoagulation should be used from 
weeks 14 to 35, with the use of low-molecular-weight heparin for the first 14 weeks 
and after 35 weeks in anticipation of labour. In patients with a high risk of valve 
thrombosis a regimen of oral anticoagulation, replaced by low-molecular-weight 
heparin after 35 weeks should be used. 
 
Inheritance risk 
When advising women with AS about pregnancy, the risk of recurrence should be 
discussed, as the pattern of inheritance of BAV suggests an autosomal dominant 
trend, with reduced penetrance.55 The occurrence rates of congenital heart disease 
in offspring is reported to be 3-26% in patients with AS.56,57 The risk is higher if the 
affected parent is the mother rather than the father (risk ratio 6.3).58 Recent reports 
showed that the incidence of familial clustering is high in patients with BAV; 
approximately 35% of patients have at least one additional family member with BAV, 
and the prevalence of BAV in first-degree relatives is 9%.55,59 This is much higher 
than the 1% rate expected in the general population.2 Recently, the increased risk of 
identifying BAV in the parent or sibling of the proband with any form of left-heart 
obstructive lesion was described.60 This suggested that BAV may represent a very 
mild manifestation of the genetic risk that underlies severe LV outflow tract 
obstruction, and that consequently, patients with BAV are at high risk for having a 
severely affected offspring. BAV usually occurs in isolation, but association with other 
cardiovascular anomalies is found in approximately 20%. Coarctation of the aorta (6-
9%) and a patent ductus arteriosus occur most frequently.1 Importantly, BAV occurs 
in 50-60% of patients with coarctation of the aorta,61 and in 11% of patients with 
hypoplastic left heart syndrome or interrupted aortic arch.62 The association of BAV 
with abnormalities of the ascending aorta and coarctation of the aorta suggests a 
common underlying developmental defect involving the aortic valve and the wall of 
the aorta. Interestingly, both structures have a common neuroectodermal origin.28 
The specific genetic locus and protein abnormality in patients with BAV is still 
unknown. Knowing the gene or genes responsible for the development of BAV will 
enable better genetic counselling. 
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POTENTIAL MEDICAL TREATMENTS 
 
Statins 
At present, there is no generally accepted pharmacological therapy for AS. Recent 
insights into the pathogenesis of calcification of the aortic valve suggest that it is an 
active process with features reminiscent of atherosclerosis. Immunohistochemical 
studies on trileaflet aortic valves with varying degrees of valve stenosis have 
demonstrated the presence of inflammation, lipid infiltration63 and production of 
proteins that mediate tissue calcification.64,65 In comparing the disease process at the 
tissue level in patients with severe stenosis undergoing aortic valve replacement, T-
lymphocyte infiltration was present in both bicuspid and tricuspid aortic valves, with a 
similar pattern and extent.66 These findings provide evidence that the 
pathophysiology of the stenotic process in patients with BAV and tricuspid aortic 
valves is similar, but that different stress-sharing properties of BAV give rise to an 
earlier onset and more rapid progression of stenosis. 
Additionally, atherosclerotic risk factors, such as total cholesterol and systemic 
hypertension, were associated with AS in patients with BAV.6 Other epidemiologic 
studies have confirmed that AS and atherosclerosis share several common risk 
factors, including older age, male sex, diabetes, smoking, hypertension and 
increased serum low-density lipoprotein (LDL) and lipoprotein (a).67 These 
observations have led to the hypothesis that pharmacological strategies effective in 
atherosclerosis might slow the progression of AS. Statins have emerged as a 
powerful and safe pharmacotherapy for both primary and secondary prevention of 
coronary heart disease. Evidence from experimental, animal and clinical studies have 
demonstrated that statins can also reduce the progression of AS. Statins inhibit 
calcification in cultured porcine aortic valve myofibroblasts by inhibiting the 
cholesterol biosynthetic pathway.68 Recent clinical studies demonstrate that 
treatment with statins in patients with calcific AS may slow the rate of progression of 
stenosis,69-72 decrease native aortic valve calcium accumulation,73,74 and delay the 
degeneration of bioprosthetic aortic valve (Tables 1 and 2).75 However, these studies 
were retrospective and nonrandomized. It was hypothesized that statins can exert 
their beneficial effect by lowering low-density lipoprotein (LDL)-cholesterol, which is 
an important risk factor for AS. Interestingly, Rosenhek and colleagues showed that 
cholesterol levels did not correlate with hemodynamic progression of AS, and 
suggested that the effect of statins may be caused by their pleiotropic or anti-
inflammatory effects. In addition, some investigators even suggest that statins may 
limit aortic dilatation by reducing the production of matrix metalloproteinases in the 
aortic wall, thereby preventing the degradation of matrix components. Recently, 
Cowell and colleagues reported the results of the first randomized trial of statin 
therapy in patients with calcific AS.76 In contrast to the previous retrospective studies, 
this study did not show slower progression of AS in patients receiving statins. 
Aortic stenosis at young adult age 
 31
Furthermore, aortic valve calcium progression was similar in the intervention and 
placebo groups. The authors proposed several reasons for the lack of a beneficial 
effect of statins. Statin treatment at an advanced stage may not be beneficial, and it 
is possible that statin treatment only has a favourable effect in an earlier stage of the 
disease. Secondly, a small effect on the progression of AS may have been missed, 
as the study was powered to detect a difference in progression of aortic jet velocity of 
0.15 m/s/year. A small decrease in disease progression is still clinically important in 
young adult patients. In addition, there are differences between AS and 
atherosclerosis that may explain the difference in effect of statins. In contrast to 
atherosclerosis, AS is associated with a virtual absence of smooth muscle cell 
proliferation and lipid-laden macrophages, and is dominated by earlier and more 
extensive mineralization. Finally, the mechanism of clinical events is different. In 
atherosclerosis, plaque instability is the key element. In AS, progressive increase of 
the leaflet stiffness is responsible for the onset of events. These differences may 
have implications for the pharmacologic treatment and management of AS. Results 
of larger, randomized, controlled trials are needed before statins can be excluded as 
a potential treatment for AS. The authors’ group will start a smaller randomized study 
dedicated to AS in young adults (18-45 years of age) at the end of 2005 in the 
Netherlands and Belgium. 
 
Table 1. Studies on the effect of statins on the progression of aortic stenosis 
* Only patients with a initial serum low-density lipoprotein cholesterol ≥ 125 mg/dl. FU = Follow-up 
Author & 
Year Study design 
Study 
population 
(n) 
Mean 
age 
(years) 
Mean 
FU 
(years) 
Parameter 
progression 
aortic 
stenosis Statins No Statins P Value 
Aronow 
(2001)69 Retrospective 180 82 2.8 
Increase in 
peak gradient 
(mmHg/yr) 3.4 ± 1.0 6,3 ± 1.4* <0.0001 
Novaro 
(2001)71 Retrospective 174 68 1.8 
Decrease in 
valve area 
(cm2/yr) 0.06 ± 0.16 0.11 ± 0.18 0.03 
Bellamy 
(2002)70 Retrospective 156 77 3.7 
Decrease in 
valve area 
(cm2/yr) 0.04 ± 0.15 0.09 ± 0.17 0.04 
Rosenhek 
(2004)72 Retrospective 211 70 2.0 
Increase in 
aortic velocity 
(m/s/yr) 0.10 ± 0.41 0.39 ± 0.42 0.0001 
Cowell 
(2005)76 Prospective 134 68 2.1 
Increase in 
aortic velocity 
(m/s/yr) 0.20 ± 0.21 0.20 ± 0.21 0.95 
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Table 2. Studies of low-density lipoprotein levels and medication use on change in aortic valve 
calcium detected by electron-beam computed tomography. 
Author Year Study design 
Study 
population 
(n) 
Mean 
age 
(years) 
Mean 
FU 
(years) Study groups 
Increase in 
aortic valve 
calcium P Value 
Pohle73 2001 Retrospective 104 65 1.3 LDL ≤ 3.36 mmol/L 9% <0.0001 
      LDL > 3.36 mmol/L 43%  
Shavelle74 2002 Retrospective 65 67 2.5 Statin therapy 12.1% 0.006 
      No statin therapy 32%  
Cowell76 2005 Prospective 133 68 2.1 Statin therapy 22.3% 0.93 
      No statin therapy 21.7%  
O’Brien80 2005 Retrospective 123 68 2.6 ACEI 6.4% <0.001 
      No ACEI 29.3%  
 
Angiotensin-converting enzyme inhibitors 
As previously mentioned AS and atherosclerosis share several similarities. 
Angiotensin-converting enzyme (ACE) inhibitors have been demonstrated to be 
effective in decreasing clinical events in patients with atherosclerosis.77 ACE 
inhibitors interfere with the renin-angiotensin system and exert various beneficial 
actions on vascular tissues beyond their blood pressure-lowering effect. ACE 
inhibitors reduce atherogenesis in experimental models both by inhibiting the 
conversion of inactive angiotensin I to active angiotensin II, and by decreasing 
bradykinin levels, which in turn releases nitric oxide. This results in improved 
endothelial function and a decrease in smooth muscle cell proliferation.78 Recently, 
the renin-angiotensin system has also been investigated in aortic valve disease 
pathogenesis. In an immunohistochemical study, the presence of ACE and its 
enzymatic product angiotensin II was demonstrated in sclerotic and stenotic aortic 
valves, which cannot be found in normal valve tissue.79 ACE and angiotensin II 
colocalize with calcium in aortic valve lesions. It remains unclear whether ACE is 
produced locally by lesion macrophages or whether it is carried into lesions on LDL-
cholesterol particles. These findings provide the basis for further investigations 
examining the role of ACE inhibitors in reducing the progression of AS. Recently, the 
same group also found a significant association between ACE inhibitors use and a 
lower rate of aortic valve calcium accumulation assessed by serial electron beam 
computed tomography (Table 2).80 However, in the retrospective study by Rosenhek 
and colleagues, there was no significant difference in disease progression between 
patients taking ACE inhibitors compared with those who did not.72 It cannot be 
excluded that the initiation of ACE inhibitors at an earlier stage of disease and longer 
treatment intervals may lead to a positive effect on disease progression, but so far, 
convincing evidence is lacking. It is possible that ACE inhibitors exert their long-term 
clinical effect by other mechanisms, in that they may have a favorable impact on the 
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LV hypertrophy and remodeling as a response to pressure overload. LV hypertrophy 
is an important risk factor for adverse cardiac events and has also been identified as 
an important predictor of outcome after aortic valve replacement. Finally, there is 
some concern that patients with AS might be at particular risk of severe hypotension 
when treated with ACE inhibitors. Theoretically this effect is caused by a sudden 
decrease in the systemic vascular resistance in patients with fixed cardiac output, but 
there are few data to support this. Two recent studies suggest that the use of ACE 
inhibitors may be safe in AS. O’Brien and colleagues demonstrated that the use of 
ACE inhibitors is safe and well tolerated in patients with mild-to-moderate AS with 
preserved LV function.81 Chockalingam and colleagues showed that ACE inhibitors 
were well tolerated in symptomatic patients with severe AS who were not candidates 
for surgery, but patients with reduced LV function were prone to develop 
hypotension.82 A low start dose and individual titration seems warranted. 
 
β-blockers 
In patients with Marfan syndrome, β-blocker therapy is of proven benefit for slowing 
the rate of aortic root dilatation, reducing the development of aortic complications and 
improving survival rate.83 Increased body weight or an end-diastolic aortic diameter of 
more than 40 mm was significantly associated with lack of desired response,83 
suggesting that β-blockers must be given at an adequate dose and early in the 
course of the disease to optimize the potential benefit. β-blockers are believed to 
exert a beneficial effect by their negative chronotropic and inotropic actions, which 
lessen the rate and rise of the arterial pulse over time. Marfan syndrome results from 
mutations in the gene encoding fibrillin-1, a fundamental extracellular matrix 
component of the aortic media.84 The fibrillin-rich microfibrils play a prominent role in 
maintaining tissue elasticity by linking vascular smooth muscle cells to adjacent 
elastin fibrils. Fibrillin-1 content has been shown to be reduced in the aortic wall of 
patients with BAV, suggesting a similar pathophysiology.26 As previously mentioned, 
young adult patients with AS usually have BAV, which is associated with a high risk 
of aortic dilatation and dissection. Whether β-blockers are useful in the treatment of 
patients with BAV is not clear, but by extrapolating the results of Marfan patients it 
seems logical to advice β-blockade at least in patients who already have dilatation of 
the ascending aorta. A prospective study is needed, especially since theoretically, a 
negative influence of ß-blockade on the clinical condition of the patient may be 
expected in the case of moderate-to-severe stenosis. 
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EXPERT COMMENTARY 
 
AS is not an innocent disease, and although balloon valvuloplasty and valve 
replacement can be performed with low peri-procedural morbidity and mortality, even 
after successful intervention, these patients definitely have a lower survival rate. 
Symptomatic patients are at high risk for sudden death. In addition to symptoms and 
severity of stenosis, severe LV hypertrophy may become an independent indicator 
for intervention. The implication of severe LV hypertrophy in these patients is 
unknown, but may be the cause of ventricular arrhythmias. Experimental models are 
elucidating the role of LV hypertrophy as a compensatory or maladaptive response to 
AS. The other possible cause for early death is aortic dissection, and careful follow-
up of the dimensions of the ascending aorta with echo and magnetic resonance 
imaging is necessary, possibly with active intervenance. 
Pregnancy is often well tolerated in patients with AS, and in an asymptomatic 
patient with normal exercise testing, the risks and disadvantages of an intervention 
performed only on the basis that the patient is contemplating pregnancy outweigh the 
risks of a well-guided pregnancy. Pregnancy should be discouraged in patients with 
severe AS. Iatrogenic damage (e.g., cesarean delivery or labor induction) should be 
avoided in the practical care during pregnancy and delivery. A team including an 
obstetrician, anaesthetist and cardiologist should make a individual delivery plan for 
each patient that is written down and also available during night-shifts. 
Experimental studies provided insight into the pathogenesis of calcification of 
the aortic valve, laying the foundation for clinical studies. Progress has been made 
toward medical therapy for AS. More evidence is mounting from retrospective clinical 
studies that statins could be of special interest in preventing AS progression. 
However, the first randomized trial in patients with calcific AS failed to show a benefit 
of statins. Larger trials are ongoing and may provide a definitive answer. Special 
considerations should be given to the timing of therapy (early valve lesion versus 
end-stage calcific AS), the sample size needed to demonstrate any clinical effect, 
and the dose of the medication. 
 
 
FIVE-YEAR VIEW 
 
AS in young adults is usually the result of a stenotic BAV, and more insight in the 
pathophysiology of the valvular and vascular manifestations of the BAV will provide 
better management of these patients. The pathogenesis of calcification of the aortic 
valve has been elucidated by immunohistochemical and clinical studies. Despite the 
lack of a beneficial effect of statins in the first randomized trial in older patients with 
AS, the results of two larger randomized trials will become available in 5 years time. 
Currently, most patients with AS will eventually require an intervention. Technical 
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advances in the field of surgery or percutaneous aortic valve replacement will be of 
great benefit for the patient. As the ideal prosthesis to replace the diseased human 
aortic valve is not yet available, research on tissue engineering focusing on the in 
vitro generation of functional, living semilunar heart valve replacements is promising, 
but many technical obstacles must be overcome before tissue engineered heart 
valves are introduced into routine surgical practice. 
The natural history of young adult patients with AS is not clear and it would be 
of great value if a national or international registry were set up. In The Netherlands, 
great efforts are made on the registry of adult patients with a congenital heart 
disease (CONCOR®). Long-term follow-up of patients with AS will provide valuable 
data regarding outcome and risk stratification. Finally, the authors expect that the 
gene or genes responsible for the development of BAV will be found within 5 years, 
enabling better genetic counselling. 
 
Key issues 
- Aortic stenosis (AS) at young adult age is usually the result of a stenotic bicuspid aortic valve (BAV), 
eventually requiring an intervention in nearly all patients. 
- BAV, which is the most common cardiac congenital anomaly, is not only associated with valvular 
complications, but aortic dilatation/dissection are also important complications. 
- Pregnancy is feasible in patients with mild and moderate AS with low maternal mortality, but 
multidisciplinary guidance and individual information on inheritance risks is essential. Patients with severe 
AS have more cardiac complications during pregnancy and should be advised against it until relief of 
stenosis. 
- Calcification of BAV likely results from a combination of mechanical stress on the abnormal valve and an 
active disease process reminiscent of atherosclerosis. Inflammation, lipid infiltration, and proteins that 
mediate tissue calcification play a pivotal role. 
- Pharmacological treatment, such as statins, angiotensin-converting enzyme inhibitors and β-blockers, may 
be of use in patients with AS. Further research investigating their potential beneficial role is necessary. 
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ABSTRACT 
 
Background 
Little data are available on the natural history of young adults with congenital valvular 
aortic stenosis (AS). The aim of the present study was to determine the progression 
rate of AS in young adults, and to identify predictors of stenosis progression and 
outcome. 
 
Methods 
Retrospective study of all patients seen at a single centre diagnosed with congenital 
AS (≥2.5 m/s) between 1992 and 2005, excluding patients with severe aortic 
regurgitation. The slope of the regression of the aortic jet velocity on the time elapsed 
since the baseline study was used to define the rate of progression of stenosis. 
 
Results 
A total of 84 adults (mean age, 23.5±7.9 years) were studied who had at least two 
echocardiograms >1 year (5.6±2.6 years) apart. The annual progression of aortic jet 
velocity was 0.09±0.15 m/s per year. Multivariable linear regression analysis 
identified older age (p<0.001) as an independent predictor of faster haemodynamic 
progression. During the follow-up period of 7.7±2.7 years, no patient died and 35 
patients (42%) underwent aortic valve intervention. By multivariable Cox regression 
analysis, severe AS (≥4.0 m/s) and rapid progression of aortic jet velocity (≥0.2 
m/s/year) were independent predictors of intervention. Cumulative intervention-free 
survival for patients with severe AS was 78±8% at 3 years and 48±10% at 5 years 
versus respectively 98±2% and 96±3% for patients with mild-to-moderate AS (log-
rank: p<0.001). 
 
Conclusions 
Progression of congenital AS was relatively low in young adults compared to elderly 
with degenerative AS. Older age was associated with more rapid progression. 
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INTRODUCTION 
 
Congenital valvulvar aortic stenosis (AS) is the most common left heart obstructive 
lesion in young adults. Scarce data, however, are available on the natural history of 
congenital AS in this population. Most natural history studies were performed in 
children, where the disease is considered progressive with a high-risk of sudden 
cardiac death.1-5 Based on this high risk, the ACC/AHA guidelines recommend 
intervention in children and young adults when the peak aortic gradient exceeds 70-
80 mmHg even when there are no symptoms.6 As interventions (e.g. balloon 
valvuloplasty, Ross procedure) for AS become more frequent, information on the 
natural history in young adults becomes more difficult to acquire. This information is 
important as a reference for the management of these patients and is necessary for 
developing guidelines for this special patient group. 
So far studies on rate of progression of AS were mainly performed in older 
patients with calcified aortic valves or mixed groups.7-9 Only limited serial echo-
Doppler data are available in young adult patients with congenital AS.10 No predictors 
of progression and outcome have been established in this patient group. 
The aim of the present study was to determine the rate of haemodynamic 
progression of stenosis, and identify predictors of AS progression and clinical 
outcome in young adult patients with congenital valvular AS. 
 
 
METHODS 
 
Patient selection 
All consecutive patients, who attended the outpatient clinic for adult congenital heart 
disease at the Thoraxcentre between 1992 and 2005, with isolated congenital 
valvular AS were identified. Inclusion criteria were: (1) aortic jet velocity ≥ 2.5 m/s, (2) 
no severe aortic regurgitation (grade 4), (3) at least two complete echocardiographic 
studies ≥ 1 year apart, (4) age 16-50 years, and (5) no history of aortic valve 
replacement. Eligible patients were not excluded for previous balloon or surgical 
valvulotomy or (repaired) aortic coarctation.  
 Two hundred and twelve adult patients with congenital valvular AS were 
identified in the database of the adult congenital heart clinic at the Thoraxcentre. 
Eighty-four patients were included. One hundred and twenty-eight patients were 
excluded for the following reasons: aortic valve replacement (either during childhood 
or before 1992) in 68 patients; no or very mild AS with aortic jet velocity < 2.5 m/s in 
38 patients; severe AR in 5 patients, and absence of a follow-up echocardiography in 
17 patients.  
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Clinical data 
Follow-up status was obtained by review of hospital records and by use of civil 
registries. At baseline the following variables were recorded: age, gender, cardiac 
symptoms, cardiac rhythm, prior surgical procedures, comorbidity and medical history 
using the European Paediatric Cardiac Coding. From each clinical visit, clinical 
events were recorded including onset of symptoms (e.g. angina, congestive heart 
failure, (near)syncope, or decreased exercise tolerance), and cardiac interventions 
(e.g. balloon aortic valvuloplasty, surgical valvulotomy, and aortic valve replacement). 
The primary indication for aortic valve intervention was also recorded. End points 
were defined as death or aortic valve intervention during follow-up. 
Information on survival was obtained in 82 of the 84 patients (98%). The 
survival status of two patients who had moved abroad could not be retrieved, and the 
last available follow-up data were used.  
 
Echocardiographic data 
All echocardiographic studies were performed in a standard manner and included 
parasternal long- and short-axis, as well as four-chamber, two-chamber and apical 
long-axis views. The aortic jet velocity was recorded using continuous-wave Doppler 
from that window yielding the highest velocity signal. Aortic and mitral regurgitant 
severity was graded none to severe (grade 0 to 4) on the basis of colour flow 
imaging.11 Left ventricular (LV) end-systolic diameter, LV end-diastolic diameter 
(LVEDD), interventricular septum (IVS) and posterior left ventricular wall thickness 
(LVPW) were derived from the M-mode analysis at the level of the mitral valve 
chordae. LV mass was calculated using the Devereux-modified formula 12: LV mass 
= 0.8{1.04 ((LVEDD+LVPW+IVS)3 – LVEDD3)}+0.6. LV hypertrophy was defined by a 
body surface area-indexed threshold of >134 g/m2 and >110 g/m2 for men and 
women, respectively.13 The aortic valve was defined as calcified if there was 
thickening and increased echogenicity of the leaflets in the parasternal long-axis 
views.  
In order to obtain robust data on stenosis progression, all available 
echocardiographic studies (n = 411) of the study group between 1992 and 2005 were 
used to determine the rate of haemodynamic progression of stenosis. The first 
available study with an aortic jet velocity ≥2.5 m/s was used as the baseline study 
and the most recent study or the last study before an end point (i.e. balloon aortic 
valvulotomy, surgical valvulotomy, aortic valve replacement or death) was used as 
the final study. The mean number of studies used per patient was 5±2. 
There are different echocardiographic measures of stenosis severity, e.g. 
aortic jet velocity, mean transvalvular gradient, and continuity equation aortic valve 
area. As our aim was to follow disease severity over time, we used the most 
reproducible measure which is the aortic jet velocity.14 
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Statistical analysis 
To estimate the annual change of aortic stenosis severity, we used the slope of the 
regression of the aortic jet velocity on the time elapsed since the baseline study. 
Exploratory analysis of a series of echocardiographic studies with an interval of >10 
years, showed that the aortic jet velocity tended to change in a linear manner over 
time. The patients’ slopes were given equal weight in subsequent analyses, even 
when based on different numbers of observations. Continuous data are presented as 
mean ± standard deviation and categorical variables as counts and percentages. 
Differences between groups were analyzed by the unpaired Student’s t tests for 
continuous variables and χ2 analysis or Fisher’s exact tests for categorical variables, 
where appropriate. Correlations were sought with Pearson’s correlation coefficient. 
Stepwise multiple linear regression analysis was performed for determining 
independent predictors of stenosis progression. Probabilities of intervention-free 
survival were obtained by Kaplan-Meier estimates (including standard errors) for the 
levels of various prognostic factors. Cox regression analysis was used to evaluate 
the prognostic significance of these variables. Variables with a p-value <0.10 in the 
univariable Cox regression analysis were included in the multivariable Cox 
regression model. The proportional hazard assumption was checked for each 
categorical variable through visual inspection of log-log survival curves. For 
continuous variables, the linearity assumption was checked graphically using the 
Martingale residuals. A p-value of <0.05 was considered statistically significant. All 
statistical analyses were performed using SPSS 12.0 for Windows (SPSS, Chicago, 
III, USA). 
 
 
RESULTS 
 
Characteristics of the Patients 
Eighty-four patients with serial echocardiographic examinations at least 1 year apart 
were included in the study (Table 1). Mean age at baseline visit was 23.5±7.9 years 
(range, 16-50) and 59 patients (70%) were male. Associated congenital heart 
disease was encountered in 15 patients (18%): aortic coarctation (n=13, repaired in 
11), closed VSD (n=3), and repaired patent arterial duct (n=5) (not mutually 
exclusive). Twenty-four patients (29%) had a prior history of aortic valve intervention 
(13 open aortic valvotomies, 15 balloon valvuloplasties). All patients were 
asymptomatic and were in sinus rhythm at baseline.  
 
Progression rate of aortic stenosis severity and its predictors 
The mean interval between the first and final echocardiographic study was 5.6±2.6 
years (range, 1.0-11.8). Overall, aortic jet velocity increased with a rate of 0.09±0.15 
m/s per year (Figure 1).  
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Table 1. Baseline patient characteristics of all patients and of patients with or without intervention 
during follow-up 
 All patients 
N=84 
Intervention 
N=35 
No intervention 
N=49 
Age (years), range 23.5±7.9 25.8±9.7 22.0±5.9 
Age ≥25 years 28 (33%) 15 (43%) 13 (27%) 
Gender (male) 59 (70%) 25 (71%) 34 (69%) 
Bicuspid aortic valve 50 (60%) 26 (74%) 24 (49%) 
Prior intervention aortic valve* 24 (29%) 11 (31%) 13 (27%) 
Open aortic valvulotomy 13 (16%) 6 (17%) 7 (14%) 
Balloon aortic valvuloplasty 15 (18%) 6 (17%) 9 (18%) 
Aortic jet velocity (m/s) 3.63±0.65 4.09±0.57 3.29±0.49 
Aortic jet velocity ≥4.0 m/s 27 (32%) 23 (66%) 4 (8%) 
Peak aortic gradient (mmHg) 54.3±19.6 68.2±17.9 44.3±13.8 
Progression aortic jet velocity ≥ 
0.2 m/s/year 
16 (19%) 13 (37%) 3 (6%) 
Aortic valve calcification 8 (10%) 8 (23%) 0 (0%) 
Aortic regurgitation    
None/ Grade 1 32 (38%) 12 (14%) 20 (24%) 
Grade 2 27 (32%) 12 (34%) 15 (31%) 
Grade 3 25 (30%) 11 (31%) 14 (29%) 
LV end-diastolic dimension (mm) 53.3±7.1 53.7±6.6 53.0±7.5 
LV end-systolic dimension (mm) 30.8±6.3 29.2±6.3 31.9±6.1 
Fractional shortening (%)† 42.4±7.4 45.9±7.1 39.9±6.1 
LV mass index (g/m2) 128.4±40.4 141.9±37.4 118.8±40.0 
LV hypertrophy 42 (50%) 23 (66%) 19 (39%) 
Duration of follow-up (years) 7.7±2.7 9.4±2.0 6.5±2.5 
* 2 patients had an open aortic valvulotomy and balloon aortic valvuloplasty 
† All patients had a normal systolic left ventricular function, determined by a fractional shortening > 
25% 
 
According to univariable analysis the annual rate of progression of aortic jet velocity 
was significantly related to age and aortic valve calcification (Table 2). The rate of 
progression of aortic jet velocity in those with calcification of the aortic valve 
compared with those without calcification was 0.20±0.18 m/s per year versus 
0.08±0.14 m/s per year (p=0.03), respectively. The mean age was higher in patients 
with aortic valve calcification than without calcification (34.0±12.5 versus 22.4±6.4, 
p<0.001). The youngest patient with calcification was 17 years. Rate of progression 
was not statistically different in those with or those without bicuspid aortic valve, male 
sex, left ventricular hypertrophy, grade 3 aortic regurgitation, or prior intervention of 
the aortic valve. Stepwise multiple regression analysis was performed to identify 
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independent predictors of the annual rate of progression of aortic jet velocity. All 
variables with a p-value <0.10 in the univariable analysis were entered in the model. 
Annual rate of progression was independently influenced by age (p<0.001, Beta 
0.36). 
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Figure 1. Changes in aortic jet velocity during follow up. (A) Patients without aortic valve intervention 
during follow-up. (B) Patients with aortic valve intervention during follow-up. 
 
Table 2 . Predictors of progression of aortic jet velocity 
 Univariable analysis  
Multivariable 
analysis 
Variable t r p-value  β p-value 
Age (years)  0.36 0.001  0.36 <0.001 
Aortic valve calcification 2.3  0.03  -  
Aortic jet velocity (m/s)  0.18 0.09  -  
Fractional shortening (%)  0.17 0.12    
Bicuspid aortic valve 1.3  0.18    
Gender (male)  -1.1  0.28    
Prior aortic valve intervention 0.8  0.40    
Moderate to-severe AR -0.5  0.60    
Left ventricular hypertrophy 0.4  0.66    
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Clinical outcome 
During a mean follow-up duration of 7.7±2.7 years (range, 1.0-13.1) no mortality 
occurred. Of the total study group, 35 of 84 patients (42%) underwent an intervention 
of the aortic valve. Twenty-nine patients (83%) had an aortic valve replacement (17 
mechanical valves, 7 homografts, 5 autografts), five patients (14%) had a balloon 
valvuloplasty, and one patient (3%) a surgical valvulotomy. Two patients had 
concomitant coronary artery bypass grafting during aortic valve replacement. Overall, 
mean age at intervention was 30.8±9.9 years. Mean age at intervention was higher in 
patients who received a mechanical aortic valve compared to patients who received 
a tissue valve or valvotomy (34.6±11.7 versus 25.7±5.1, p=0.006). Severe 
symptomatic AS was the reason for intervention in 16 patients (46%), including 3 
patients with concomitant severe AR. Symptoms included decreased exercise 
tolerance confirmed by exercise testing (n=5), angina (n=4), dizziness (n=5), 
dyspnoea at exercise (n=3), and syncope (n=2) (not mutually exclusive). Severe 
asymptomatic AS was the reason for intervention in 17 patients (51%), including 4 
patients with a pregnancy wish and 3 patients with concomitant severe AR. Severe 
asymptomatic AR was the primary indication for intervention in two patients, and one 
of them had an impaired left ventricular function. All other patients had a normal left 
ventricular systolic function. Overall, excluding one patient with severe AR and mild 
AS, the mean aortic jet velocity at the final study before intervention was 4.84±0.60 
m/s. No difference in stenosis severity was noted just before intervention between 
asymptomatic and symptomatic patients. Kaplan-Meier intervention-free survival for 
the total group was 92±3% at 3 years, 81±4% at 5 years, and 49±7% at 8 years 
(Figure 2A). In order to study the natural history, a sub analysis was performed for 
patients without prior aortic intervention (Figure 2B). In this group, estimated 
intervention-free survival was 97±2% at 3 years, 88±4% at 5 years, and 52±8% at 8 
years. 
 
Predictors of clinical outcome 
The severity of baseline aortic stenosis was the most powerful predictor of 
intervention (Table 3). Estimated intervention-free survival for patients with severe 
(≥4.0 m/s) aortic stenosis was 78±8% at 3 years, and 48±10% at 5 years as 
compared to 98±2% at 3 years, and 96±3% at 5 years for patients with mild to 
moderate stenosis (log rank: 42.7, p<0.001) (Figure 3A). 
Patients with a faster progression of aortic jet velocity (≥0.2 m/s/year) also had 
a significantly higher intervention-rate (Figure 1 and 3B). Estimated intervention-free 
survival for patients with fast progression aortic stenosis was 73±11% at 3 years, and 
52±13% at 5 years as compared to 96±2% at 3 years, and 87±4% at 5 year for 
patients with slower progression (log rank: 21.3, p<0.001). Gender, age, prior aortic 
valve intervention, aortic valve calcification, bicuspid aortic valve, and left ventricular 
hypertrophy were not found to be significant predictors of outcome. 
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Figure 2. (A) Cumulative Kaplan-Meier intervention-free survival for the total group (interventions: 
aortic valve replacement n=18, balloon valvuloplasty n=5, surgical valvotomy n=1). (B) Cumulative 
Kaplan-Meier intervention-free survival for patients with prior aortic valve intervention compared to 
patients without intervention (log-rank: 2.6, p=0.10). 
 
 
Table 3. Predictors of aortic valve intervention 
 Univariable analysis  Multivariable analysis 
Variable 
Hazard ratio 
(95% CI) p-value  
Hazard ratio 
(95% CI) p-value 
Aortic jet velocity (m/s) ≥4.0 m/s 7.8 (3.8-15.9) <0.001  6.0 (2.8-13.1) <0.001 
Annual change in aortic jet velocity ≥0.2 
m/s/year 4.6 (2.3-9.3) <0.001  4.6 (2.1-9.9) <0.001 
Aortic valve calcification 4.9 (2.1-11.4) <0.001  2.3 (0.9-5.7) 0.07 
Left ventricular hypertrophy 2.3 (1.2-4.7) 0.02  1.7 (0.8-3.7) 0.19 
Bicuspid aortic valve 2.3 (1.1-4.8) 0.04  1.8 (0.8-4.1) 0.14 
Prior aortic valve intervention 1.8 (0.9-3.7) 0.11    
Age ≥25 years 1.6 (0.8-3.1) 0.17    
Moderate-to-severe aortic regurgitation 0.9 (0.4-1.9) 0.80    
Gender (male)  1.1 (0.5-2.2) 0.87    
CI, confidence interval 
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DISCUSSION 
 
This study of young adult patients with asymptomatic congenital valvular AS showed 
a low rate of progression, with a wide variability. Older age was associated with more 
rapid progression of stenosis. As expected, severe AS and rapid progression of 
aortic jet velocity were independent predictors of aortic valve intervention.   
The rate of progression of aortic jet velocity was relatively low, being only 
0.09±0.15 m/s per year. The observed rate is much lower than the rate of 
progression in older patient groups (mean age 55-75) with degenerative AS, which 
varies from 0.23 to 0.40 m/s per year.7-9 We found that older age was an independent 
predictor of faster progression. Aging leads to calcification of the aortic valve and this 
process is likely to be the cause of faster stenosis progression. In our study, patients 
with aortic valve calcification were older than patients without calcification. 
Remarkably, aortic valve calcification was not found to be an independent predictor 
of haemodynamic progression by multivariable analysis. As the study population was 
young (upper limit of inclusion was 50 years), there was only a small number of 
patients with aortic valve calcification (10% of the total population). This could be an 
explanation for this negative finding.  
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Figure 3. (A) Cumulative Kaplan-Meier intervention-free survival for patients with severe AS (≥4.0 
m/s) compared to patients with mild or moderate AS (<4.0 m/s) (log-rank: 42.7, p<0.001). (B) 
Cumulative Kaplan-Meier intervention-free survival for patients with fast progression (≥0.2 m/s per 
year) compared to patients having slow progression (<0.2 m/s per year)  (log-rank: 21.3, p<0.001).  
 
Recent insights into the pathogenesis of calcification of the aortic valve suggest that 
this is an active process with features reminiscent of atherosclerosis.15 Inflammation, 
lipid infiltration, dystrophic calcification, ossification, and endothelial dysfunction have 
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been observed in both diseases.16-19 Furthermore, hypercholesterolaemia, raised 
lipoprotein Lp(a), smoking, hypertension, and diabetes have been reported to be 
common risk factors for both.15 Although, the pathogenesis of calcification of tricuspid 
and bicuspid aortic valves are similar, calcification has been described to occur 
earlier in patients with bicuspid aortic valve.19,20 In our study one patient with a 
bicuspid aortic valve showed calcification at age 17. This is probably related to 
altered mechanical stress on the valve due to malformation of the aortic valve, 
leading to endothelial disruption.  
A high rate of aortic valve interventions was observed: 8% had an intervention 
at 3 years of follow-up, increasing to 19% at 5 years, and 51% at 8 years. Severe AS 
and rapid progression of aortic jet velocity were independent predictors of aortic 
valve intervention. These results are not surprising, and reflect common practice to 
intervene in patients with severe AS with rapid increase in severity of stenosis. 
Interestingly, 54% of the patients who underwent an intervention were asymptomatic, 
stressing the fact that a more aggressive approach (i.e. early intervention) is applied 
in this young patient group as compared to elderly with AS, where usually a wait-for-
symptoms strategy is employed. In elderly, valve replacement in asymptomatic 
patients is not recommended, although recently a trend towards earlier intervention is 
seen.6,21 In young adults with AS, there is controversy about the optimal timing of 
aortic valve replacement, especially in asymptomatic patients. The risk of sudden 
death must be weighed against operative risks and long-term outcome after 
operation. The Second Study on the Natural History of Congenital Heart Defects 
showed that sudden cardiac death occurred in 6.7% of children and adolescents with 
congenital AS.1 However, scarce information is available on the risk of sudden death 
in the adult population with congenital AS and thus a high-risk group cannot be 
identified.22,23 Potential risk factors that can identify young adult patients with AS who 
will benefit more from early intervention are abnormal exercise testing (e.g. 
symptoms, abnormal blood pressure response), marked LV hypertrophy, LV systolic 
dysfunction and high plasma levels of natriuretic peptides.24,25 In our study, left 
ventricular hypertrophy was only a predictor of valve intervention in the univariable 
analysis, suggesting that hypertrophy was not an independent predictor but rather an 
adaptive response to pressure overload. In patients undergoing aortic valve 
intervention, left ventricular systolic function at the timing of intervention was normal 
in almost all patients (97%). This implies that in our study population left ventricular 
function was not an issue in selecting patients for valve intervention. 
The treatment modalities in young adults differ from the elderly population. In 
children and young adults, balloon valvuloplasty is recommended for stenotic non-
calcified aortic valves with no significant regurgitation.6 However, only five patients 
underwent balloon valvuloplasty during the study period, while 29 underwent valve 
replacement. The long-term outcome of balloon valvuloplasty is good, but restenosis, 
significant aortic regurgitation, and ultimate need for valve replacement are important 
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sequeala.26 In our study, there was a trend towards more interventions in patients 
who had a prior intervention (e.g. balloon or surgical valvotomy) compared with 
patients without a prior intervention (true natural history group) (Figure 2B). When 
valve replacement was performed, most patients received a mechanical valve (59%), 
followed by homografts (24%) and autografts (17%). The benefits of the complex 
autograft procedure in young adults, however, seem less clear than in children (i.e. 
growth potential).  
 
Clinical implications 
The present study provides data on the clinical course of adult patients with 
congenital AS. The rate of progression in the total population is low, however 
increases when the patient gets older. Based on this study, half of the patients with 
an aortic jet velocity ≥ 4.0 m/s will have an intervention of the aortic valve within the 
next 5 years. As patients with severe AS have a high risk of aortic valve intervention 
in the near future, they require careful follow-up every 6 months. In contrast, patients 
with mild to moderate AS are unlikely to have an intervention and may need check-
ups at larger intervals. 
The similarities between aortic stenosis and atherosclerosis have been a great 
stimulus for research on drugs that can delay stenosis progression, the most 
promising agents being statins and ACE-inhibitors.27 Surprisingly, a recent 
randomised trial failed to show an effect of statins in older patients with calcified 
aortic valves.28 Maybe, statin therapy should be started earlier, when no calcification 
is present. 
 
Study limitations 
Several potential limitations must be noted. By excluding patients who underwent 
valve replacement before the study period only the natural history of less severe 
patients were selected. The retrospective design necessitated a review of patients’ 
medical records, and therefore the exact reason for intervention in asymptomatic 
patients was sometimes not exactly clear. Furthermore, our study population 
consisted of patients receiving care in a tertiary centre and may not be completely 
representative owing to referral bias. Together with the given sample size and the 
possible effects of multitesting, e.g. inflation of type I error, all conclusions of the 
present study must be drawn with caution. 
 
Conclusion 
Young adults with congenital valvular AS had a lower rate of progression than elderly 
with degenerative AS. Older age was an independent predictor of fast progression. 
Despite the low progression rate, there was a high rate of aortic valve interventions in 
this tertiary referral centre. 
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SUMMARY 
 
The optimal timing of surgical repair of aortic ectasia is determined by the natural 
course of the underlying disease, risk of surgery, and post-surgical outcome. In 
general, surgery for ascending thoracic aortic aneurysms is indicated at a diameter of 
5.5 cm or greater. Earlier surgery (4.5-5.0 cm) is recommended for patients who are 
at increased risk of aortic dissection and rupture, including patients with Marfan’s 
syndrome, familial thoracic aortic aneurysm, bicuspid aortic valve, family history of 
Marfan’s syndrome plus aortic dissection, and patients with a rapid progressive aortic 
dilatation (≥0.5 cm/year). For most descending thoracic aortic aneurysms, surgery is 
recommended at an aortic diameter of ≥6.0 cm. Symptomatic aneurysms require 
surgery regardless of size. 
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INTRODUCTION 
 
The incidence of thoracic aortic aneurysm is estimated to be around six cases per 
100,000 patient years, with males being affected two to four times more often than 
females. The location of the aneurysms is most often the ascending aorta (60%), 
followed by aneurysms of the descending aorta (40%), whereas arch aneurysms 
(10%) and thoracoabdominal aneurysms (10%) occur less frequently.1 The normal 
diameter of the ascending aorta is <2,1 cm/m2 and <1.6 cm/m2 for the descending 
aorta (corrected for body surface area).2 Dilatation is considered a diameter above 
the norm for age and body surface area, and an aneurysm has been defined as a 
50% increase above the normal diameter. Several causes of thoracic aortic 
aneurysm have been identified, including Marfan’s syndrome, familial thoracic 
aneurysms, and bicuspid aortic valves (Table 1).1 The feared consequences of 
thoracic aortic aneurysms are dissection and rupture, both of which are lethal 
conditions. Mortality is especially high in case of rupture, with fewer than half of the 
patients reaching the hospital alive, mortality at 6 hours is 54% and at 24 hours 
reaches 76%. Detailed information on the natural history and operative risk of 
thoracic aortic aneurysms is necessary to determine the optimal timing of 
prophylactic thoracic aortic surgery. 
 
 
PATHOGENESIS AND ETIOLOGY 
 
Aneurysms of the ascending aorta most often result from cystic medial degeneration, 
which has the appearance of smooth muscle cell necrosis and elastic fiber 
degeneration with cystic spaces in the media filled with mucoid material.1 Medial 
degeneration leads to weakening of the aortic wall, which in turn results in aortic 
dilatation and aneurysm formation. Cystic medial degeneration occurs to some extent 
with aging and is accelerated by hypertension. When such aneurysms involve the 
aortic root, the anatomy is often referred to as annuloaortic ectasia. 
 
Marfan’s syndrome 
Marfan’s syndrome, with a prevalence of 1 per 5,000, is the classical disorder 
associated with cystic medial degeneration of the ascending aorta. More than 100 
mutations have been described in one of the genes for fibrillin-1 (FB1), which is a 
major component of microfibrils of elastin. These mutations result in both a decrease 
in the amount of elastin in the aortic wall and a loss of elastin’s normally highly 
organized structure. As a consequence, the aorta exhibits markedly abnormal elastic 
properties leading to progressive increases in stiffness and dilatation.1 
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Table 1. Causes of thoracic aortic aneurysms1 
Cause Remarks 
Hereditary fibrillinopathies: 
 
- Marfan syndrome Classical disorder with cystic medial degeneration due to 
mutations in the fibrillin-1 gene. Aortic aneurysms typically occur 
at the level of the sinuses but can occur in the entire aorta. 
Accounts for 6-9% of dissections. 
- Ehlers-Danlos syndrome Defects in type III collagen cause hyperelasticity, aortic root 
disease is uncommon. 
- Familial TAA syndrome Autosomal-dominant mode of inheritance, but marked variability 
in expression and penetrance. Males present at a younger age. 
Hereditary vascular diseases: 
 
- Bicuspid aortic valve Approximately 50% have a dilatation of the ascending aorta, 
cystic medial degeneration is regarded as the main cause.  
Vascular inflammation: 
 
- Takayasu arteritis Results in aortic dilatation in 15% of cases, mostly in women. 
- Syphilis Spirochetal infection of the aortic media cause obliterative 
endarteritis of the vasa vasorum. Currently rare due to antibiotic 
treatment. 
- Giant-cell arteritis Typically affects the temporal or cranial arteries, but can also 
produce thoracic aortic aneurysms (11%). 
- Ankylosing spondylitis Associated with inflammation of fibrocartilage, potentially directed 
at tissues rich in fibrillin-1. 
- Behçet disease Leads more to local aneurysm formation and perforation than 
dissection 
- Kawasaki syndrome Coronary aneurysms are the main sign, but also other arterial 
segments can be involved. More circumscript aneurysm 
formation. 
Deceleration trauma: 
 
- High speed accidents Often involves the aortic isthmus, however, most often result in 
transection of the descending aorta at the level adjacent to the 
left subclavian artery 
TAA, thoracic ascending aneurysm 
 
Familial thoracic aortic aneurysm 
It has been estimated that as many as 19% of patients with a thoracic aortic 
aneurysm or dissection have a family history of this disorder independent of those 
with a connective tissue disorder (e.g., Marfan or Ehlers-Danlos syndrome).1 An 
autosomal-dominant mode of inheritance has been suggested, but there is marked 
variability in the expression and penetrance of the disorder. Some candidate genes 
have been proposed but the genetic background of this syndrome is incompletely 
understood and therefore genetic screening is not always feasible. 
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Bicuspid aortic valve 
There is a strong association between bicuspid aortic valves and ascending aortic 
aneurysms. Approximately 50% of young men with normally functioning bicuspid 
aortic valves have an aortic dilatation (20% at the level of the sinuses, 44% at the 
proximal ascending aorta). Once thought to be the consequence of post-stenotic 
dilatation, currently cystic medial degeneration has been found to be the underlying 
cause of aortic dilatation. Fedak et al showed that ascending aortic specimens from 
patients with bicuspid aortic valves have significantly less fibrillin-1 compared to 
patients with tricuspid aortic valves, independent of patient age or aortic valve 
function.3 Interestingly, samples of the pulmonary arteries of the same subjects 
showed a similar reduction in fibrillin-1 content among those with bicuspid aortic 
valves, explaining the high degree of neo-aortic dilatation in patients with a 
pulmonary autograft procedure. In a recent study, Schmid et al found that compared 
with tricuspid aortic valve controls, the aortic aneurysm of those with a bicuspid aortic 
valve demonstrated more lymphocyte infiltration and smooth muscle cell apoptosis.4 
These results suggest that walls of aneurysms associated with bicuspid aortic valves 
are weaker compared to other types of aneurysms and are more similar to findings in 
Marfan patients. 
Although patients with Marfan’s syndrome are at a higher risk of aortic 
dissection compared to patients with a bicuspid aortic valve (44% versus 6%), 
bicuspid aortic valve disease are responsible for more cases of aortic dissection than 
Marfan’s syndrome (14% versus 6-9%) due to the higher incidence of bicuspid aortic 
valves in the general population (1-2%). 
 
 
NATURAL HISTORY 
 
During life the size of the aorta increases, with a normal expansion rate of about 0.0 
to 0.2 cm/year.2 In a large longitudinal study (n=332) by Davies et al the mean rate of 
growth for all thoracic aneurysms was found to be 0.1 cm/year.5 The rate of growth 
was greater for aneurysms of the descending or thoracoabdominal aorta (0.19 
cm/year), chronic dissected thoracic aneurysms (0.14 cm/year), and aneurysms of 
patients with Marfan’s syndrome.5 Furthermore, larger aneurysms expand more 
rapidly than smaller ones, probably due to La Place’s law (circumferential wall stress 
is proportional to the product of pressure and radius). However, the rate of expansion 
within a population is extremely variable, thus rendering such mean growth rate of 
little value in predicting aneurysm growth for the individual patient. 
Several studies have shown that the most important determinant of dissection 
or rupture is the size of the aneurysm (Figure 1).5,6 It should be noted that the annual 
risk of adverse events is extremely high for patients whose aneurysms have 
exceeded 6.0 cm in diameter (odds ratio for rupture: 27 compared to those with an 
Chapter 4 
 60
aneurysm <4.9 cm). Cut-off values of aneurysm size for the cumulative lifetime risk of 
rupture or dissection were previously found by the same group to occur at 6.0 cm for 
the ascending aorta and 7.0 cm for the descending  (Figure 2).6 More recently, the 
relative aortic size (aortic diameter/ body surface area) has been identified as a more 
important predictor of complications than the absolute aortic size.7 
Aneurysms appear to rupture at somewhat smaller sizes in patients with 
Marfan syndrome. Many patients with Marfan syndrome and aortic dissection have a 
family history of dissection, and these patients are at increased risk of rupture or 
dissection. Pregnant women with Marfan syndrome are at particular risk for aortic 
dissection, particularly those who already have aortic root dilatation, with most cases 
of dissection occurring during the third trimester or peripartum period. However, this 
risk appears to be low in women with an aortic root diameter <40 mm. 
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Figure 1. Yearly risk of adverse events (rupture, dissection, and death) according to aortic size.6 
 
RISK OF THORACIC AORTIC SURGERY 
 
For optimal timing of intervention, it is also important to determine the surgical risk. 
The operative risk of morbidity and mortality has decreased significantly, perhaps 
attributable to improving surgical techniques and increased use of end-organ 
protective adjuncts (e.g., selective antegrade cerebral perfusion, hypothermia). 
Current data on the risk of elective thoracic aortic surgery are presented in Table 2.6 
It is important to realize that the presented complication rates only hold for 
experienced surgeons in large centers. Surgery of the aortic arch carries a high risk 
for stroke from embolization of atherosclerotic debris or from global ischemic injury 
during circulatory arrest.1 The most feared nonfatal complication of resection of 
thoracic descending aortic aneurysm is spinal cord injury leading to paraplegia.1 
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Figure 2. Influence of aortic size on cumulative, lifetime incidence of natural complications of aortic 
aneurysm. The incidence of natural complications (rupture or dissection) is plotted along the y-axis, 
and the aortic size along the x-axis. The plot for the ascending aorta is shown in the upper panel and 
for the descending aorta in the lower panel. Note the hinge point at 6 and 7 cm for the ascending and 
descending aorta, respectively. Reprinted from Elefteriades,6 with permission from the Society of 
Thoracic Surgeons. 
 
Elective repair of aortic root disease is associated with lower operative risk compared 
to emergency repair for marked dilatation or dissection. In a study of 675 patients 
with Marfan’s syndrome the 30 day mortality for elective repair, urgent repair, or 
emergency repair was 1.5, 2.6, and 11.7%, respectively.8 Elective surgical repair has 
been shown to improve survival significantly, confirming that surgical repair protects 
life long-term.5  
 
Table 2. Current risk of elective thoracic aortic surgery6 
 Mortality Stroke Paraplegia 
Ascending aorta/ aortic arch 2.5% 8.3% 0.0% 
Descending aorta/ thoracoabdominal aorta 8.2% 4.1% 2.0% 
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MANAGEMENT 
 
Serial imaging of aneurysms 
The large individual variation in growth rate, requires regular follow-up of patients 
with an aneurysm. The optimal imaging modality depends on the location of the 
aneurysm. Transthoracic echocardiography is effective for imaging the aortic root. 
For aneurysms at other sites, contrast-enhanced computed tomography (CT) 
scanning and magnetic resonance angiography (MRA) are the preferred methods, as 
they can visualize the entire aorta. This is important as multiple aneurysms occur in 
13% of patients diagnosed with a thoracic aneurysm.  
 Every patient with an aortic aneurysm detected by echocardiography or 
suspected otherwise (i.e. chest x-ray) should receive an initial CT or MRA of the 
entire aorta. Patients with Marfan’s syndrome and bicuspid aortic valve can then be 
followed by serial evaluation with transthoracic echocardiography on a yearly basis, 
with a repeat CT or MRA  every 3-5 years. These studies are indicated more 
frequently when there is a significant increase in aneurysm size. For patients with an 
aneurysm in the aortic arch or descending thoracic aorta, serial follow-up with a CT 
or MRA is required on a yearly basis and even every 3-6 months when there is a 
significant increase in aneurysm size (according to the aortic diameter).1 Ideally, the 
serial studies should be performed with the same technique in the same center, so 
that direct comparisons can be made between comparable images. Finally, in first-
degree relatives of patients with a thoracic aortic aneurysm (with a familiar etiology) 
screening with CT or MR is indicated. 
 
Surgical management 
The decision to operate is determined by the natural history of the aneurysm and the 
anticipated morbidity and mortality of the proposed surgical procedure (see above). 
As the size of the aneurysm is the most important predictor of dissection or rupture, 
elective surgery must be performed before the aneurysm reaches its critical size. In 
general, surgery for thoracic aortic aneurysms is indicated at a diameter ≥5.5 cm for 
ascending aortic aneurysms and ≥6.0 cm for descending aortic aneurysms.1 Earlier 
surgery for ascending aortic aneurysms, at a diameter of 5.0 cm or greater, is 
recommended for patients who are at increased risk of aortic dissection or rupture 
(e.g., Marfan’s syndrome, familial thoracic aortic aneurysm, or bicuspid aortic valve).1 
When patients with a bicuspid valve  develop severe stenosis or regurgitation 
necessitating aortic valve surgery, prophylactic replacement of the ascending aorta 
can be considered even earlier (≥4.5 cm), as these patients would otherwise remain 
at high risk for subsequent aortic dissection and would need another operation. 
Moreover, in Marfan patients a cut-off value of 4.5 cm is considered for those with 
rapid and progressive aortic dilatation (≥0.5 cm/year), those with a family history of 
Marfan’s syndrome plus aortic dissection, and women contemplating pregnancy. In 
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contrast to abdominal aortic aneurysms, however, no randomized trial has evaluated 
the benefit of early surgery versus careful routine follow-up for small thoracic aortic 
aneurysms. It is important to realize that these data are for asymptomatic aneurysms 
and that symptomatic aneurysms require surgery regardless of size. 
 
Medical management 
Currently, the choice of medical treatment to prevent aortic dilatation and reduce the 
risk of dissection or rupture is limited. In a small randomized study of patients with 
Marfan’s syndrome, treatment with propranolol has shown to slow the progression 
rate of aortic dilatation, and was associated with fewer aortic events and lower 
mortality.9 Whether this treatment is of value for other patients with thoracic aortic 
aneurysms is not known, but seems plausible. The beneficial effects of β-adrenergic 
blockers are probably secondary to blunting of the hemodynamic stress (reduction of 
dP/dt) that is imposed on a structurally deficient aortic wall, however, lowering blood 
pressure alone could also explain the beneficial effect. Recently, losartan, an 
angiotensin II type 1 receptor (AT1) blocker, has shown to prevent aortic aneurysm in 
a mouse model of Marfan’s syndrome by antagonizing transforming growth factor β 
(TGF-β) signaling.10 In contrast to propranolol, AT1 blockade by losartan appears to 
achieve full correction of the phenotypic abnormalities (e.g., elastic fiber 
fragmentation) in the aortic wall. This suggests that AT1 antagonism might achieve 
superior protection over β-adrenergic blocking agents. Furthermore, HMG-CoA 
reductase inhibitors (statins) and angiotensin-converting enzyme inhibitors have 
been associated with a reduced abdominal aortic aneurysm growth. Further research 
is necessary to elucidate their role in patients with thoracic aortic aneurysms. 
 
 
Conclusions 
Although data on the natural history of thoracic aortic aneurysms are limited, it is well 
established that the risk of rupture or dissection increases with aneurysm size. 
Prophylactic surgery for ascending thoracic aneurysms is indicated at a diameter of 
5.5 cm or greater for those with low operative risk. Earlier surgery, at a diameter of 
5.0 cm or greater, is indicated for patients at high risk for dissection or rupture, 
including patients with Marfan’s syndrome, familial thoracic aortic aneurysm, and 
bicuspid aortic valves. Surgery can be considered even sooner (≥4.5 cm) in special 
cases, including Marfan syndrome patients with a family history of Marfan’s 
syndrome plus aortic dissection, Marfan women contemplating pregnancy, and 
patients with bicuspid aortic valve undergoing aortic valve replacement. For most 
descending thoracic aortic aneurysms, surgery is recommended at an aortic diameter 
of ≥6.0 cm. Symptomatic aneurysms require surgery regardless of size. 
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ABSTRACT 
 
Aims 
To investigate outcome and complications of implantable cardioverter defibrillators 
(ICD) in adults with congenital heart disease (CHD) and to identify predictors of (in-) 
appropriate shocks. 
 
Methods and results 
Sixty-four CHD patients ≥18 years at first ICD-implantation (63% tetralogy of Fallot, 
age at implantation 37±13 years) were identified using the Dutch adult CHD registry 
and a Belgian tertiary care centre database. Median follow-up duration was 3.7 
years. Early complications included pocket haematoma (n=3), lead failure (n=2) and 
pneumothorax (n=2). Late complications occurred in 11 (17%) patients, including 
lead failure (n=6), and electrical storm (n=3). Overall, 30 device-related re-
interventions were performed in 20 patients (31%), including 4 premature generator 
changes and 7 lead replacements. Half of the patients received ≥1 shock, and 46 
shocks in 15 patients (23%) were classified as appropriate. One-hundred-and-sixty 
shocks in 26 patients (41%) were classified inappropriate. No predictors of (in-) 
appropriate shocks were identified, except tetralogy of Fallot being associated with 
less appropriate shocks than patients with other CHD (HR 0.29, p=0.02).  
 
Conclusion 
The ICD provided effective therapy in a quarter of adults with CHD with low 
complication rates. The incidence of inappropriate shocks, however, appeared to be 
excessive and warrants further attention.  
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INTRODUCTION 
 
Sudden cardiac death (SCD) is the leading cause of mortality in adults with 
congenital heart disease (CHD), particularly in patients with repaired cyanotic defects 
and left heart obstructive lesions.1,2 The incidence of SCD has been estimated to be 
~1 per 1000 patient-years, which is 25 to 100 times greater than in the general 
population.2 Several predictors of late SCD have been proposed, including the 
occurrence of (non-) sustained ventricular tachyarrhythmias, prolonged QRS 
duration, increase in QRS duration, older age at repair and atrial arrhythmias.3,4 
Implantable cardioverter defibrillators (ICD) have emerged as the primary 
therapeutic option for survivors of SCD and high-risk, mainly ischemic heart disease, 
patients.5 Information on the outcome of ICD therapy in adults with CHD is limited.6-9 
In reports that focus on paediatric congenital heart disease ICD recipients, the prior 
surgical interventions and the complex cardiac anatomy have been shown to 
complicate the procedure. Furthermore, growth has been related to long-term 
complications, like lead failure.6 In adults, additional long-term sequelae (i.e. 
arrhythmias) and residual lesions may decrease the benefit of ICD therapy. Adults 
with CHD, especially those with tetralogy of Fallot (TOF), are prone to develop 
supraventricular tachyarrhythmias, which are a well-known cause of inappropriate 
shocks.10 Inappropriate shocks and the need for re-interventions with their own 
challenges are important issues in this relatively young and active population. The 
impact of ICD therapy on the quality of life in this relatively young patient population 
may warrant specific considerations.  
The objective of the present multi-centre study was to investigate 
complications and outcome of ICD therapy in adults with CHD, including the possible 
identification of predictors of (in-) appropriate shocks.   
 
 
METHODS 
 
For the present study, all adults with CHD after ICD implantation were identified 
using the nation-wide CONgenital CORvitia (CONCOR) registry in the Netherlands 
and a Belgian tertiary care centre’s adult CHD database. Crosscheck with the local 
ICD registries of the 6 participating tertiary centres implanting ICDs revealed a total 
of 83 ICD recipients. After exclusion of patients < 18 years at first implantation and 
those with additional primary electrical disease or cardiomyopathy, 64 patients with 
structural CHD were identified. The central medical ethics committee in the 
Netherlands and the local Belgian ethics board approved the protocol and informed 
consent was obtained from all patients.  
 Baseline data prior to ICD implantation were registered from the patient files 
including age, gender, height, weight, blood pressure, cardiac diagnosis, surgical 
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procedures, New York Heart Association (NYHA) functional class at time of 
implantation, and use of anti-arrhythmic drugs. The last echocardiogram prior to ICD 
implantation was used to determine pulmonary and systemic ventricular end diastolic 
diameter, qualitative ventricular function, degree of right and left ventricular outflow 
tract obstruction, and severity of subpulmonary and systemic valve regurgitation. The 
QRS width and QTc interval were measured on the last ECG prior to ICD 
implantation. The presence of ventricular ectopy and (non-) sustained VT were 
identified on the last Holter monitoring. Detailed information concerning the ICD 
implantation were recorded, including index event for ICD, type of ICD, type of leads, 
defibrillation threshold, duration of intervention, and duration of postoperative stay. 
Early (intervention-related) and late complications (e.g. pocket haematoma, pleural 
effusion, lead failure, thrombo-embolic events, pneumothorax, haemothorax, T wave 
oversensing, pocket and other infections) were documented. Follow-up data were 
obtained from review of medical records and stored intracardiac electrocardiograms. 
Appropriate shock was defined as an ICD shock, delivered in response to a 
ventricular arrhythmia. Inappropriate shock was an ICD shock delivered for reasons 
other than ventricular arrhythmia. Outcome-data included appropriate shocks, 
inappropriate shocks, ICD re-interventions, and cardiac and non-cardiac death. The 
scheduled follow-up differed between centres, but close follow-up (every 3 to 6 
months) is standard after ICD implantation. Median follow-up time was 3.7 years 
(range: 0.1-13.6).  
 
Statistical analysis 
Descriptive statistics for nominal data were expressed in absolute numbers and 
percentages. After checking for normality, mean values and standard deviations were 
calculated for normally distributed continuous variables. Medians and ranges were 
computed for continuous variables with non-normal distribution. Comparison of 
continuous variables between groups were made by unpaired Student’s t-tests. In 
case of a skewed distribution, the Mann-Whitney U test was used. When comparing 
frequencies, the χ2 test or Fisher Exact test was used, where applicable. Cumulative 
Kaplan-Meier survival curves were constructed for each outcome variable. Patients 
without an inappropriate or appropriate shock, respectively, were censored at the 
date of most recent follow-up. Univariable Cox-regression analysis was used to 
evaluate the prognostic significance of the following variables concerning the 
occurrence of appropriate or inappropriate shocks: age at ICD implantation, gender, 
body mass index, QRS width>180 ms, history of atrial arrhythmias, tetratology of 
Fallot, single chamber ICD device, secondary prophylaxis, positive PES, impaired 
subpulmonary ventricular function, and impaired systemic ventricular function. A 
separate analysis was performed for the subgroup of TOF patients including 
additional variables as age at repair, moderate/severe pulmonary regurgitation, and 
right ventricular dilatation. Hazard ratios (95% CI) are presented. The proportional 
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hazard assumption was checked for each categorical variable through visual 
inspection of log-log survival curves. For continuous variables, the linearity 
assumption was checked graphically for all variables using the Martingale residuals. 
There was no sign of violation of the assumptions. Multivariable analysis was not 
attempted because of the low number of events. All tests were two-tailed and a p-
value <0.05 was considered statistically significant. As there was a high amount of 
testing, we present exact p-values to show the significance of the findings. All 
statistics were performed using SPSS version 12.0.  
 
 
RESULTS 
 
Patient characteristics 
The baseline characteristics of the 64 included adults with CHD are summarized in 
Table 1. The majority of patients had repaired TOF (n=40, 63%). In the remaining 24 
patients the following structural defects were present: complete transposition of great 
arteries after atrial switch operation (d-TGA) (n=7), corrected double-outlet right 
ventricle (n=5), repaired ventricular septal defects (n=3), congenital aortic 
regurgitation with aortic valve replacement (n=2), repaired aortic coarctation (n=2), 
atrial septal defect (n=2, 1 uncorrected), unrepaired double chambered right ventricle 
(n=1), congenital pulmonary stenosis with previous balloon dilatation (n=1) and 
uncorrected Ebstein malformation (n=1). 
The index event before ICD implantation was cardiac arrest in 13 (20%), 
spontaneous sustained VT in 26 (41%), (pre)syncope in 14 (22%), palpitations in 4 
(6%), and other in 7 (11%). Detailed data on the sustained monomorphic VT was 
available in 20 of 26 patients (77%) , showing a mean cycle length of 302±75 ms. 
The sustained monomorphic VT was hemodynamically tolerated in 8 of 26 patients 
(31%) .  
 In the subgroup of TOF patients, the index event was cardiac arrest in 6 
(15%), spontaneous sustained VT in 18 (45%), (pre)syncope in 11 (28%), 
palpitations in 1 (3%), and other in 4 patients (10%). Nine TOF patients (23%) had a 
relieve of residual hemodynamic lesions just before (n=7) or after (n=2) ICD 
implantation. The following interventions were performed: pulmonary valve 
replacement (n=7), balloon dilatation of pulmonary valve (n=1), and infundibulectomy 
(n=1). 
Programmed Electrical Stimulation (PES) performed in 44 patients prior to ICD 
implantation, mainly resulted in sustained monomorphic VTs. In 20 of the 25 patients 
(80%), who did not present with cardiac arrest or spontaneous sustained ventricular 
tachyarrhythmia, PES was performed. In 18 (90%) of them sustained ventricular 
tachyarrhythmias were induced. In the two patients without a positive PES, one had 
experienced syncope and a spontaneous nonsustained VT documented on Holter 
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Table 1. Baseline characteristics of 64 adults with CHD ≥18 years at first ICD implantation.  
Variable Tetralogy of 
Fallot (n=40) 
Other CHD 
(n=24) 
Total 
(n=64) 
Age at first implantation 36±10 38±17 37±13 
Male 24 (60) 19 (79) 43 (67) 
BMI (kg/m2) 23.7±5.5 23.6±3.5 23.6±4.8 
NYHA functional class    
I 27 (68) 18 (75) 45 (70) 
II 10 (25) 5 (21) 15 (23) 
III 3 (8) 1 (4) 4 (6) 
History of atrial tachyarrhythmias 12 (30) 8 (33) 20 (31) 
Anti-arrhythmic drug therapy    
Class I 1 (3) 2 (8) 3 (5) 
Class II 11 (28) 4 (17) 15 (23) 
Class III 21 (53) 9 (38) 30 (47) 
Class IV 3 (8) 1 (4) 4 (6) 
ECG    
       Available 39 (98) 22 (92) 61 (95) 
       Sinus rhythm 34 (87) 18 (82) 52 (85) 
       Paced 4 (10) 3 (14) 7 (12) 
       Atrial fibrillation 0 (0) 1 (3) 1 (2) 
       Atrial rhythm 1 (3) 0 (0) 1 (2) 
       QRS duration (ms)* 172±23 131±34 158±33 
       QRS duration >180 ms* 10 (29) 1 (5) 11 (20) 
       QTc interval (ms)* 479±50 453±34 470±46 
24-h Holter    
       Performed 20 (50) 18 (75) 38 (59) 
       Mean heart rate (beats/min) 71±15 72±11 72±13 
       Minimum heart rate (beats/min) 51±14 45±10 48±13 
       Maximum heart rate (beats/min) 120±24 121±26 121±24 
       Documented episodes of NSVT 6 (30) 8 (44) 14 (37) 
Programmed electrical stimulation    
       Performed 31 (78) 13 (54) 44 (69) 
       Negative 4 (13) 2 (15) 6 (14) 
       NSVT 1 (3) 1 (7) 2 (5) 
       SMVT 21 (68) 6 (46) 27 (61) 
       SPVT 4 (13) 0 (0) 4 (9) 
       VF 1 (3) 4 (31) 5 (11) 
Echocardiogram    
 Performed 40 (100) 23 (96) 63 (98) 
 Impaired pulmonary ventricular function 13 (33) 7 (30) 20 (32) 
 Impaired systemic ventricular function 4 (10) 7 (30) 11 (17) 
 Pulmonary regurgitation (≥moderate) 8 (20) 1 (  4) 9 (14) 
All data are presented as n (%), unless stated otherwise.  
BMI, body mass index; NYHA, New York Heart Association; NSVT, nonsustained ventricular 
tachycardia; SMVT, sustained monomorphic ventricular tachycardia; SPVT, sustained polymorphic 
ventricular tachycardia; VF, ventricular fibrillation 
* Excluding patients with pacemaker. 
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 registration, and the other had a history of presyncope without documented VT. In 
the 5 patients who did not have PES, 4 patients had had spontaneous nonsustained 
VT (Holter monitoring (n=3), telemetry(n=1)) and the remaining fifth patient had 
experienced two episodes of unexplained syncope. 
In 7 patients at least 1 ablation procedure to address the monomorphic VT 
was performed. All were unsuccessful and the attending cardiologists subsequently 
decided to implant an ICD. 
Details on the ICD implantation, complications and outcome are summarized 
in Table 2. The devices were implanted between March 1990 and October 2005 
(Figure 1). ICDs were manufactured by Medtronic (n=37), Guidant (n=19), St Jude 
Medical (n=6), ELA Medical and Biotronik (both n=1). Almost all ICDs (97%) were 
implanted in the subclavicular position using standard trans-venous techniques. One 
ICD was implanted in the abdominal position and another in the subclavicular 
position using epicardial patches. ICD programming was intended to avoid 
inappropriate therapy and tailored according to the clinical presentation. In 36 
patients (56%) one tachycardia detection zone (VF zone: 314±20 ms) was 
programmed. In 28 patients (44%) the tachycardia detection zones were 
programmed to recognize fibrillation and either one (n=24) or two tachycardia zones 
(n=4). The programmed fibrillation and tachycardia zones were 288±24 ms and 
346±48 ms respectively, and antitachycardia pacing (ATP) was activated in 22 of 
these 28 patients (79%). 
 
Complications and re-interventions 
Eight early complications occurred in 8 different patients (13%) leading to extended 
hospital stay or re-hospitalisation. The most common early complication was pocket 
haematoma (n=3, two patients were on anticoagulation). Other early complications 
were: micro-dislodgment requiring lead repositioning (n=2), pneumothorax (n=2), and 
fever without known cause (n=1). There was no peri-procedural mortality.  
Late complications, excluding inappropriate shocks, occurred in 11  patients 
(17%). The cumulative rate of late complications was 3%, 10%, and 28% at 1, 3, and 
5 years, respectively. Lead failure, the most prominent complication, was observed in 
6 patients (9%) with a median time to failure of 3.9 years (range 2.1-6.5). No 
inappropriate therapies were caused by these lead dysfunctions. Thrombo-embolic 
events occurred in four TOF patients, including 2 cerebrovascular accidents, 1 
transient ischemic attack and 1 venous occlusion (see below). No new-onset atrial 
fibrillation was documented in these patients. One patient had a persistent left 
superior venous caval system connecting to the left atrium, who developed a stroke 
four months after ICD implantation shortly after an attempted closure with an 
Amplatzer device. Another patient with a history of Wallenberg’s syndrome 
developed a stroke 2 years after implantation. The third patient developed a transient 
ischemic attack 4 years after implantation. In these last two patients no right-left  
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Table 2. Implantation related data, complications and outcome of ICD therapy in 64 adults with CHD.  
Variable Tetralogy of 
Fallot  (n=40) 
Other CHD 
(n=24) 
Total 
(n=64) 
Median duration of follow-up (years) 4.0 (0.1-13.6) 2.8 (0.3-7.3) 3.7 (0.1-13.6) 
Type of ICD    
Single chamber 19 (48) 9 (38) 28 (44) 
Dual chamber 21 (52) 15 (62) 36 (56) 
Defibrillation threshold testing    
Available 13 (33) 21 (88) 34 (53) 
Defibrillation threshold (J) 15±7 18±6 16±6 
Median duration of postoperative stay (days) 3 (1-25) 3 (1-50) 3 (1-50) 
Early complications    
Pocket haematoma 3 (8) 0 (0) 3 (5) 
Lead failure 1 (3) 1 (4) 2 (3) 
Pneumothorax 2 (5) 0 (0) 2 (3) 
Fever without known cause  1 (3) 0 (0) 1 (2) 
Late complications    
Lead failure 4 (10) 2 (8) 6 (9) 
Thrombo-embolic event 4 (10) 0 (0) 4 (6) 
Electrical storm 1 (3) 2 (8) 3 (5) 
Infection 0 (0) 1 (4) 1 (2) 
T-wave oversensing 1 (3) 0 (0) 1 (2) 
Luxation ICD 1 (3) 0 (0) 1 (2) 
Appropriate therapy    
Number of patients 7 (18) 8 (33) 15 (23) 
Median time to first shock (years) 4.8 (0.4-6.6) 1.5 (0.0-3.4) 2.3 (0.0-6.6) 
Median number of shocks  1 (1-16) 2 (1-9) 1 (1-16) 
Inappropriate therapy    
Number of patients 16 (40) 10 (42) 26 (41) 
Median time to first shock (years) 1.7 (0.0-4.4) 0.3 (0.0-6.2) 0.6 (0.0-6.2) 
Median number of shocks  4 (1-22) 4 (1-11) 4 (1-22) 
Re-intervention of ICD 17 (43) 3 (13) 20 (31) 
Anti-arrhythmic drug therapy at last follow-up    
Class I 1 (3) 1 (4) 2 (3) 
Class II 17 (43) 7 (29) 24 (38) 
Class III 16 (40) 8 (33) 24 (38) 
Class IV 1 (3) 1 (4) 2 (3) 
All data are presented as n (%), unless stated otherwise. 
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Figure 1. Bar graph of number of adults with congenital heart disease undergoing first implantation of 
ICD per calendar year. Note the steady increase in the number of ICD implantations. 
 
shunting was identified and the cerebrovascular accidents were considered not to be 
ICD-related.   
Thirty device-related re-interventions were performed in 20 patients (31%). 
The cumulative rate of re-interventions was 0%, 14%, and 51% at 1, 3, and 5 years, 
respectively. Four patients had 2 re-interventions and 2 patients had 4 re-
interventions. Twenty-five of the 30 re-interventions were ICD replacements 
performed in 19 patients, including 19 uncomplicated ICD replacements, 3 upgrades 
to dual-chamber devices, 1 upgrade of abdominal device to transvenous single-
chamber device, 1 downgrade to a single-chamber device due to venous occlusion, 
and 1 downgrade to a pacemaker (on patient’s request). Reasons for ICD 
replacement were: early end-of-life (<3 years after implantation) in 4, late end-of-life 
in 16, and device recall in 5. In addition, 7 lead replacements were necessary in 6 
patients and reposition of the ICD in 1 patient. Three patients had an ICD 
replacement and lead replacement during the same procedure. During follow-up, the 
following complications of re-interventions were observed: pocket haematoma (n=2) 
and a high defibrillation threshold needing a high-energy device (n=1). 
Appropriate and inappropriate ICD shocks 
During the study interval, 32 of the 64 patients (50%) had at least one shock 
(88 episodes, 206 shocks). Of the 206 shocks, 46 (22%) in 15 patients (23%) were 
appropriate, with a median time to first appropriate shock of 2.3 years (range 0.0-6.6) 
(Table 2). The number of appropriate shocks for the 15 patients ranged from 1 to 16 
shocks (median 1). Forty-three shocks were given for spontaneous monomorphic VT 
(cycle length 291±56 ms), 2 for VF, and 1 for spontaneous polymorphic VT. The 
index events of the subgroup of patients with an appropriate shock during follow-up 
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were: cardiac arrest in 3, spontaneous sustained VT in 5 (4 hemodynamically not 
well tolerated), (pre)syncope in 4, palpitations in 2, and spontaneous nonsustained 
VT in 1. Eleven of these 15 patients (73%) had a PES, which were all positive. 
Furthermore, 11 of 36 patients (31%) with a positive pre-implant PES experienced an 
appropriate shock for ventricular arrhythmia.   
The majority of shocks, 160 shocks (78%) in 26 patients (41%), were 
classified as inappropriate with a median time to first inappropriate shock of 0.6 years 
(range 0.0-6.2). Patients who had inappropriate shocks experienced a median of 4 
inappropriate shocks, with a range of 1 to 22 shocks. All inappropriate shocks were 
triggered by supraventricular (including sinus) tachycardias. In response to 
inappropriate shocks, anti-arrhythmic drugs (mainly beta-blockers) were instituted or 
increased in 19 of 26 patients (73%) . VT/VF detection zones were reset in 10 
patients, algorithms for SVT discrimination and ATP were changed in 3 and 2 
patients, respectively. In 7 of the 64 patients (11%)  radiofrequency isthmus ablation 
after ICD implantation was performed, of which 5 patients had experienced 
inappropriate shocks. Additional His-bundle ablation during the same hospital stay 
and redo-isthmus ablation were necessary in two of the 7 patients. After ablations, no 
inappropriate shocks were recorded. 
 
Predictors for appropriate and inappropriate ICD shocks 
None of the recorded baseline characteristics, besides the diagnosis of tetralogy of 
Fallot, including well-known risk factors of SCD appeared to predict (in-)appropriate 
therapies in our patient population (Table 3). The presence of  TOF was associated 
with less appropriate shocks compared to patients with other congenital heart defects 
(HR 0.29, 0.10-0.84, p=0.02). A separate analysis was performed for the subgroup of 
TOF patients including additional variables as age at repair, moderate/severe 
pulmonary regurgitation, and right ventricular dilatation. No predictors of 
inappropriate or appropriate shocks were detected. 
 
Freedom of (in)appropriate shocks and overall survival 
In an attempt to estimate the risk of recurrent SCD, and thus potential impact of ICD 
on survival, freedom from appropriate shock therapy was estimated (Figure 2). 
Freedom was 94%, 85%, 72% at 1, 3, and 5 years, respectively. Freedom from 
inappropriate shocks, however, was 77%, 67%, 47% at 1, 3, and 5 years, 
respectively.  
Overall survival was 98% at 5 years. One patient with d-TGA and Mustard 
correction died six months after ICD implantation due to septic shock, associated 
with endocarditis. He received the ICD as a bridge to heart transplantation after 
experiencing spontaneous nonsustained VT and severe dysfunction of the systemic 
ventricle. 
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Table 3. Predictors of appropriate and inappropriate therapy in adults with CHD (n=64) 
Variable Appropriate shock therapy  Inappropriate shock therapy 
 HR (95%CI) p-value  HR (95%CI) p-value 
Age at ICD implantation 0.96 (0.92-1.01) 0.12  0.98 (0.95-1.02) 0.29 
Male gender 1.09 (0.37-3.20) 0.88  1.49 (0.62-3.57) 0.38 
BMI>25 0.43 (0.14-1.34) 0.14  1.23 (0.55-2.75) 0.61 
QRS width >180 ms 2.00 (0.60-6.70) 0.26  0.77 (0.26-2.34) 0.65 
History of atrial arrhythmias 0.97 (0.33-2.84) 0.95  1.29 (0.57-2.88) 0.54 
Tetralogy of Fallot 0.29 (0.10-0.84) 0.02  0.77 (0.34-1.76) 0.53 
Single chamber ICD device 1.68 (0.55-5.14) 0.36  1.90 (0.85-4.25) 0.12 
Secondary prophylaxis*  0.47 (0.16-1.38) 0.17  1.75 (0.73-4.21) 0.21 
Positive PES† 1.96 (0.25-15.4) 0.52  0.69 (0.19-2.48) 0.57 
Impaired subpulmonary 
ventricular function 
1.28 (0.42-3.84) 0.66  1.19 (0.50-2.84) 0.70 
Impaired systemic ventricular 
function 
2.34 (0.62-8.87) 0.21  1.22 (0.36-4.15) 0.76 
* Index event: cardiac arrest or spontaneous sustained VT. 
† Compared to patients with a negative PES. 
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Figure 2. Cumulative Kaplan-Meier survival depicting freedom from appropriate (A) and inappropriate 
shocks (B) after first ICD implantation. Freedom from appropriate shocks was 94% at 1 year, 87% at 2 
years, and 72% at 5 years after ICD implantation. Freedom from inappropriate shocks was 77% at 1 
year, 71% at 2 years, and 47% at 5 years after ICD implantation. 
 
Chapter 5 
 76
DISCUSSION  
 
The present, to our knowledge, largest and first multi-centre study that analysed the 
outcome of ICD therapy in adults with CHD suggests that this therapy is effective in a 
quarter of the patients (23%) with low early and late complication rates during a 
median follow-up of 3.7 years. The number of inappropriate shocks (41%), however, 
is relatively high caused by supraventricular tachycardias. 
 In the face of the increased risk of SCD in CHD patients, the search for 
predictors of SCD and risk reducing therapy is rational. Silka et al. showed in a large 
CHD cohort (n=3,589) that primarily patients with repaired cyanotic (e.g. TOF and 
TGA) and left heart obstructive lesions (e.g. corrected aortic stenosis and aortic 
coarctation) are at risk.2 The majority of our study patients (72%) had TOF or TGA, 
however, only 3% had left heart obstructive lesions. No clear explanation for this 
discrepancy was found. Perhaps, these patients receive ICD therapy at a younger 
age. This is supported by the survey of the Paediatric Electrophysiology Society 
reporting left heart obstructive lesions in 5 of the 22 paediatric patients (23%) with 
CHD receiving an ICD.11  
Most adult SCD research has also focussed on TOF and TGA patients. 
Gatzoulis et al. stressed the importance of QRS duration and the annual progression 
of QRS duration as independent risk factors for the development of sustained VT and 
sudden death.3 The early lengthening of the QRS duration after TOF repair results 
from surgical injury to the right bundle branch and myocardium, whereas later 
widening reflects right ventricular dilation often due to chronic pulmonary 
regurgitation.12,13 Other important risk factors are older age at repair, transventricular 
approach of repair, RV dilatation, and pulmonary regurgitation. 3,13-15 Recently, an 
impaired left ventricular function was identified as an important risk factor.16  
After identification of the patients at risk, interventions to reduce the risks need 
to be searched. Catheter ablation and surgical repair of underlying hemodynamic 
abnormalities are sound treatment options. Therrien et al. have shown that 
pulmonary valve replacement for pulmonary regurgitation, a well-known long-term 
sequel in patients with previous TOF repair leads to stabilization of QRS duration. In 
conjunction with intraoperative cryo-ablation, it decreased the incidence of pre-
existing atrial and ventricular tachyarrhythmia.17 Van Huysduynen et al. showed that 
pulmonary valve replacement even reduces QRS duration and that the amount of 
QRS reduction is related to the success of the operation, as expressed by the 
reduction in RV end-diastolic volume.18   
ICD therapy has proven a welcome addition in the therapeutic arsenal against 
SCD. Many randomised controlled trials investigating the use of ICDs for primary or 
secondary prevention have shown to improve survival in a spectrum of  patients with 
ischemic heart disease. Even without the evidence of randomised controlled trials, 
there is consensus that SCD survivors with CHD are also candidates for ICD 
Outcome of ICDs in adults with CHD 
 77
implantation.5 However, no consensus exists regarding prophylactic therapy for 
adults with  CHD who are at lower risk for SCD, such as nonsustained VT, induced 
VT, or unexplained syncope. In spite of the diagnostic tools and abundance of risk 
factors, no single predictor of SCD in adults with CHD  has been found.  
In the present study, we tried to identify potential predictors of appropriate shocks. 
However, the known risk factors of SCD, including a positive PES, did not predict the 
occurrence of appropriate shocks. PES was performed in 69% of the patients, with 
induced sustained ventricular tachyarrhythmias in 82%. In contrast, Khairy et al., 
demonstrated that a positive PES in patients after TOF repair did predict future 
clinically VT and SCD.19 It is important to realize that our study population was a 
selected population at high-risk of sudden cardiac death. Known risk factors for 
sudden cardiac death are already weighted in the clinical decision process. This 
could potentially influence our ability to identify predictors of appropriate shocks. 
Our finding that the diagnosis of TOF was associated with less appropriate 
shocks might imply that the abundance of risk factors described for this subgroup has 
decreased the threshold to consider ICD therapy in these patients. An decreased 
threshold could mean that more TOF patients had an ICD as primary prevention. 
However, this was not the case as the percentage of primary prevention was 
identical in both groups (TOF vs. other CHD, 40% vs. 38%, p=1.0). Another 
explanation could be that the other CHD group might consist of patients at higher risk 
for SCD. To identify adults with CHD who are at high risk of SCD and profit from ICD 
therapy, more large scale, international, cohort studies with long-term follow-up are 
required for sufficient statistical power to sort out the independent risk factors.4  
Despite the complexity of the cardiac anatomy, the associated extra-cardiac 
malformations and underdeveloped or obstructed vascular access that may exist in 
this population, only few early complications (13%) occurred after ICD implantation. 
Alexander et al. reported a similar incidence of early complications.6 Pocket 
haematoma was the most frequent (5%) implantation related complication. In most 
reports on ICD placement in CHD patients, mainly paediatric patients, early lead 
dysfunction was a more prominent complication.6,20,21  
Lead dysfunction and electrical storms were the most important late 
complications. A new finding was the relatively frequent occurrence of cerebral 
vascular events during follow-up. The presence of a right to left shunt could have 
played a role in 1 of the 3 events. To what extent the cerebral vascular events could 
be attributed to the ICD implantation remains to be elucidated.  
Although most re-interventions could be attributed to expected end of life, two 
of the 4 patients needing re-intervention for early replacement had received multiple 
inappropriate shocks (6 and 8 shocks, respectively). Prevention of inappropriate 
shocks and improvement of technical capability of the battery may reduce the need 
for re-interventions, which subsequently may decrease the accompanying 
complications.  
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The percentage of patients receiving inappropriate therapy in this study is high 
(41%) in comparison with other types of cardiovascular disease and even compared 
to other reports on CHD patients; the majority of articles report a rate below 
25%.6,7,21-23 Most inappropriate shocks were due to atrial arrhythmias, which are 
known long-term complications in TOF and TGA patients.10,24 This implies that ICD 
therapy should be combined with therapy directing atrial arrhythmias. 
Radiofrequency ablation has been successfully employed for supraventricular 
tachycardia and may be of value in selected patients.25 For patients with atrial 
arrhythmias requiring re-operation, a modified maze procedure should be 
considered. Furthermore, patients need to be educated that compliance with rate 
control anti-arrhythmic drugs is essential when they need an ICD. The management 
of inappropriate shocks in CHD patients poses a unique challenge,9 and every effort 
should be taken to avoid inappropriate shocks. Moreover, the PainFREE trial has 
clearly shown that activating ATP for fast VT is effective in 81% of episodes, thereby 
significantly reducing the number of appropriate shocks.26 The majority of appropriate 
shocks in our study cohort were given for VT. Several appropriate shocks could have 
been prevented by using two tachycardia detection zones with activation of ATP.  
ICD therapy was effective, delivering ≥ 1 potential life saving shock, in 23% of 
the patients during an average of 3.8 years follow-up. Interestingly, no difference in 
the percentage of appropriate shocks was found between patients receiving ICD 
implantation for primary or secondary prevention (28% vs. 21%, p=0.49). The 
percentage of patients receiving appropriate shocks equalled to an average of ~6% 
per year of follow-up. This rate is approximately the same as found in patients with 
hypertrophic obstructive cardiomyopathy (7% per year), where the indication for ICD 
implantation is more clear.27 Other CHD studies report higher appropriate shock rates 
ranging from 7.5% up to 22.4% per year of follow-up, in a more secondary preventive 
setting. Appropriate shocks, however, cannot be used as a surrogate mortality end 
point because VT is not invariably fatal and mortality due to bradyarrhythmias are 
also prevented by an ICD, and therefore care must be taken not to extrapolate the 
results to a survival benefit.  
 
Study Limitations 
This study has limitations inherent to any retrospective study. Moreover, this report 
has the limitations of a limited cohort size and lack of a control group. The small 
numbers limited our ability to identify predictors of (in-)appropriate therapy. Together 
with the possible effects of multitesting, e.g. inflation of type I error, all conclusions of 
the present study must be drawn with caution.  
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Conclusions 
In summary, ICD therapy proved to be effective in 23% of adults with CHD and was 
associated with low complication rates. The high incidence of atrial arrhythmias in 
CHD patients, especially in TOF and d-TGA patients, caused an excessive incidence 
of inappropriate shocks, with probably high impact on the mental state of this 
vulnerable patient population, warranting a careful decision process for ICD 
implantation. A prospective controlled study with long-term follow-up will be required 
to definitively establish the benefit of ICD therapy in adults with CHD. The present 
study does not support a more liberal use of ICDs in CHD patients without covering 
the problem of inappropriate shocks. 
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ABSTRACT 
 
Discussion exists whether discrete subaortic stenosis (DSS) is a congenital or 
acquired cardiac defect. Currently, it is regarded an “acquired” cardiac defect 
presumably secondary to altered flow patterns due to morphological abnormalities in 
the left ventricular outflow tract, as have been shown by some studies in the pediatric 
population. In this report, we demonstrated a steepened aortoseptal angle in adults 
with DSS without previous cardiac surgery in comparison to controls. Our results 
strengthen the hypothesis that altered flow patterns due to a steepened aortoseptal 
angle are a substrate for development of DSS in adults. 
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INTRODUCTION 
 
Controversy exists regarding the origin (congenital vs. acquired) of discrete subaortic 
stenosis (DSS).1,2 Currently, DSS is considered an “acquired” cardiac defect, 
presumed to be secondary to altered flow patterns due to morphological 
abnormalities in the left ventricular outflow tract3,4 These morphological abnormalities 
may include subtle abnormalities such as a small aortic annulus, an increased mitral-
aortic valve separation and a steep aortoseptal angle.4-6 DSS usually is diagnosed 
after the first year of life and causes left ventricular outflow tract obstruction with 
sometimes rapid progression of stenosis during childhood.7,8 The relationship 
between morphological abnormalities and the occurrence of DSS has been studied in 
the pediatric population, however, no data exist for the patients with DSS at adult 
age. The main purpose of the present study was to assess the aortoseptal angle in 
adults with DSS in comparison to age-matched controls.  
 
 
METHODS 
 
Patients with isolated DSS without previous cardiac surgery and ≥18 years old were 
identified from our local database. DSS was diagnosed, by means of two-
dimensional Doppler echocardiography, when a fixed subvalvular obstruction causing 
subaortic flow acceleration detectable by color Doppler imaging was present. Only 
patients with short segment subaortic obstruction according to the morphologic 
classification of Choi and Sullivan, were included in the study. Exclusion criteria 
were: 1) dynamic subaortic obstruction, associated or not, with hypertrophic 
cardiomyopathy, 2) LVOT obstruction caused by either accessory mitral valve tissue 
or the support system of mitral valve prosthesis, 3) complex left ventricular outflow 
tract obstruction, such as tunnel subaortic narrowing or subaortic stenosis secondary 
to malalignment of the ventricular septum. An age- and gender-matched control 
group (healthy volunteers) with a normal echocardiographic examination was chosen 
for comparison.  
The maximal flow velocity in the LVOT was recorded using continuous-wave 
Doppler from that window yielding the highest velocity signal. Aortic regurgitant 
severity was graded none to severe on the basis of colour flow imaging.9 The 
aortoseptal angle was determined from the standard parasternal long-axis view, 
defined as the angle formed by the long axis of the ascending aorta and the plane of 
the ventricular septum (Figure 1A). This measurement was performed in the manner 
of Sigfusson et al. at end-diastole, just before aortic valve opening.6 To measure the 
aortoseptal angle, the midline axis of the aortic root was constructed by bisecting the 
root at the level of the aortic annulus and above the sinotubular junction. The midline 
of the septum was constructed by bisecting the septum at the level of the mitral 
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leaflet tips and 2 cm apically from that point. These measurements were performed 
by two independent observers (SCY and JWRH) unaware of the results of the other 
observer. 
Continuous data are presented as mean ± standard deviation and 
dichotomous variables as counts and percentages. Differences between groups were 
analyzed by the unpaired Student’s t tests for continuous variables and χ2 analysis or 
Fisher’s exact tests for categorical data, where appropriate. The reliability of the 
aortoseptal angle measurements was assessed by evaluating the interobserver 
variability for all subjects, which was measured as the absolute difference between 
observers as percentage of the mean. A two-tailed p-value of <0.05 was considered 
statistically significant.  
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Figure 1. (A) Measurement of the aortoseptal angle (AoSA) from the parasternal long-axis view in 
early systole. (B) Results of aortoseptal angle measurements in both patients and controls. Error bars 
denoted 95% confidence interval of the mean. 
 
RESULTS 
 
A total of 23 patients (14 males) with DSS and 15 controls (11 males) were included 
in the present study. Age at study was similar in patients and controls (33 ± 13 versus 
33 ± 6 years, respectively, p = NS). The mean maximal LVOT velocity was 3.4 ± 0.9 
m/s. Aortic regurgitation was present in 19 patients (87%), and was graded mild in 8 
patients (35%), moderate in 10 (43%), and severe in 1 (4%). The aortoseptal angle 
was significantly steeper in patients with DSS than in controls (115 ± 9° vs. 123 ± 7°, 
respectively, p <0.01, Figure 1B). The interobserver variability for measurement of 
the aortoseptal angle was 2.7 ± 1.8%.  
Steepened aortoseptal angle may be a risk factor for DSS 
 89
DISCUSSION 
 
To the best of our knowledge, the present study shows for the first time that the 
aortoseptal angle is steeper in adults with isolated DSS compared to normal control 
subjects. The mechanisms of DSS development and progression have been studied 
in the pediatric population.3,4,6 Chronic flow disturbances at the LVOT level have 
been postulated as the cause of altered septal shear stress. Different morphologic 
abnormalities can cause nonlaminar flow that increase septal shear stress, including 
an increased mitral-aortic fibrous distance, a smaller LVOT and a steeper aortoseptal 
angle.3,4,6 Kleinert et al. have clearly demonstrated that these morphologic features 
precede the development of DSS in children.4 Experimental flow studies have 
demonstrated that an increased septal shear stress triggers a basic genetic 
predisposition to developing cellular growth factors. The morphologic changes act 
both in the onset and in the progression of the subaortic obstruction. As a steep 
aortoseptal angle is associated with a higher septal shear stress,3, this report 
suggests that increased shear stress is a cause of DSS development in adults. 
In conclusion, in accordance to children a steepened aortoseptal angle was found in 
adults with DSS, strengthening the hypothesis that this morphologic feature may be 
responsible for DSS development in adults.  
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ABSTRACT 
 
Background 
Abnormalities of the aortic root are common in patients with a bicuspid aortic valve. 
Our aim was to investigate the elastic properties of the aortic root in patients with 
congenital aortic valvular stenosis (AS) in comparison with age- and gender-matched 
controls, and to investigate the influence of stenosis severity and aortic size on aortic 
root elasticity.  
 
Methods 
Thirty-two adults (mean age 30.4 ± 7.5 years, 22 men) with congenital AS without 
previous cardiovascular surgery were prospectively studied. Aortic root elasticity 
indices such as aortic stiffness index (ASI), aortic root distensibility (ARD), and aortic 
strain were calculated with the use of M-mode echocardiography.  
 
Results 
ASI was significantly higher in patients compared to controls, 8.5 ± 8.4 versus 4.0 ± 
1.4, respectively (P < 0.01). Other indices of aortic root elasticity were similar 
between patients and controls: ARD was 4.2 ± 3.6 versus 4.3 ± 1.9 x 10-6 cm2/dynes, 
respectively, and aortic strain was 12.4 ± 9.6 versus 13.5 ± 5.0%, respectively (P = 
NS for all). Correlations were found between aortic size and indices of aortic elasticity 
(i.e., aortic strain and ARD), denoting that an increased aortic dimension is 
associated with a stiffer aorta. Interestingly, no correlations were found between 
indices of severity of AS and aortic elasticity, suggesting that an abnormal aortic 
elasticity is independent of stenosis severity.  
 
Conclusions 
Congenital AS results in abnormal aortic elastic properties, independent of stenosis 
severity. Furthermore, there seems to be a relationship between aortic dimensions 
and aortic stiffness. 
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INTRODUCTION 
 
Abnormalities of the thoracic aorta are common in patients with a bicuspid aortic 
valve (BAV). Approximately 50% of patients with BAV have a dilated aortic root 
regardless of the presence or absence of hemodynamically significant valve 
dysfunction,1-3 which is probably due to aortic medial disease (i.e., fragmentation of 
elastin, abnormal collagen and smooth muscle cell, increased ground substance).4-8 
These abnormalities within the aortic media results in BAV being responsible for 6-
10% of all aortic dissections.9 It has been estimated that approximately 5% of BAV 
patients will develop aortic dissection during their lifetime.9 Besides aortic dilatation 
and dissections, a clear correlation with the presence of aortic coarctation has been 
found, BAV occurs in 25-85% of patients with coarctation of the aorta.10  
Once thought to be the consequence of post-stenotic dilatation, currently 
aortic medial disease (“cystic medial degeneration”) has been found to be the 
underlying cause of aortic dilatation and possibly abnormal aortic elastic properties.4-8 
Patients with normally functioning BAV have been shown to have abnormal elastic 
properties of the aortic root compared to controls, expressed by an increased aortic 
stiffness and a decreased aortic distensibility assessed by M-mode 
echocardiography.11 Moreover, a recent MRI study has shown that the aortic stiffness 
in BAV patients is comparable to those of Marfan patients.12 However, the effect of a 
stenotic BAV on the elastic properties of a structurally deficient aortic wall has not 
been investigated. Local flow perturbations above the stenotic valve could have an 
influence on the aortic elasticity. The aim of the present study was to compare the 
elastic properties of the aortic root in a homogenous population of patients with 
congenital valvular aortic stenosis (AS) to age- and gender-matched controls. In 
addition, we investigated whether stenosis severity or aortic dimensions influenced 
aortic elasticity. 
 
 
METHODS 
 
Study population 
Thirty-two young adults with congenital valvular AS (aortic jet velocity ≥2.5 m/s, all 
BAV) were prospectively examined from May 2005 till November 2006. Exclusion 
criteria were: 1) previous cardiovascular surgery; 2) the presence of moderate-to-
severe aortic regurgitation; 3) aortic coarctation. All results were compared with those 
of 32 age- and gender-matched controls. All patients underwent transthoracic 
echocardiography. The study was approved by the local ethics committee, and 
informed consent was obtained from each patient.  
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Blood pressure measurement 
With the patient in supine position, systolic (SBP) and diastolic blood pressures 
(DBP) were measured with an automated mercury cuff sphygmomanometer from the 
left arm after 10 minutes of rest. Blood pressure values were averaged from 3 
consecutive measurements.  
 
Transthoracic echocardiography. 
 While in the left lateral decubitus position, all patients underwent a complete two-
dimensional echocardiography and Doppler study using a Philips Sonos 7500 system 
(Philips, Best, The Netherlands). Systolic and diastolic aortic root diameters (SD and 
DD, respectively) were recorded in M-mode at a level of 2 cm from the annulus from 
a parasternal long-axis view (Figure 1). Gain, depth, and sector angles were 
individualized for the best measurement. SD and DD were measured at the time of 
maximum anterior motion of the aorta and at the start of the QRS complex, 
respectively.  
 
Figure 1. Measurements of systolic (SD) and 
diastolic (DD) diameters of the aortic root are shown 
on the M-mode tracing obtained at a level of 2 cm 
above the aortic valve. 
 
 
 
 
 
 
 
 
 
 
Aortic elastic properties were calculated according to previously proposed and 
evaluated formulas:13,14 aortic stiffness index (ASI) = ln(SBP/ DBP) × DD/ (SD − DD), 
aortic root distensibility (ARD) (cm2/dyne × 10− 6) = 2 × (SD − DD)/ (DD × PP), and 
aortic strain (%)= ((SD − DD) / DD) x 100%, where ln = natural logarithm, and PP = 
pulse pressure. M-mode tracings of the left ventricular dimension in end-diastole and 
end-systole, interventricular septal thickness and left ventricular posterior wall 
thickness were measured according to the criteria of the American Society of Echo-
cardiography.15 Aortic jet velocity (Vmax) was assessed by continuous-wave Doppler 
recordings from multiple windows. The peak aortic gradient was calculated using the 
simplified Bernoulli equation (4 x Vmax2), and the aortic valve area was calculated 
using the continuity equation.  
DD
SD
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Statistical analysis 
All continuous data are expressed as mean ± SD. For comparison between patients 
and controls, an unpaired Student’s t test was used. Correlations between aortic 
elasticity (i.e., ASI, ARD, aortic strain), aortic dimensions (i.e., aortic systolic and 
diastolic dimension), and stenosis severity (i.e., aortic jet velocity, peak aortic 
gradient, and aortic valve area) in patients were investigated with Pearson’s 
correlation analysis. SPSS (version 13.0, SPSS Inc., Chicago, Illinois) was used for 
statistical calculations. A two-tailed P <0.05 was considered statistically significant.  
 The reproducibility of the aortic diameter measurements was tested in all 
patients at both systole and diastole by 2 independent observers (SCY and AN). The 
interobserver variability was expressed as the absolute difference between 2 
measurements in percent of their mean. In addition, the Bland-Altman method was 
used to determine the agreement between 2 observers.  
 
 
RESULTS 
 
Clinical, echocardiographic, hemodynamic, and aortic elasticity data are presented in 
Table 1. Patients and controls were similar with regard to age, body surface area, 
systolic blood pressure, and pulse pressure. As expected, patients with congenital 
AS had higher LV mass and larger aortic roots compared to controls. Furthermore, 
there was a small but significant difference in the DBP between groups (73.5 ± 7.8 in 
patients versus 78.7 ± 11.7 mm Hg in controls, P = 0.04). When comparing indices of 
aortic elasticity between patients and controls, ASI was significantly higher in patients 
compared to controls (8.5 ± 8.5 versus 4.0 ± 1.4, respectively, P < 0.01). However, 
aortic strain and ARD were similar in both groups (Figure 2).  
Correlation analysis showed an association between end-diastolic aortic 
dimensions and several indices of aortic elasticity (Figure 3). No correlations were 
found with systolic aortic dimensions. There was a significant correlation between 
end-diastolic aortic size and aortic strain (r = –0.40, P = 0.02), and between end-
diastolic aortic size and ARD (r = -0.47, P = 0.006). No correlations were found 
between three indices of stenosis severity (i.e., aortic jet velocity, peak aortic 
gradient, and aortic valve area) and indices of aortic elasticity or aortic dimensions.  
 The interobserver variability as expressed as the mean ± SD difference in 
values obtained by 2 observers for the measurements of aortic diameter at systole 
was –0.07 ± 0.15 cm, with an absolute difference (as percent of the mean) of 3.9 ± 
2.9%. At diastole, the difference between these observations was –0.01 ± 0.14 cm, 
with an absolute difference of 3.4 ± 3.2%. 
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Table 1. Clinical and echocardiographic characteristics of the study population 
Characteristic Controls (n=32) AS patients (n=32) P-value 
Clinical data    
• Age (yrs) 30.5 ± 8.2 30.4 ± 7.5 NS 
• Body surface area (m2) 1.96 ± 0.16 1.96 ± 0.24 NS 
• Gender (male/ female) 22 / 10 22 / 10 NS 
Echocardiographic data    
• End-diastolic LV diameter (mm) 46.9 ± 3.9 54.5 ± 7.4 <0.001 
• End-systolic LV diameter (mm) 29.2 ± 3.7 33.9 ± 7.1 <0.01 
• LV mass (g) 147.4 ± 31.7 209.3 ± 69.2 <0.001 
• LV mass index (g/m2) 75.4 ± 15.7 106.0 ± 30.4 <0.001 
• Peak aortic gradient (mm Hg) - 57.6 ± 22.3 - 
• Aortic valve area (cm2) - 1.34 ± 0.59 - 
Hemodynamic data    
• Systolic BP (mm Hg) 127.7 ± 16.2 125.6 ± 13.9 NS 
• Diastolic BP (mm Hg) 78.7 ± 11.7 73.5 ± 7.8 0.04 
• Pulse pressure (mm Hg) 49.0 ± 10.4 52.1 ± 15.5 NS 
Aortic root data    
• Aortic systolic diameter (cm) 2.65 ± 0.29 3.41 ± 0.56 <0.001 
• Aortic diastolic diameter (cm) 2.34 ± 0.28 3.05 ± 0.53 <0.001 
• Aortic strain (%) 13.5 ± 5.0 12.4 ± 9.6 NS 
• Aortic distensibility (cm2/dynes x 10-6) 4.3 ± 1.9 4.2 ± 3.6 NS 
• Aortic stiffness index (β) 4.0 ± 1.4 8.5 ± 8.4 <0.01 
Variables are expressed as means ± SD. BP = Blood pressure; LV = left ventricle. 
 
DISCUSSION 
 
Although numerous studies have demonstrated abnormalities of the aortic wall in 
BAV patients,1-8 the number of studies evaluating the effect of BAV on the vascular 
function of the aorta is limited.11,12,16,17 In the present study, we demonstrated that 
these patients have an abnormal aortic elasticity, which seems to be related to the 
dimensions of the aorta, but is independent of stenosis severity. 
BAV is associated with aortic root dilatation.1,18 Histological examination of the 
dilated aorta in BAV patients have shown aortic medial disease, which is 
characterized by degeneration and fragmentation of elastic fibers, loss of smooth 
muscle cells, increase in collagenous fibers, and replacement of degenerated tissue 
with interstitial collections of mucoid material.4-8 Marfan syndrome is the classical 
disorder with aortic medial disease (“cystic medial necrosis”),19 but there is increasing 
evidence that the presence of a BAV is also associated with aortic medial disease.4-8 
Nistri et al.11 have previously shown that patients with a non-stenotic BAV 
have abnormal elastic properties of the aortic root compared to controls. BAV 
patients showed an increased ASI compared to controls (10.2 ± 5.3 versus 5.0 ± 2.0, 
respectively, P <0.001).11 Similar results were found in our patient population with 
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Figure 2. Values of aortic root elasticity indices   Figure 3. Linear regression analysis showing  
such as aortic stiffness index, aortic distensibility,  the correlation between aortic size and  
and aortic strain in patients and controls. Error bars  indices of aortic root elasticity. Dashed lines  
denotes 95% confidence interval of the mean. Denotes 95% confidence interval of the 
regression line (solid line) 
Chapter 7 
 98
 
stenotic bicuspid valves (ASI: 8.5 ± 8.5 versus 4.0 ± 1.4, respectively, P < 0.01). In 
our study, we observed no differences regarding ARD and aortic strain between 
patients and controls. These elastic parameters, however, are more pressure 
dependent than ASI.20,21 Thus, ASI is a more robust marker of elasticity, than ARD 
and aortic strain. 
Remarkably, no correlation was found between indices of stenosis severity 
and indices of aortic elasticity or aortic dimensions. These results strengthen the 
hypothesis that aortic root abnormalities (i.e., dilatation and stiffness) are 
independent of stenosis severity, and this study confirms more strongly that this is 
mainly a consequence of the presence of a congenital malformed aorta instead of 
previously thought post-stenotic dilatation. Furthermore, the higher aortic stiffness in 
patients with congenital valvular AS could contribute to an increased afterload, which 
potentially could have a negative influence on LV function and on the development of 
LV hypertrophy, as demonstrated previously for patients with degenerative AS.22 
Another interesting finding of our study is that there seems to be a correlation 
between aortic dimensions and aortic elasticity (Figure 3). A larger aortic size was 
associated with reduced ARD and aortic strain, however, no correlation was found 
between aortic size and ASI. The exact mechanism is not clear. A possible 
relationship between aortic size and stiffness could be explained by the presence of 
“cystic medial necrosis”. Elastin fibers normally bear aortic stresses, providing the 
aorta its biological Windkessel function.23 When the elastin fibers fragment and 
degenerate, the aortic wall stretches and the vessel dilates. Wall stress is than 
transferred to the less extensible collagenous elements in the aortic wall, leading to 
increased stiffness. As the aorta becomes stiffer, it opposes a higher afterload to left 
ventricular ejection, it augments systolic and pulse pressure, and it reduces coronary 
blood flow.24 Furthermore, Bonderman et al.8 showed that in BAV patients arterial 
medial remodelling precedes aortic dilatation. It would be interesting to know whether 
an increased aortic stiffness could be used as a risk factor for identifying patients at 
risk of progressive aortic dilatation, and subsequently dissection.  
 We recently published a prospective study in older patients (mean age 65 ± 11 
years) with degenerative AS who were planned for aortic valve replacement.25 One 
year after aortic valve replacement, ASI changed from 19.6 ± 10.8 at baseline to 8.4 
± 3.5 (P <0.05), and was comparable with those of age-, sex-, and risk-factor-
matched controls. These results suggest improvement of aortic elastic properties 
after relieve of the obstruction. Whether this also occurs in patients with congenital 
AS seems unlikely, as we were unable to find a correlation between stenosis severity 
and aortic root elasticity. In congenital AS patients requiring aortic valve replacement, 
ASI may be used in addition to the aortic dimension in the decision process whether 
or not to include the aortic root in the operation.  
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Study limitations 
Several potential limitations must be noted. First, the method we used to evaluate 
aortic root elasticity is non-invasive and used pulse pressure in the brachial artery 
instead of the aortic pulse pressure in order to calculate ASI. These two pressures 
are not identical because of pulse pressure amplification from center to periphery.23 
Furthermore, M-mode measurements may be problematic in the aortic root because 
the aorta is displaced to the apex of the heart during systole. An alternative would be 
2-D measurements to evaluate aortic size. However, the method we used is well 
established, has good reproducibility, and its results are closely related to those 
obtained by direct invasive measurements.11,26,27 Second, the observation that an 
increased aortic dimension is associated with more stiffening would be strengthened 
by a longitudinal follow-up study with repeated echocardiograms at regular intervals. 
In particular, it would be interesting to see whether progression of aortic dilatation is 
associated with more stiffening, or vice versa. Third, a recent study demonstrated the 
influence of BAV phenotype (anterior-posterior vs. left-right orientation) on aortic 
elastic properties.16 In our study population the exact BAV phenotype could not be 
reliably determined with transthoracic echocardiography. This merits further attention. 
Finally, given the small sample size, all conclusions of the present study must be 
drawn with caution. 
 
Conclusions 
Adults with congenital valvular AS have abnormal aortic elastic properties in 
comparison to age- and gender-matched controls. Moreover, the increased aortic 
stiffness is independent of stenosis severity, suggesting that the decreased aortic 
elasticity is mainly the consequence of the abnormal aortic wall associated with 
bicuspid aortic valves. Finally, an increased aortic dimension is associated with a 
decreased aortic elasticity, suggesting stiffening of the aorta when dilatation occurs.  
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ABSTRACT 
 
Aims 
To evaluate the accuracy of real-time three-dimensional echocardiography (RT3DE) 
using a biplane and multiplane method in determining left ventricular (LV) mass 
compared to cardiac magnetic resonance imaging (CMR).  
 
Methods and Results 
LV mass was measured in 18 adult patients with congenital aortic stenosis using 
CMR and echocardiography (M-mode, two-dimensional echocardiography (2DE), 
and RT3DE). RT3DE data were analysed using a biplane and multiplane method. No 
geometric assumptions were necessary using the multiplane RT3DE method.  
With regard to biplane or multiplane RT3DE, no tendency of over- or 
underestimation of LV mass was observed. Pearson’s correlation coefficients for 
RT3DE versus CMR were 0.84 and 0.90 for the biplane and multiplane method, 
respectively. In addition, the accuracy of both RT3DE methods were comparable 
(Fisher’s R-to-Z transformation: Z=0.69, P=NS). Finally, off-line analysis using 
biplane RT3DE was significantly faster than multiplane RT3DE (3.8±1.2 vs. 7.8±1.7 
minutes, P<0.001). 
 
Conclusions 
Biplane RT3DE provided an accurate estimate of LV mass in patients with concentric 
left ventricular hypertrophy, which was not improved by multiplane RT3DE. The 
accuracy and speed of analysis renders biplane RT3DE an attractive tool in daily 
clinical practice for assessing the degree of LV hypertrophy. 
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INTRODUCTION 
 
Left ventricular (LV) hypertrophy is associated with increased morbidity and mortality 
in patients with congenital aortic stenosis and may be an important risk factor for long 
term outcome.1 To use the severity of LV hypertrophy as an indicator for surgical 
intervention, a reliable, reproducible, and widely available diagnostic method is 
warranted. Echocardiography is the imaging modality most commonly used to 
evaluate LV mass because of its practical and economical advantages over cardiac 
magnetic resonance (CMR). However, the accuracy of linear (M-mode) or 2-
dimensional echocardiography (2DE) images is limited, as they both rely on 
geometric assumptions of uniform chamber size and shape. Furthermore, the 
unintended use of oblique planes leads to overestimation of LV mass measurements 
by M-mode, and foreshortening of apical views leads to underestimation of LV mass 
measurements by 2DE.2-7 
 Considering these limitations, real-time three-dimensional echocardiography 
(RT3DE) appears to be an attractive alternative for accurate evaluation of LV mass, 
especially since it can be measured directly from the three-dimensional data sets. 
Several methods for LV mass analysis from RT3DE data sets are available. A limited 
approach of RT3DE data is to select the nonforeshortened 2- and 4-chamber long-
axis view and compute LV mass derived from model based biplane volumes (biplane 
RT3DE analysis).6 A more comprehensive approach is to trace the endocardial and 
epicardial surfaces in multiple long-axis planes and correct the tracings in the short-
axis views (multiplane RT3DE analysis). We hypothesize that a more accurate 
estimate of LV mass will be acquired with multiplane RT3DE analysis, as no 
geometrical assumptions are required.8-10 
The aim of the present study was to evaluate the accuracy of biplane and 
multiplane RT3DE compared to the current “gold standard” for LV mass values 
obtained from CMR images. In addition, we evaluated if RT3DE was more accurate 
than the conventional M-mode and 2DE techniques. 
 
METHODS 
 
We prospectively recruited 18 consecutive adult patients (13 men, age 30±8 years, 
weight 80±12 kg) with congenital aortic stenosis who visited the outpatient clinic for 
Adult Congenital Heart Disease of the Thoraxcentre. The M-mode, 2DE and RT3DE 
data acquisition were performed on the same day, and the CMR study was 
performed 26±14 days after the echocardiographic data acquisition. There were no 
changes in the patient’s clinical status between the echocardiographic examination 
and the CMR study. The mean peak aortic jet velocity was 3.7 ± 0.8 m/s and all 
patients were in sinus rhythm. The institutional review board approved the study, and 
all patients gave written informed consent.  
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CMR  
A clinical 1.5-Tesla MRI scanner with a dedicated cardiac four-element phased-array 
receiver coil was used for imaging (Signa CV/I, GE Medical Systems, Milwaukee, 
Wisconsin USA). Repeated breath-holds and gating to the electrocardiogram were 
applied to minimize the influence of cardiac and respiratory motion on data collection. 
Cine-MRI was performed with a steady-state free-precession technique (FIESTA, 
GE) with the following imaging parameters: repetition time, 3.0 to 3.4 ms; echo time, 
1.5 ms; flip angle, 45°; temporal resolution, 47 ms; section thickness, 8mm; section 
gap, 2 mm; field of view, 300 x 340 mm; and matrix size 224 x 256. To cover the 
entire LV, 10 to 12 consecutive slices were acquired in short axis orientation and a 
single 4-chamber and 2-chamber orientation. 
CMR cine loops were analyzed offline with dedicated commercial software 
(CAAS- MRV, Pie Medical Imaging, Maastricht, The Netherlands) by one 
experienced CMR cardiologist (RJMvG) blinded to the results of the 
echocardiographic analysis. The endocardial and epicardial border of the LV were 
traced manually on the long-axis views. The calculated intersection points with the 
short-axis images were the basis of the automatic contour detection.11 In every short-
axis slice, manually corrections were performed when necessary, including the 
papillary muscles and trabeculations in the LV cavity. Myocardial mass was 
calculated by taking the difference of the end-diastolic endocardial and epicardial 
volume multiplied by 1.05 g/mL, which is the density of myocardium.12,13 
 
RT3DE acquisition 
Data acquisition was performed by one experienced sonographer (JSM) using 
second harmonic imaging with a matrix-array transducer (X4, 2 to 4 MHz) connected 
to a commercial ultrasound system (SONOS 7500, Philips Medical Systems, Best, 
The Netherlands). Care was taken to include the entire LV within the pyramidal scan 
volume. RT3DE datasets were then acquired with wide-angled acquisition (93° x 84°) 
mode in which 4 wedge-shaped sub volumes (93° x 21° each) were obtained from 4 
different cardiac cycles during held respiration without moving the transducer. 
Acquisition was triggered to the R wave of every other cardiac cycle to allow time for 
storage of each sub volume, resulting in a total acquisition time of 7 heartbeats. 
 The RT3DE datasets were analyzed using 2 different commercial software 
packages: 3DQ-Qlab (Philips Medical Systems, Best, The Netherlands) and 4D 
Echo-View (TomTec Imaging Systems GmbH, Munich, Germany) for the biplane and 
multiplane analysis, respectively. Two independent observers (SCY and AN) blinded 
to the results of the CMR analyzed the RT3DE datasets by using first the biplane 
method, followed by the multiplane method. LV mass was calculated with the use of 
a specific mass of myocardial tissue of 1.05 g/mL. 
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Figure 1. (A) Biplane analysis: an example of anatomically correct LV apical views from the RT3DE 
data set by 3DQ-Qlab. The red line in the short-axis view corresponds to the apical 2-chamber view 
and the green line in the short-axis view corresponds to the apical 4-chamber view. (B) Multiplane 
analysis: an example of endocardial and epicardial tracings in LV apical views by 4D Echo-View. Note 
the short-axis view (bottom left) showing the tracings corresponding to the long-axis views. A2C = 
apical 2-chamber; A4C = apical 4-chamber; SA = short-axis. 
 
 
Figure 2. An example of corresponding short-axis views from apex to base. (A) CMR images. (B) 
Short-axis views in the same patient showing the manually traced endocardial and epicardial surfaces 
by 4D Echo-View. This view allows manually correction of tracings made in the long-axis images.  
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Biplane RT3DE data analysis 
The pyramidal volume data were displayed in 3 different cross sections (Figure 1A). 
The anatomically correct 2- and 4-chamber views with the largest long-axis 
dimensions were selected as previously described by Mor-Avi et al.6 In these 2 
planes, endocardial and epicardial contours were traced manually at end-diastole. 
The papillary muscles and trabeculations were included in the LV cavity to be 
consistent with the CMR measurements. The traced contours were then used to 
calculate LV volumes by use of the biplane Simpson formula incorporated in the 
analysis software. In addition, the LV long-axis dimension in the 2- and 4-chamber 
view was measured as the distance between the level of the mitral annulus and the 
most distal point at the apical endocardium. 
 
Multiplane analysis RT3DE data 
Multiplane analysis was performed as previously described by our group8. The 
anatomically correct 2- and 4-chamber views with the largest long-axis dimension 
were selected in the same manner as described above (Figure 1B). Around this user-
defined LV long axis, the software generated 8 uniformly spaced apical long-axis 
images 22.5° apart. In each view, epicardial and endocardial contours were manually 
traced at end-diastole with the papillary muscles and trabeculations included in the 
LV cavity. Once the points were manually traced on the eight long-axis planes, the 
position of the manually traced contours was verified in multiple short axis views from 
base to apex, and corrected when necessary (Figure 2). The traced contours were 
then used to calculate LV myocardial volume and mass. 
 
2D Echocardiographic measurements 
The 2DE imaging was performed by one experienced sonographer (JSM) with a S3 
transducer with second harmonic imaging from the apical window with the patient in 
the left lateral decubitus position. The 4- and 2-chamber views were acquired during 
held respiration, while care was taken to avoid foreshortening. Images were stored 
digitally and analyzed offline (EnConcert, Philips Medical Systems) by 2 independent 
observers (SCY and AN). For both apical views, end-diastolic frames were selected 
at the start of the R wave. In each view, endocardial and epicardial contours, 
including the papillary muscles and trabeculations in the LV cavity, were traced 
manually. The traced contours were used to calculate endocardial and epicardial LV 
volumes by the biplane Simpson’s formula.14 The difference between the epicardial 
and endocardial volumes was computed for each view and multiplied by the specific 
mass of myocardial tissue to represent a biplane estimate of LV mass. In addition, 
the LV long-axis dimension in the 2- and 4-chamber view was measured as 
described for biplane RT3DE. 
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M-mode measurements 
M-mode imaging was performed by one experienced sonographer (JSM) from a 
parasternal long-axis position using a standard transthoracic transducer. 
Measurements of the interventricular wall thickness (IVS), posterior wall thickness 
(PW), and LV internal diameter (LVID) were performed at end-diastole according to 
the recommendations of the American Society of Echocardiography.15 LV mass was 
calculated according to the cube formula using the correction described by Devereux 
et al.: LV mass (g) = 0.8 {1.04((IVS+LVID+PW)3 – LVEDD3)} + 0.6.16 
 
Inter- and intraobserver variability 
To determine the interobserver variability for 2DE and RT3DE evaluations of LV 
mass, all measurements were repeated by a second observer (AN) blinded to the 
values obtained by the first observer (SCY). To assess intraobserver variability, all 
measurements were repeated 1 month later by an observer (SCY) blinded to the 
results of the previous measurements. Inter- and intraobserver variability was 
calculated as the absolute difference between the 2 measurements in percent of their 
mean. The inter- and intraobserver variability could not be measured for the M-mode 
technique as the measurements were already performed during acquisition, making 
blinding impossible. 
 
Statistical analysis 
All values were expressed as mean±SD. Difference between each echocardiographic 
technique and CMR was evaluated by a paired t test. Agreement between 
techniques was evaluated by linear regression analysis with Pearson’s correlation 
coefficient and the standard error of the estimate (SEE). The difference between the 
correlation coefficients of the biplane and multiplane RT3DE was tested using the 
Fisher R-to-Z transformation test. In addition, Bland-Altman analysis was used to 
determine the bias and 95% limits of agreement (1.96 SD) between 
echocardiographic measurements and CMR.17 These analyses were performed for 
the first observer (SCY). Inter- and intraobserver variability values were averaged for 
all patients and tested by use of a paired t test for significance of differences between 
techniques. Values of P <0.05 were considered significant. 
 
 
RESULTS 
 
Acquisition of RT3DE data sets was feasible in all patients (acquisition time <2 
minutes). The CMR value of LV mass was 177±48 g. Off-line image processing and 
tracing required 2.0±0.4 minutes for 2DE, 3.8±1.2 minutes for biplane RT3DE and 
7.8±1.7 minutes for multiplane RT3DE (P <0.001 between techniques). Linear 
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regression analysis and Bland-Altman analysis are shown in Figures 3 and 4, 
respectively. 
Mean LV mass with M-mode echocardiography was 209±68 g, which was 
significantly higher than the CMR values (P= 0.005). A Pearson’s correlation of r = 
0.79 (SEE 43 g, P<0.001) with CMR values was observed. Bland-Altman analysis 
confirmed the overestimation by M-mode echocardiography by demonstrating a bias 
of 32 g with 95% limits of agreement at ±82 g. 
Mean LV mass with 2DE was 155±31 g, which was significantly lower than the 
CMR values (P=0.02). A correlation of r=0.69 (SEE 23 g, P<0.001) with CMR values 
was observed. Bland-Altman analysis confirmed the underestimation by 2DE by 
demonstrating a bias of -22 g with 95% limits of agreement at ±68 g. The LV long-
axis dimension was 8.8±0.8 cm in the 4-chamber view and 8.8±0.6 cm in the 2-
chamber view. 
Biplane RT3DE yielded a mean LV mass of 183±46 g, which was similar to the 
CMR values (P=NS). A Pearson’s correlation of r=0.84 (SEE 26 g, P<0.001) with 
CMR values was observed. Bland-Altman analysis showed no significant over- or 
underestimation by the RT3DE-technique as reflected by a bias of 6 g with 95% limits 
of agreement at ±53 g. The LV long-axis dimension was 9.2±0.9 cm in the 4-chamber 
view and 8.8±0.7 cm in the 2-chamber view. The LV long-axis value in the 4-chamber 
view was significantly larger using biplane RT3DE compared to 2DE (P<0.05). 
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Figure 3. Regression analyses of LV mass measurements by M-mode (upper left), 2DE (upper right), 
biplane RT3DE (bottom left), and multiplane RT3DE (bottom right) against CMR values. Solid line: 
regression line; dashed lines: 95% confidence intervals.  
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Figure 4. Bland-Altman analyses of LV mass measurements by M-mode (upper left), 2DE (upper 
right), biplane RT3DE (bottom left), and multiplane RT3DE (bottom right) against the mean value of 
CMR and echocardiographic measurements. Horizontal solid lines represent mean difference between 
each echocardiographic technique and CMR; dashed lines, 95% limits of agreement (±1.96 SD 
around the mean). 
 
Finally, multiplane RT3DE yielded an LV mass of 181±41 g, which was similar to the 
CMR values (P=NS). A correlation of r = 0.90 (SEE 20 g, P<0.001) with CMR values 
was observed. Bland-Altman analysis showed no significant over- or underestimation 
by the RT3DE-technique as reflected by a bias of 4 g with 95% limits of agreement at 
±41 g. The accuracy of LV mass measurement was similar between the biplane and 
multiplane RT3DE method (Fisher’s R-to-Z transformation: Z=0.69, P=NS). 
 The interobserver variability was 17±13% for the 2DE technique, 9±7% for the 
biplane RT3DE technique, and 11±6% for the multiplane RT3DE technique (P<0.05 
between 2DE and biplane RT3DE, P=0.11 between 2DE and multiplane RT3DE). No 
difference in interobserver variability was observed between the biplane and 
multiplane RT3DE technique. The intraobserver variability was 8±6% for the 2DE 
technique, 9±9% for the biplane RT3DE technique, and 11±7% for the multiplane 
RT3DE technique (P=NS between techniques). 
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DISCUSSION 
 
As expected, LV mass measurements from RT3DE data could be achieved with 
higher accuracy and lower interobserver variability than conventional 
echocardiographic techniques (M-mode, 2DE). Interestingly, LV mass measurements 
by biplane RT3DE was as accurate as multiplane RT3DE in patients with concentric 
LV hypertrophy. 
Quantification of LV mass has traditionally been based on M-mode 
measurements of myocardial thickness, coupled with geometrical modelling of the 
LV, or model-based calculations from manually traced endocardial and epicardial 
contours obtained from 2DE images. Our results, however, showed that M-mode 
significantly overestimates LV mass probably due to oblique cuts,and that 2DE 
underestimates LV mass due to foreshortening.2-7 An improved accuracy of LV mass 
measurement was found for RT3DE, either by biplane or multiplane analysis, 
compared to conventional echo techniques. Measurements of the LV long-axis 
dimensions showed that offline cross sectioning of the RT3DE data provided 
significantly less foreshortened and thus anatomically more correct apical views than 
conventional 2DE measurements, thus explaining the improved accuracy of biplane 
RT3DE analysis. Furthermore, we hypothesized that the accuracy of RT3DE could 
be improved further by increasing the number of long-axis planes used to trace the 
endocardial and epicardial boundaries and to correct the tracings on short-axis 
images. We found, however, that the accuracy of multiplane RT3DE analysis was not 
better than biplane RT3DE analysis using 2 orthogonal planes. A similar outcome 
has been shown by Teupe et al., reinforcing the fact that using multiple planes does 
not increase accuracy in normally shaped ventricles.18 Multiplane RT3DE analysis 
may be of extra value in patients with nonconcentric LV hypertrophy, like 
hypertrophic obstructive cardiomyopathy, but not convincingly in a population with 
concentric LV hypertrophy.9 We recently demonstrated that LV mass measurement 
can be achieved with high accuracy by multiplane RT3DE in patients with abnormally 
shaped left ventricles due to congenital heart disease.8 
Another important finding of our study is that RT3DE measurements varied 
less between observers compared to 2DE measurements (significant for the biplane 
analysis, and showing a trend for multiplane analysis), reflecting reduced operator 
dependency. Both the interoberver and intraobserver variability of RT3DE are ±10%, 
indicating that this technique is acceptable for clinical use and will improve the 
reliability of follow-up data. CMR, however, remains superior with variability values 2-
4% reported by multiple investigators.13,19 This difference may be explained by the 
relatively limited ability of ultrasound imaging compared with CMR to visualize the 
endocardial and epicardial borders. 
The time needed for the acquisition and analysis of RT3DE data are 
acceptable. The acquisition time for one RT3DE data set is relatively fast and is 
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limited to 7 heartbeats, with an acquisition time of less than 2 minutes. Off-line image 
processing and tracing required 3.8±1.2 minutes for biplane RT3DE analysis and 
7.8±1.7 minutes for multiplane RT3DE analysis. Interestingly, it is possible to directly 
measure LV mass using the biplane RT3DE method on the ultrasound system (not in 
this study) during acquisition thus avoiding off-line analysis. Recently, custom 
software has been developed, incorporating semi-automated detection of the LV 
endocardial and epicardial surface, which will allow even more rapid and accurate 
measurement of LV mass.20  
Several limitations are inherent to RT3DE. The size of the heart may be to big 
to fit into the scan volume thereby reducing accurate measurements of LV mass.9 
Fortunately, this was not the case in our population, but this can be encountered in 
patients with LV dilatation or ventricular aneurysms. Another limitation of RT3DE is 
that factors that reduce 2DE image quality, including a small intercostal space and 
abundant body fat, also apply for RT3DE. In addition, the relatively large footprint of 
the X4 matrix transducer probably influences image quality in a negative way. 
Technical improvements in the near future will probably include an expansion of the 
scan volume without loss of spatial resolution and a smaller footprint of the matrix 
transducer. 
 
Study limitations 
Several potential limitations must be noted. Test-retest variability (summation of 
variability in acquisition and analysis), which is more representative for the clinical 
situation, was not tested in the current study. Despite this shortcoming, one would 
expect that the variability in acquisition is lower when using RT3DE as it 
encompasses the whole left ventricle in one dataset in contrast to 2DE. This should 
however be confirmed in another study. Together with the given sample size, all 
conclusions of the present study must be drawn with caution.  
 
Conclusions 
Despite several limitations of RT3DE, our study showed that RT3DE data obtained 
with commercially available equipment provided images with sufficient detail to allow 
easy and fast offline analysis of LV mass. The biplane RT3DE method is a rapid and 
accurate method for clinical assessment of LV hypertrophy, avoiding overestimation 
of LV mass using M-mode which is currently the most applied clinical method for 
determining LV hypertrophy. Multiplane RT3DE might be the preferred method for 
eccentric LV hypertrophy and abnormal shaped ventricles. Biplane RT3DE is as 
accurate as multiplane RT3DE  in patients with concentric LV hypertrophy. Although 
CMR remains the gold standard for assessement of LV hypertrophy, in daily clinical 
practice biplane RT3DE is an attractive tool due to the low costs, easy accessibility, 
and speed of acquisition and analysis. 
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ABSTRACT 
 
Aims 
We aimed to compare velocity-encoded cine cardiovascular magnetic resonance 
(CMR) with an established echocardiographic method for noninvasive measurement 
of aortic valve area (AVA) using the continuity equation.  
 
Methods and Results 
Twenty consecutive young adults with stenotic bicuspid aortic valves were examined 
with CMR and transthoracic echocardiography (TTE). CMR AVA was calculated by 
the continuity equation, dividing stroke volume by the maximum jet velocity-time 
integral (VTIAorta) in the aorta, the stroke volume measured both by ventricular volume 
analysis and by phase contrast velocity mapping at 4 levels (1 subvalvar and 3 
supravalvar). Stroke volumes measured at all levels correlated well with those from 
volumetric analysis. The CMR AVAs calculated using volumetric analysis and VTIAorta 
from jet velocity mapping correlated and agreed well with TTE AVA measurements 
(R2 = 0.83). When CMR AVA was calculated more rapidly using volume flow and 
VTIAorta both measured from the same trans-jet velocity acquisition, R2 was 0.74, with 
a bias and limits of agreement of 0.02 (-0.44, 0.47) cm2.  
 
Conclusions 
Continuity equation calculation of the AVA using CMR velocity mapping, with or 
without ventricular volumetric measurement, correlated and agreed well with the 
comparable and widely accepted TTE approach. 
Quantification of AS using velocity-encoded CMR 
 119
INTRODUCTION 
 
Timing of intervention in adult patients with aortic valve stenosis is largely based on 
the severity of stenosis and the presence of symptoms.1 Currently, transthoracic 
echocardiography (TTE) is the clinical standard for the evaluation of aortic stenosis. 
Standard TTE parameters of aortic stenosis severity include measurement of peak 
aortic velocity (Vmax), mean transaortic pressure gradient, and continuity equation 
aortic valve area (AVA).2 Continuity equation AVA (actually area of the vena 
contracta) is calculated from the principle that volume flow proximal to the valve 
equals volume flow through the narrowed orifice. Measurements of AVA are 
achieved by recording two velocity-time integrals (VTIs) from Doppler velocity 
waveforms acquired proximal and distal to the valve, along with a measurement of 
the cross sectional area of the left ventricular outflow tract (LVOT).3 Several studies 
have shown good concordance of echocardiographic and invasive catheter-based 
estimates of aortic valve area.3-5 
To date, most cardiac magnetic resonance (CMR) studies for the 
quantification of stenotic aortic valves have focused on direct planimetry of the 
stenotic aortic valve,6-12 although the dimensions of CMR voxels relative to the size 
and shape of the stenotic orifices make this approach questionable, especially in 
severe or irregularly shaped stenoses. Only one previous study has investigated the 
use of velocity-encoded cine magnetic resonance (VEC-MR) for calculation of AVA 
by the continuity equation.13 In the standard continuity equation, the stroke volume is 
estimated by multiplying VTILVOT by the cross-sectional LVOT area. But this is not the 
only possible approach by CMR since phase contrast velocity mapping can also 
determine the stroke volume more directly by measuring the volume of flow through 
planes transecting the LVOT, the stenotic jet or the proximal ascending aorta. 
Furthermore, the stroke volume calculated from standard left ventricular analysis can 
be used, as long as there is no significant mitral regurgitation. In theory, it is thus 
possible to determine AVA using the continuity equation [AVA = stroke volume/ 
VTIAorta] with direct input of stroke volumes instead of LVOT areas and VTILVOT. 
The purpose of the present study was to compare CMR measurements of 
AVA using the continuity equation with those calculated by echocardiography using 
the standard continuity equation, the LV stroke volumes being measured by CMR 
either by volumetric analysis or by direct flow measurement at one or more levels.  
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METHODS 
 
Patient Population 
We prospectively recruited 20 consecutive young adult patients (13 men, age 35 ± 4 
years) with aortic stenosis (all bicuspid aortic valves) who visited the outpatient clinic 
for Adult Congenital Heart Disease of the Thoraxcenter from December 1, 2005 until 
September 25, 2006. The only exclusion criteria were those for general CMR 
suitability14 and the presence of a significant mitral regurgitation. The institutional 
review board approved the study protocol, and all patients gave written informed 
consent.  
 
Transthoracic echocardiography 
Patients were imaged with TTE by a single experienced sonographer (JMG), with the 
use of a commercially ultrasound system (Sonos 7500, Philips Medical Systems, 
Best, The Netherlands) with a 2 to 4-MHz, 128-element, phased-array transducer. 
Images were acquired by using standard imaging windows with short breath-holds 
used as needed. Doppler flow data were acquired from the LVOT region in pulsed 
wave mode and from the aortic valve in continuous wave mode. The LVOT diameter 
was measured in the parasternal long-axis view in midsystole at the same level as 
the LVOT pulsed wave Doppler velocity measurement, and then converted to LVOT 
area [LVOT area 
 
= pi*(0.5*LVOT diameter)2]. 
 Peak velocities and VTIs were used to calculate AVA according to the 
continuity equation [AVA = stroke volume/ VTIAorta], where the Doppler-derived stroke 
volume is calculated by [SV = LVOT area * VTILVOT]. Calculations were based on the 
single best representative heartbeat as selected independently by the expert 
sonographer (JMG), blinded to the CMR data.  
 
Cardiovascular magnetic resonance imaging  
A clinical 1.5-Tesla MRI scanner with a dedicated cardiac eight-element phased-
array receiver coil was used for imaging (Signa CV/I, GE Medical Systems, 
Milwaukee, Wisconsin). Electrocardiographic gating was used, with cine images 
acquired during expiratory breath-holds. A standard ventricular function examination 
was performed by initial acquisition of steady-state free-precession (SSFP) cine 
images in standard long axis planes (2- and 4-chamber view, and LVOT view) by one 
experienced CMR cardiologist (RJMvG). The following imaging parameters were 
used: 6-10 s per breath-hold per slice (depending on heart rate); 24 phases per slice 
location; field of view (FOV), 300 x 340 mm2; repetition time, 3.0 to 3.4 ms; echo 
time, 1.5 ms; flip angle (α), 45°; matrix, 224 x 256. To cover the entire left ventricle, 9-
12 short axis slices, 8 mm slice thickness with 2 mm gap, were acquired 
perpendicular to the 4-chamber long-axis view of the left ventricle. 
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Figure 1. (A) Cine CMR image in the 
LVOT plane showing the location of the 
four velocity mapping planes at Levels 0, 
+, ++ and –. From these, both magnitude 
(B and D) and corresponding phase 
images (C and E) were reconstructed. 
Note the stenotic bicuspid aortic valve 
(arrow in B) and the oval LVOT tract 
(arrow in D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the quantitative flow measurements, a retrospectively gated phase contrast 
sequence was used during expiratory breath-holds (<15 seconds), velocity encoded 
through-plane in the slice select gradient direction. The following imaging parameters 
were used: 30 frames/ heartbeat; FOV, 400 x 200 mm2; repetition time, 6.5 ms; echo 
time, 3.1 ms; flip angle (α), 30°; matrix, 256 x 128. The LVOT cine views were used 
to locate four velocity-mapping planes parallel to the aortic valve plane at its greatest 
excursion toward the apex (typically, end-systole). One plane was located at the tips 
of the aortic valve, and the other three were positioned parallel to this, but offset +12, 
+6, and -18 mm (Figure 1). The naming convention adopted for these slices is as 
follows, moving from the aorta towards the LVOT: Level ++, Level +, Level 0, and 
A
C
D
B
+
++
-
0
E
Level -
Level +
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Level -. Typically, the velocity encoding range (VENC) was 2.0 m/s for the LVOT 
(Level -) and 4.0 m/s in the aorta (Levels 0, + and ++). For the aorta, VENC was 
initially 4.0 m/s but was increased a priori if the peak velocity could be predicted to be 
greater, based on the patient’s functional images, for example when they showed 
limited valve opening or a narrow systolic jet. Flow images were re-acquired with a 
higher VENC if velocity aliasing occurred.  
 For the quantitative flow measurements, the data were transmitted to an 
offline image processing station (Cine version 3.4, GE Medical Systems, Milwaukee, 
Wisconsin), and the quantitative flow images were analyzed by an independent 
observer (SCY) unaware of the echocardiographic data. 
 For each of the 4 CMR imaging levels, regions of interest (ROIs) were drawn 
on each of the 30 frames of the cine to include the lumen of the LVOT, the aortic 
valve, or the aorta, depending on slice position. Peak velocities were determined by 
extracting the greatest velocity recorded in any pixel within the ROI across the valve 
flow field. Flow and peak velocity data (Figure 2) were exported to a spreadsheet and 
stroke volumes and VTIs determined. VTIs and stroke volumes were calculated by 
using Simpson’s rule to integrate the peak velocity (cm/s) and aortic flow (ml/s), 
respectively, versus time (ms) during systole. Only the VTI from the level with the 
highest Vmax (VTIAorta) was used for further calculation of AVA and statistical analysis. 
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Figure 2. Aortic flow rate (solid line) and peak aortic velocities (dashed line) measured at level +. The 
area under the curve during systole was used for calculation of stroke volume and VTIAorta, 
respectively. Note the presence of aortic regurgitation characterized by a negative flow.  
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CMR AVA was calculated using the continuity equation [AVA = SV / VTIAorta], the 
stroke volumes being determined by three different methods (Table 1). To investigate 
if stroke volumes measured from the flow images were accurate, these stroke 
volumes were compared with those calculated by the standard left ventricular 
analysis using commercially available software (CAAS-MRV, Pie Medical Imaging, 
Maastricht, The Netherlands) by one independent observer (RJvG) unaware of 
stroke volumes measured from the flow images.   
When using method C (comparable to the method used in ultrasound), there 
are several approaches for the measurement of the LVOT area by CMR. In 
ultrasound the practices norm is to measure the diameter of the LVOT and assume 
the cross-section to be circular. The LVOT diameter was therefore measured from 
the LVOT view at mid systole at Level -, and assumed to be circular for consistency 
with ultrasound. 
According to the American College of Cardiology/ American Heart Association 
(ACC/ AHA) guidelines,1 aortic stenosis with a valve area >1.5 cm2 was considered 
as mild, 1.0 to 1.5 cm2 as moderate, and < 1.0 cm2 as severe.  
 
Table 1. Three different methods of AVA calculation by CMR 
Method Formula AVA calculation 
(SV/ VTIAorta) 
Description SV determination 
A (LVEDV – LVESV) / VTIAorta  SV by LV volumes 
B Flow-time integral aorta / VTIAorta SV by VEC-MR (flow data) at aortic level 
C (LVOT area * VTILVOT) / VTIAorta SV by VEC-MR (peak velocity data) at LVOT level 
AVA = Aortic valve area, LV = Left ventricle, LVEDV = Left ventricular end-diastolic volume, LVESV = 
Left ventricular end-systolic volume, LVOT = Left ventricular outflow tract, SV = Stroke volume, VEC-
MR = Velocity-encoded cine magnetic resonance, VTI = Velocity-time integral  
 
Statistical analysis 
All continuous data are expressed as mean ± SD. The correlation between CMR and 
TTE methods was determined by linear regression analysis, including standard 
errors of the estimate (SEE). Agreement between techniques was evaluated by the 
standard paired t-test. Furthermore, Bland-Altman analysis was used to determine 
the mean of the difference with 95% limits of agreement (±1.96 standard deviation).15 
A two-tailed probability value <0.05 was considered statistically significant. All 
statistical analyses were performed using SPSS software (version 12.0, SPSS Inc., 
Chicago, Illinois).  
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RESULTS 
 
All patients (n=20) completed the imaging protocols without difficulty. The CMR study 
was performed 24 ± 14 days after the echocardiographic data acquisition. There was 
no change in clinical status or medication use between the echocardiographic exam 
and the CMR study. The patient population showed a wide range in severity of aortic 
stenosis, with valve areas measured by TTE from 0.80 to 2.28 cm2 (mean 1.34 ± 
0.45 cm2). Based on TTE, patients were classified as having mild (n=6), moderate 
(n=9), or severe aortic stenosis (n=5). All patients were in sinus rhythm, and 12 
patients (60%) had at least mild aortic regurgitation (maximal 2+, qualitative 
assessment). The left ventricular ejection fraction measured by CMR averaged 59 ± 
9%, ranging from 42% to 74%.  
 
Flow measurements 
Measurements by CMR of peak velocities in the aorta correlated well with those by 
TTE (R2 = 0.88, SEE 0.30 m/s). The correlation was less good between CMR and 
TTE measurement at LVOT level (R2 = 0.60, SEE 0.15 m/s). Bland-Altman analysis 
gave the following mean differences and limits of agreement between CMR and TTE 
peak velocities: –0.11 (-0.68 to 0.46) m/s at aortic level, and 0.12 (-0.17 to 0.41) m/s 
at LVOT level. The highest peak aortic velocity was found at level 0 (at the tips of the 
valve) in 9 patients (45%), and at level + in the remainder (55%).   
 VTIs incorporate more data than peak velocities and are thus more robust. 
CMR data correlated well with TTE data for VTIAorta, and correlated moderately with 
TTE for VTILVOT (Figure 3). Bland-Altman analysis demonstrated a small but 
significant difference between CMR and TTE measurements for VTIAorta and VTILVOT 
with relatively large limits of agreement for VTILVOT. 
 Stroke volumes measured directly from flow acquisitions at all four levels 
showed good correspondence with stroke volume measurements by volumetric 
analysis, with no statistically significant differences (Table 2). The best correlation 
with volumetric measurements (R2 = 0.73, SEE 12.3 ml) was found when flow 
volume was measured at level +, with a bias of 0.3 ml and limits of agreement of –
23.3 to 23.8 ml. Doppler-derived stroke volumes showed only moderate correlation 
(R2 = 0.42, SEE 17.2 ml) with CMR volumetric data, with a nonsignificant bias of 6.2 
ml and limits of agreement of -28.1 to 40.4 ml.  
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Figure 3. Comparisons between CMR and TTE measurements of peak velocity-time integrals (VTI) at 
aortic (A and B) and LVOT (C and D) levels. The VTIAorta measured by CMR correlated well with TTE 
(A), with slight underestimation as shown by the Bland-Altman analysis (B), while correlation was 
poorer for VTILVOT (C), with a slight overestimation by CMR relative to TTE (D).  
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Figure 4. Comparisons between CMR (method B) and TTE measurements of aortic valve areas 
(AVA). For the CMR measurements, using the modified continuity equation, the stroke volumes and 
VTIs were measured from the same CMR velocity map at the level (0 or +), which was found to yield 
the highest peak velocity.  
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Table 2. Comparison of stroke volume measurements by VEC-MR at each of the four levels to CMR 
ventricular volumetric analysis 
Stroke volume (ml) Linear regression analysis  Bland-Altman analysis 
 R2 SEE Slope Interce
pt 
 Bias Limits of agreement 
Level - 0.64 11.03 0.75 24.6  0.1 -23.0, 23.2 
Level 0 0.65 12.91 0.89 11.1  0.8 -24.2, 25.7 
Level + 0.73 12.31 1.03 -2.7  0.3 -23.3, 23.8 
Level ++ 0.64 16.35 1.10 -8.4  1.5 -29.9, 32.9 
 
 
Table 3. Comparison of AVA calculation by CMR to TTE 
 Linear regression analysis  Bland-Altman analysis 
 R2 SEE Slope Interce
pt 
 Bias Limits of agreement 
Method A 0.83 0.17 0.81 0.25  -0.01 -0.38, 0.36 
Method B 0.74 0.23 0.83 0.25  0.02 -0.44, 0.47 
Method C 0.69 0.36 1.19 0.11  0.37* -0.34, 1.08 
* p<0.001 by paired Student’s t test 
 
AVA measurements 
Table 3 shows linear regression and Bland-Altman comparisons of the four types of 
CMR measurement of AVA that we tried with those by TTE. 
 Figure 4A shows the AVAs measured by CMR, with stroke volume and jet 
velocity measurements derived from the same velocity-encoded acquisition (method 
B), plotted against the TTE AVA measurements for all 20 patients. The Bland-Altman 
plot shows a mean bias, CMR-TTE, of only 0.02 cm2 with relatively small limits of 
agreements (Figure 4B).  
Measurements of AVA by the standard continuity equation using CMR 
(method C), assuming a circular LVOT, were larger than by TTE, despite a good 
correlation (bias = 0.37 cm2, p = 0.04, R2 = 0.69, SEE 0.36 cm2).  
 
 
DISCUSSION 
 
In routine clinical practice, TTE has become the accepted standard for evaluation of 
aortic valve stenosis, as it is non-invasive, readily available, fast, and can be 
performed at reasonable cost. The echocardiographic assessment includes 
measurement of peak aortic velocity and calculation of continuity equation AVA. 
Peak velocities, however, are dependent on the volume flow rate, overestimating the 
severity of stenosis when flow is elevated, as in the presence of aortic regurgitation, 
or underestimating the severity of stenosis if flow is reduced, i.e., when there is left 
ventricular systolic dysfunction or mitral regurgitation. Calculation of AVA by the 
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continuity equation has the advantage of taking the flow rate into account. 
Echocardiographic measurements have prognostic value as most studies of 
outcomes have used echocardiographic indices.16-18 In most patients the 
echocardiographic study is adequate for the assessment of stenosis, although in 
certain situations, TTE may not be reliable due to poor acoustic windows, 
calcification of the aortic valve limiting accurate measurements of LVOT diameter, 
eccentric jets (especially in patients with congenital aortic stenosis), and inaccurate 
jet localization. Where echocardiographic results are inconclusive, a comparable 
investigation by CMR for congenital or acquired valvular heart disease would be 
valuable. There may also be cases where CMR is chosen anyway for the 
investigation of additional congenital or acquired cardiovascular pathology. 
Most CMR studies for the quantification of stenotic aortic valves have focused 
on direct planimetry of the stenotic aortic valve or jet area, and they have shown 
varied although generally acceptable results.6-12 However, our clinical experience 
regarding the accuracy of CMR planimetry is not consistent, there being cases where 
the borders of the orifice, or rather the jet, remain unclear. This is not surprising given 
the typical CMR slice thicknesses of 5mm or more, relative large pixel dimensions 
compared to jet area, and the splayed or fragmented nature of some post stenotic 
jets. There is also potential for error due to misplacement of the slice due to motion of 
the valve or inconsistency in the position of breath holds. It is also unclear how signal 
loss due to parajet shear and turbulence effects edge discrimination.  
The use of velocity encoding to determine the peak VTI within a jet may be 
less subject to these limitations because only the voxel or voxels located fully within 
the core of the jet are required for determination of the peak velocity and peak VTI, 
and the jet core will usually extend 10 mm or more beyond the orifice rendering exact 
plane position less crucial. Furthermore, voxels that span the boundaries of the jet or 
vessel lumen do contribute to volume flow measurements, but, theoretically at least, 
partial volume averaging in these voxels should matter less when flow (spatial mean 
of velocity x area for each phase of the cycle) rather than jet area is the subject of 
measurement. This appears to have been the case as the cardiac outputs derived 
from our CMR flow measurements correlated and agreed well with those by CMR 
ventricular volumetric analysis in our study population, where no patient had 
significant mitral regurgitation. Furthermore, although much reluctance exists to 
measure stroke volume at the level of the highest recorded velocity, the correlation 
and agreement were as good if not better when stroke volume was measured at this 
level, presumably at or close to the vena contracta. This may be explained by the 
relatively laminar flow within the jet at this level, rather than the convergent flow 
upstream or the divergent and turbulent flow downstream. However, it is important to 
realize that our patient cohort did not include patients with peak velocities >5.0 m/s. 
At high values phase contrast CMR underestimate velocity (and therefore flow),13 
which is suggested to be due to intra-voxel dephasing characterized by signal loss in 
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the magnitude image. Echo time minimization is essential to reduce error. Other 
problems associated with CMR velocity data are ghosting artifacts, and movement of 
the aortic valve during contraction.  
In our comparative study, CMR results correlated and agreed well with TTE 
with respect to aortic jet velocity data (i.e. peak velocities and VTIs) and continuity 
equation AVAs based on volumetric (method A) or aortic flow measurement (method 
B) of stroke volumes. Previously, Caruthers et al.13 have shown that CMR correlated 
well with TTE when the standard continuity equation (method C) was used (R2 = 
0.69), by means of the identified best approach), which was confirmed by our study. 
The present study is, to our knowledge, the first to demonstrate the usefulness and 
relative advantage of aortic flow measurement of stroke volumes (method B) in 
determining the continuity equation AVA by CMR. This method is easier to use than 
the method previously proposed by Caruthers et al., and both are equally accurate.13  
The continuity equation AVA using volumetric analysis has been previously proposed 
for ultrasound (not for CMR) by Dumont et al.,19 demonstrating an additive value of 
the method, especially in patients with LVOT flow acceleration. Furthermore, Haghi 
et al.20,21 have shown that a hybrid approach, combining stroke volume measured by 
volumetric CMR data and continuous-wave Doppler data by TTE, for determining 
continuity equation AVA using the modified continuity equation correlates well with 
TTE. However, both studies determined stroke volume by the difference between 
end-diastolic and end-systolic volumes. This method could be incorrect when 
associated mitral regurgitation is present, whereas the measurements of aortic flow 
avoid this limitation. Another advantage of aortic flow measurement is that it is easier 
and faster to analyze than ventricular volumes measured from multiple short axis 
cine acquisitions. Our findings showed that estimates of stroke volumes were 
accurate at all 4 levels, and that the highest peak aortic velocities were acquired at 2 
levels (level 0 or +). Therefore, using the modified continuity equation, only 2 flow 
velocity maps will be necessary to estimate AVA. 
There are several reasons why the modified continuity equation (method A or 
B) is theoretically preferable to the standard continuity equation (method C) when 
using CMR. First, reliable measurements of LVOT peak velocity and area are needed 
for method C. This represents a potential source of error, in part because of the 
converging boundaries and ovoid cross section of the outflow tract. Waters et al.22 
have shown that VTI measurements at different levels in the post stenotic jet were 
comparable, indicating relative insensitivity to the position of the imaging plane in the 
aorta. In the LVOT, however, measurements were position-dependent, observing 
higher values when the image plane was close to the valve, which would explain the 
lower correlation between CMR and ultrasound measurements of LVOT velocities 
and VTIs in our study. Secondly, the assumption that the LVOT area is circular is 
incorrect (see Figure 1D). Baumgartner et al.23 have shown that by using the 
standard continuity equation and assuming a circular LVOT, AVA is significantly 
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underestimated by TTE compared to cardiac catheterization using the Gorlin formula. 
By using direct planimetry of the LVOT by TTE, results were more consistent with 
invasive data. By using method A or B, no assumptions regarding stroke volumes are 
required and the problems associated with determination of LVOT velocity and area 
are avoided. In spite of the limitations of the standard continuity equation used by 
TTE, however, we found relatively good correlation and agreement between AVAs 
determined by this approach and by CMR using the modified continuity equation. No 
clear explanation exists for this finding. 
 
Study limitations 
First, our study lacks a reliable gold standard because the accuracy of the results 
obtained by TTE remains uncertain. More data on the correlation between the 
described methods and invasive catheterization data (using the Gorlin formula) and 
other imaging modalities (for example direct planimetry by CT or transesophageal 
echocardiography) would be valuable.  
Second, we studied a relatively selected patient population of young adults 
with congenital aortic stenosis. However, the approach used should also be 
applicable to older patients with degenerative aortic stenosis in whom calcification is 
unlikely to compromise stroke volume and VTI measurements as much as it does 
planimetric approaches. Third, our study protocol did not include repeated 
measurements of one patient, therefore no reproducibility data are available. Finally, 
due to the small sample size, all conclusions of the present study must be drawn with 
caution.  
 
Conclusions 
We conclude that the use of the modified continuity equation for determining AVA by 
velocity-encoded CMR is feasible, simple and compares well with the established 
echocardiographic approach in patients with stenotic bicuspid aortic valves, providing 
an attractive alternative non-invasive approach to the quantification of aortic stenosis 
severity.  
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ABSTRACT 
 
A search of peer-reviewed literature was conducted to identify reports that provide 
data on complications associated with pregnancy in women with structural congenital 
heart disease. This review describes the outcome of 2491 pregnancies, including 377 
miscarriages (15%) and 114 elective abortions (5%). Important cardiac complications 
were seen in 11% of the pregnancies. Obstetric complications do not appear to be 
more prevalent. In complex CHD, premature delivery rates are high and more 
children are small for gestational age. The offspring mortality was high throughout the 
spectrum and related to the relatively high rate of premature delivery and recurrence 
of congenital heart disease. 
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INTRODUCTION 
 
Progress in the fields of diagnostic techniques and surgical intervention has 
dramatically improved long-term outcome in congenital heart disease. As a 
consequence, most patients with congenital cardiac malformations reach 
childbearing age, and many of these women wish to become pregnant. Pregnancy 
itself is a circulatory burden, primarily due to volume loading, which has a significant 
impact even on a healthy women’s life. In the face of residual lesions or sequelae 
after correction or an uncorrected maternal congenital heart defect this burden may 
have deleterious effects on the health of both the mother and her offspring.  
 To provide an accurate and contemporary overview of the cardiac, obstetric 
and neonatal complications during pregnancies in women with congenital heart 
disease, a literature review was conducted. 
 
 
METHODS 
 
A systematic search of peer-reviewed literature using PubMed, MEDLINE and the 
Cochrane Library databases was performed. Predefined limits were: a) date of 
publication after January 1st 1985 for reasons of contemporaneous applicability, b) 
the main body of text of the manuscript needed to be in English, German or French 
to reduce misinterpretation, c) the reported complications (reported in methods or in 
the results section) needed to be traceable to the patient’s primary congenital heart 
disease, e) the number of completed (not aborted or miscarried) pregnancies for the 
primary CHD category needed to be available, f) reviews and case reports 
describing ≤1 completed pregnancy were excluded. The search was performed 
separately by two independent researchers (W.D. and W.L). 
 For the present review the baseline primary congenital heart disease, the number 
of completed pregnancies, miscarriages and therapeutic abortions were recorded. In 
addition, the following complications were recorded for each completed pregnancy. 
 Cardiac complications: reported clinically significant (“requiring treatment”) 
episodes of arrhythmias (including origin and type of arrhythmia) or heart failure; 
cardiovascular events (myocardial infarction, cardiovascular mortality and/or 
cerebrovascular accidents), endocarditis (including first 6 months postpartum). 
 Obstetric complications: pregnancy induced hypertension; preeclampsia; 
eclampsia; Haemolysis Elevated Liver enzymes Low Platelets (HELLP) syndrome; 
thrombo-embolic events (confirmed deep venous thrombosis or pulmonary 
embolus); premature rupture of membranes (PROM); premature labor (< 37 weeks 
gestation); postpartum hemorrhage.  
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 Offspring complications: premature birth (delivery <37 weeks); small-for-
gestational-age birth weight (<10th percentile); fetal demise (intra-uterine death ≥ 20 
weeks of gestation); and / or perinatal mortality (death within the first year of life). 
 The used query consisted of: congenital heart disease (congenital heart disease 
(CHD) , atrial septal defect (ASD), atrioventricular septal defect (AVSD), ventricular 
septal defect (VSD), aortic stenosis (AOS), aortic coarctation, pulmonary stenosis 
(PS), pulmonary atresia (PA), tetralogy of Fallot (TOF), transposition of the great 
arteries / vessels (TGA), Ebstein’s, cyanotic heart disease, Eisenmenger and 
Fontan) followed by: AND (pregnancy OR delivery). Abstracts of the identified 
articles were read, based on this information the eligible articles were identified. 
Subsequently, full-text papers were ordered or downloaded. If a report could not be 
ordered through our library, attempts were made to contact the authors. Additional 
reports were found through cross-reading of the reference lists of the eligible articles. 
The available reports were independently read by two researchers (W.D. and W.L.) 
and classified according to the above-mentioned criteria. When discrepancies were 
discovered between the two researchers, a third independent adult congenital 
cardiologist was asked to interpret the data. This third party then decided how the 
data should be interpreted. Efforts were made to filter out duplicates; publications 
from the same institution were checked for the period of data collection. The format 
of the review was structured and analyses were performed according to the 
Cochrane guidelines. 
 
 
RESULTS 
 
The literature search was performed between November 1st 2005 and October 1st 
2006. Searching the Cochrane Library database no reviews were found. Systematic 
literature search of PubMed and MEDLINE retrieved 48 different mainly retrospective 
publications, describing 2491 pregnancies, including 377 miscarriages (15%) and 
114 (5%) elective abortions.1-48 It proved impossible to subdivide complications 
based on surgical status prior to pregnancy for every CHD category separately. 
Patients with TGA had undergone atrial correction prior to pregnancy, except for 3 
arterial switch patients. Patients with TOF all had undergone definitive repair.  All 
PAVSD patients had received bi-ventricular repair. The remaining uncorrected or 
palliated TGA, TOF and PAVSD patients were incorporated in the category (palliated 
or uncorrected) cyanotic heart disease. The other CHD cohorts contain a mix of (un-) 
corrected patients.  
 Figure 1 provides an overview of the distribution of gestations (completed, 
miscarriage and elective abortions) per congenital heart disease. Figure 2 shows the 
occurrence of the most important cardiac, obstetric and offspring complications 
recorded in the reviewed literature during completed (not aborted or miscarried) 
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pregnancies organised per CHD. Table 1-3 provides detailed information on each 
complications. 
 The most frequently encountered cardiac complication (Table 1) was clinically 
significant heart failure (4.8%). Especially patients with complex CHD: Eisenmenger, 
other cyanotic heart disease and PAVSD appeared to be at risk. Arrhythmias 
complicated 70 (4.5%) of the completed pregnancies. Most of the encountered 
arrhythmias were supraventricular tachyarrhythmias (n = 48). Ventricular 
tachyarrhythmias were reported in 9, brady-arrhythmias in 3, WPW syndrome in one 
patient, while in 9 pregnancies the exact nature of the arrhythmia was not reported. 
Cardiovascular events (myocardial infarction, stroke and cardiovascular mortality) 
were primarily documented in Eisenmenger patients and those with palliated or 
uncorrected cyanotic heart disease. 
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Figure 1. Distribution of miscarriages, completed pregnancies and elective abortions for each 
congenital heart disease separately and the overall rates. On the right hand sided also the expected 
rates in healthy women are depicted.  
 Abbreviations: ASD = Atrial septal defect, AVSD = atrioventricular septal defects, AOS = aortic 
stenosis, CC-TGA = congenital corrected transposition of the great arteries, CHD = congenital heart 
disease, CoA = aortic coarctation, Ebstein = Ebstein’s anomaly, Eisenmenger = Eisenmenger 
syndrome, Fontan = patients after Fontan repair, PAVSD = pulmonary atresia with ventricular septal 
defects, PS = pulmonary valve stenosis, TGA = complete transposition of the great arteries, TOF = 
tetralogy of Fallot, VSD = ventricular septal defect.  
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Figure 2. Overview of the most important complications encountered during pregnancy in women with 
structural congenital heart disease for each congenital heart disease separately and the overall rates. 
On the right hand sided also the expected rates in healthy women are depicted. 
 Abbreviations as Figure 1. 
 
 
  Obstetric complications (Table 2) were less well documented. In general, 
hypertensive disorders related to pregnancy do not appear to be more prevalent for 
the whole CHD cohort. Eclampsia and HELLP syndrome were reported in 
respectively 3 (PS n=2 and PAVSD n=1) and 2 (PAVSD and TGA) of the 904 
completed pregnancies (not depicted in Table 2). Especially the incidence of 
preeclampsia and eclampsia in patients with TGA, PS, aortic coarctation and PAVSD 
exceeded the expected rate of 2-3%. Thrombo-embolic events, predominantly 
pulmonary embolisms, were observed in approximately 2% of the pregnancies. 
 Foetal complications (Table 3) were incorporated more frequently in the 
methodology of the reviewed articles. Importantly overall offspring mortality was 4%, 
which could at least in part be attributed to the relatively high overall premature birth 
rate (16%) and the recurrence of CHD. The recurrence rate depended on the type of 
CHD and ranged between 0.6% (TGA) and 8% (AVSD). 
 
 
DISCUSSION 
 
The present systematic review described the outcome of 2491 pregnancies in 
women with different types of congenital heart disease. Most pregnancies were 
successful, though complications were observed. Arrhythmias, heart failure, 
cardiovascular events, rarely seen in the healthy general population, were 
documented during 11% of completed pregnancies. Obstetric complications, on the 
other hand, do not appear to be more prevalent, except for hypertensive disorders 
and thrombo-embolic events. Offspring mortality was high (4% versus < 1% in the 
general population), and particularly occurred in CHD cohorts with high rates of 
premature delivery and/ or recurrence of congenital heart disease. 
 Supraventricular and ventricular arrhythmias requiring treatment are rarely seen 
during pregnancy in healthy women.51,52 Potential factors that promote the 
development of arrhythmias are the additional circulatory burden of pregnancy and 
local electrophysiological effects, more specifically the extra volume load and the 
enhanced adrenergic receptor excitability mediated by estrogens and 
progesterone.51,52 Structural cardiac defects or residual defects after repair may 
contribute to the occurrence of clinically relevant arrhythmias. Most recorded 
arrhythmias were supraventricular in origin. In particular patients with TGA, Fontan 
repair and atrioventricular septal defects appeared at risk. Surgical scar tissue 
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 formation may play a role in the pathophysiological mechanism. In the TGA 
population most patients had undergone atrial repair (Mustard or Senning) with baffle 
formation. Patients after Fontan repair, especially after atrio-pulmonary anastomosis 
and atrio-ventricular connection, were at risk for atrial tachyarrhythmias due to the 
exposure of right atrial tissue to higher than normal pressures. In patients with 
AVSD, macro-re-entrant tachycardias are well known complications after repair and 
also (residual) left atrioventricular regurgitation may play a role in the development of 
arrhythmias.  
 In the healthy general population heart failure needing medical intervention is 
uncommon and mainly related to the development of peripartum cardiomyopathy.53 
In our review, patients with complex CHD (in particular patients with cyanotic heart 
disease, Eisenmenger syndrome and PAVSD) appeared prone to develop heart 
failure. Overall, clinically significant (“needing medical intervention”) heart failure was 
observed in almost 5% of the completed pregnancies. Most episodes resolved 
without sequelae using medication. It needs to be addressed, however, that the 
given heart failure rate may be an underestimation considering that early heart 
failure was an important reason for elective abortion. 
 Cardiovascular events (myocardial infarction, cerebrovascular accidents and 
mortality) are observed during 1:50 pregnancies. Mortality was particularly high in 
patients with Eisenmenger syndrome. Therefore, we still advocate that pregnancy 
should be discouraged in these patients. It needs to be taken into account, however 
that mortality is likely to be underestimated as most research is performed in 
retrospective or so-called “survivor” cohorts. Therefore, we have not described 
mortality as a separate complication. For accurate estimations of serious and 
relatively rare complications a large-scale (multi-centre and international) prospective 
registration remains necessary. 
 With regard to the occurrence of endocarditis, it is striking that patients with 
simple secundum ASD appear to be at greater risk. Details on the site of infection, 
the causative organism and circumstances including the presence of concomitant 
minor (anatomical or physiologic) abnormalities which may increase the risk of 
endocarditis are not described. This needs to be further investigated. 
 Pregnancy related hypertensive disorders were documented in 8.7% of the 
pregnancies which is comparable to the 8% found in the general population.54 In four 
CHD categories, however, the incidence of hypertensive disorders appears 
substantially higher. In patients with AOS, PS, Aortic coarctation, and TGA, 
hypertensive disorders occurred in respectively 12.8, 14.3, 16.0 and 16.3 percent of 
completed pregnancies. Preeclampsia is a relatively rare condition with a reported 
incidence in the developed countries between 2-3%; eclampsia is even rarer with 
estimated incidences of 4-5 cases per 10.000 live births. Both entities are generally 
associated with substantial maternal and neonatal morbidity.55,56 Preeclampsia 
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appeared to cluster in patients with aortic coarctation, PS, PAVSD and TGA. Several 
mechanisms, either solitary or combined, may be hypothesized. First, activation of 
neurohormonal pathways in patients with congenital heart disease may alter 
vascular remodeling associated with pregnancy induced hypertension and (pre-) 
eclampsia. Second, endothelial dysfunction is present in patients with congenital 
heart disease, and last oxidative stress may interact with the pathophysiological 
mechanisms behind pregnancy induced hypertension and (pre-) eclampsia. 
 During pregnancy and postpartum period, patients are at risk for thrombo-embolic 
complications due to the presence of all three components of Virchow's triad: venous 
stasis, endothelial injury, and a hypercoagulable state. Nevertheless, thrombo 
embolic events are normally seen only once per 1000 to 2000 pregnancies.57,58 
Fifteen thrombo-embolic complications occurred, which suggests that the incidence 
in women with CHD (1:50) is substantially increased compared with the general 
population. Importantly, associated disorders, e.g. the presence of inherited 
thrombophilia, malignancy, systemic disease, recent surgery or trauma, disease 
needing hormonal replacement therapy, or bone marrow diseases, was insufficiently 
documented. This finding merits further investigation. 
 Premature birth rate (16%) also appeared higher than that generally reported in 
the industrialised world (10-12%). In patients with more complex CHD, including 
Ebstein, TGA, PAVSD, Fontan, Cyanotic CHD and Eisenmenger, the preterm 
delivering rates range between 22 and 65%. Premature labor seems to play an 
important role in the higher incidence of premature birth in these CHD categories. 
Several premature deliveries were iatrogenic in nature, which may imply a greater 
tendency of the attending gynaecologist to intervene in women with congenital heart 
disease. A high incidence of premature rupture of membranes may have played a 
role in patients with TGA and Fontan. Spontaneous premature deliveries occurred 
frequently prior to 34 weeks of gestation, which has important clinical repercussions.  
 Small for gestational age children were documented in the same types of CHD as 
premature delivery, except for patients with Fontan repair. In Fontan, premature 
deliveries could mainly be attributed to the excessive occurrence of premature 
rupture of membranes. In the other types of CHD, a similar pathophysiological 
mechanism may explain the higher incidence of premature delivery as well as the 
small for gestational age children. In both complications, placental insufficiency plays 
a pivotal role. Investigation of the foetal-placental circulation in these women is 
necessary. 
 An important finding of the present systematic review is that children of women 
with congenital heart disease are at higher risk for foetal and perinatal mortality. In 
the industrialised world foetal and perinatal mortality is below 1%. Therefore, the 
chance of offspring mortality is on average increased by 4 times. Importantly in the 
types of CHD with high rates of premature delivery and/ or CHD recurrence this risk 
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was more profound, ranging up to 27.7% in women with Eisenmenger syndrome. 
The recurrence risks are in agreement with the larger genetic cohort studies. 
 Several limitations of the present systematic review need to be discussed. The 
quality of the review depends on the design of the articles included; the study 
designs ranged from prospectively included cohort studies to case series reporting 2 
completed pregnancies, therefore the results need to be judged with caution. 
Moreover, publication bias is an important factor, especially in case series. Selection 
bias is introduced by excluding articles based on earlier mentioned criteria. Under-
reporting of complications may also be an important problem. 
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ABSTRACT 
 
Background 
Pregnancy in women with congenital aortic stenosis (AS) is associated with 
increased cardiac complications. Data on non-cardiac complications are limited, and 
this information is crucial for prenatal counseling and perinatal care. The aim of this 
study was to present the maternal and perinatal outcome of pregnancy in women 
with congenital AS. 
 
Methods 
By review of the Dutch CONCOR national registry and a local Belgian tertiary care 
centre database, 35 women with congenital AS with a history of completed 
pregnancy before aortic valve replacement were enrolled in this study. Medical 
history and maternal and perinatal outcome were determined. 
 
Results 
Thirty-five women had 58 pregnancies resulting in 53 successful pregnancies, three 
miscarriages, and two abortions. The most serious cardiac complications were heart 
failure (n=2, 3.8%) and atrial arrhythmia (n=3, 5.7%). Although cardiac complications 
were present (9.4%), obstetric (22.6%) and perinatal (24.5%) complications were 
observed more often. A total of six pregnancies (11.3%) were complicated by 
hypertension-related disorders, including one case of eclampsia. Furthermore, 7 
premature births (13.2%) and 7 small-for-gestational-age births (13.2%) were 
encountered. Pregnancy in women with severe AS was characterized by an 
increased incidence of heart failure and premature labour, and shorter pregnancy 
duration. Older women (>30 years) were at increased risk of perinatal events (odds 
ratio 4.38, 95% confidence interval 1.02 to 18.81).  
 
Conclusions 
Pregnancy is generally well tolerated in women with congenital AS. Importantly, an 
excess of obstetric and perinatal complications was found, requiring more meticulous 
attention. 
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INTRODUCTION 
 
Congenital AS has an incidence of 5% in patients with a congenital heart disease, 
and is more frequently encountered in males. The stenotic lesion can occur at 
valvular, subvalvular, or supravalvular level.1 In older series, pregnancy in women 
with congenital AS is associated with a high maternal mortality rate (15-20%).2-4 
Earlier diagnosis and treatment of stenosis (e.g. balloon aortic valvotomy) has 
resulted in more women with congenital AS reaching childbearing age in relatively 
good condition. Recent pregnancy reports in AS patients (less severe patients 
compared to the older studies) are encouraging, showing a favorable pregnancy 
outcome with low maternal mortality.5-7 The current guidelines consider women with 
severe AS high-risk patients for pregnancy.8,9 
Previous studies focused mainly on cardiac complications,2-7 and only limited 
information exists on obstetric and perinatal complications in women with congenital 
AS. In these women, reduced placental perfusion may occur secondary to the fixed 
stenosis, resulting in an increased incidence of gestational disorders and other signs 
of inadequate placental perfusion (e.g. hypertensive disorders), as has been found in 
women with other left heart obstructive lesions, like unrepaired aortic coarctation.10 
The objective of the present study was to identify the magnitude of pregnancy 
risks in women with congenital AS without previous aortic valve replacement, with 
emphasis on obstetric and perinatal complications.  
 
 
METHODS 
 
Study population 
In 2005, the Dutch CONCOR registry (CONgenital CORvitia; www.concor.net) and a 
local Belgian tertiary care centre database were reviewed for all women with a main 
diagnosis of congenital AS (age 18-45 years), excluding women with concomitant 
aortic coarctation (Figure 1). Congenital AS was defined as stenosis secondary to 
bicuspid aortic valves, subvalvular, or supravalvular lesions. All women were followed 
in one of the seven participating tertiary academic centres. The institutional review 
board or ethics committee at each participating centres approved the protocol. 
Overall, 117 of the 154 women provided written informed consent and were enrolled 
in this study (participation rate 76.0%). The final study population consisted of 35 
women with ≥ 1 completed pregnancy (> 20 weeks gestation) without previous aortic 
valve replacement. 
 
Study protocol 
A detailed structured questionnaire was obtained from each patient by telephone. 
The results of the questionnaire were compared with and completed by obstetrical 
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Women with congenital AS of childbearing age
(n=154)
Women who provided written informed consent
(n=117)
Women without 
completed pregnancy 
(n=73)
Women with a
completed pregnancy 
after AVR
(n=9) 
Final study population:
Women with 
a completed pregnancy 
without previous AVR
(n=35)
 
Figure 1. Flow chart of enrollment of the final study population. AVR = aortic valve replacement 
 
data from medical records. Data were collected on congenital cardiovascular 
anomalies, previous surgical/ interventional procedures, medical history, age at 
menarche, medication, miscarriages (spontaneous foetal loss before 20 weeks 
gestation), and elective abortions. 
Detailed information concerning each completed pregnancy (> 20 weeks 
gestation) was recorded: parity status, New York Heart Association (NYHA) 
functional class, mode of delivery, use of cigarettes, use of alcohol, use of drugs, use 
of medication, and physical examination. Transthoracic echocardiographic 
assessment of left ventricular systolic function during the antepartum (baseline) and 
postpartum (within two years after delivery) period was recorded, including Doppler 
quantitation of severity of AS and aortic regurgitation. Aortic stenosis severity was 
graded mild (<3.0 m/s), moderate (3.0-4.0 m/s), or severe (>4.0 m/s).8 Aortic 
regurgitation severity was graded based on the jet diameter seen with colour flow 
Doppler.11 
 Cardiac, obstetric, and perinatal events were classified according to 
predefined criteria. Cardiac complications: symptomatic documented arrhythmia or 
symptomatic heart failure requiring treatment (according to the attending 
cardiologist); persistent NYHA functional class deterioration (>1 year postpartum); 
syncope; thrombo-embolic complications; aortic dissection; and/or endocarditis. 
Obstetric complications: pregnancy-induced hypertension (PIH, new onset 
hypertension after ≥20 weeks of gestation: blood pressure >140 mmHg systolic or 
>90 mmHg diastolic without significant proteinuria); preeclampsia (PIH criteria and 
>0.3 gram proteinuria in 24-hour urine sample); eclampsia (preeclampsia with grand 
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mal seizures); Haemolysis Elevated Liver Enzymes Low Platelets (HELLP) 
syndrome. Premature rupture of membranes (membrane rupture before the onset of 
uterine contractions); premature labour (spontaneous onset of labour <37 weeks 
gestation); postpartum haemorrhage (vaginal delivery >500ml, cesarean delivery 
>1000 ml, documented by gynecologist and requiring transfusion); and placental 
abruption. Perinatal complications: premature birth (delivery <37 weeks of gestation); 
small-for-gestational-age birth weight (<10th percentile); foetal demise (intra-uterine 
death ≥20 weeks of gestation); perinatal death (within the first month after birth); 
and/or recurrence of CHD. 
 
Statistical analysis 
A Clintrial data-entry program was used to record information and was converted to 
SPSS (version 13.0, SPSS Inc., Chicago, Illinois) for statistical analysis. Descriptive 
statistics for nominal data were expressed in absolute numbers and percentages. 
Mean values and standard deviations were presented for normally distributed 
continuous variables. For non-normal distributed continuous variables median and 
ranges were computed. Comparison of continuous variables between groups 
(repaired versus unrepaired) was made by unpaired Student’s t-tests or the Mann-
Whitney U test. When comparing frequencies, we applied the χ2 test or Fisher exact 
test, where applicable.  
Univariable logistic regression analysis was performed to identify predictors of 
pregnancy outcome, defined by a composite outcome of cardiac events (i.e. heart 
failure, transient ischemic attack, arrhythmias), obstetric events (i.e. PIH, 
preeclampsia, eclampsia, premature labour, postpartum haemorrhage; placental 
abruption; premature rupture of membranes), or perinatal events (i.e. premature 
delivery and small-for-gestational-age births). The following six baseline variables 
were assessed: severe AS, prior AS repair, history of previous completed pregnancy, 
smoking before pregnancy, smoking during pregnancy, and maternal age at 
pregnancy ≥ 30 years. Odds ratios (95% confidence intervals) are presented. Multi-
variable analysis was not attempted because of the low number of events. All tests 
were two-tailed and a P-value <0.05 was considered statistically significant. 
 
 
RESULTS 
 
Characteristics at inclusion of the enrolled 35 women with congenital AS are 
summarized in Table 1. A total of 58 pregnancies were documented, including 53 
completed pregnancies, 3 spontaneous miscarriages, and 2 elective abortions. Two 
miscarriages occurred early (<12 weeks), and all 3 miscarriages remained 
unexplained. Both elective abortions were performed due to AS-related maternal risk,  
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Table 1. Characteristics at inclusion of 35 women with congenital AS and a history of 
completed pregnancy 
Characteristic  
Number of women 35 
Age at menarche (yrs), mean ± SD 12.5 ± 1.4 
Age at first completed pregnancy (yrs), mean ± SD 25.7 ± 4.6 
Age at inclusion (yrs), mean ± SD 35.6 ± 6.8 
Women with repair 27 (77.1) 
Aortic valvotomy 8 (22.9) 
Subaortic fibromuscular shelf resection 7 (20.0) 
Surgical correction supravalvular AS 2 (5.7) 
Aortic valve replacement* 14 (40.0) 
AS classification  
Valvular 24 (68.6) 
Subvalvular  9 (25.7) 
Supravalvular 2 (5.7) 
Pregnancies  
Completed pregnancies 53 (91.4) 
Spontaneous miscarriages 3 (5.2) 
Elective abortions 2 (3.4) 
Data are presented as n (%), unless indicated otherwise 
*All aortic valve replacements were performed after pregnancy 
 
however, both women delivered children later in life. All women became pregnant 
spontaneously. Eight (22.2%) women had been advised against pregnancy because 
of perceived maternal and foetal risk. In the present study, we focus on the 53 
completed pregnancies (between December 1975 and July 2005) in the 35 women. 
Nineteen women had one child, 14 had two, and three had three children. There 
were no twin pregnancies. The mean aortic jet velocity was 3.3 ± 0.9 m/s (range 1.7 
to 5.3 m/s) before pregnancy, and all women had good systolic left ventricular 
function. Baseline characteristics for all completed pregnancies are outlined in Table 
2, and Table 3 describes cardiac, obstetric, and perinatal complications per 
pregnancy.  
 
Cardiac complications  
Important cardiovascular events (i.e. heart failure, transient ischemic attack, and 
arrhythmias) complicated 5 of 53 pregnancies (9.4%). Heart failure requiring 
treatment occurred during two pregnancies, both in women with severe AS. One 
woman with severe valvular AS required aortic valve replacement with a 
bioprosthesis at the end of her first trimester. Balloon aortic valvuloplasty was not 
possible due to severe calcification of her aortic valve. Her further pregnancy and 
delivery was uncomplicated and a healthy daughter was born at 38 weeks of 
gestation weighing 2965 grams. The second woman known with severe subvalvular 
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AS had an episode of heart failure which responded well to medical treatment (i.e. 
diuretics and digoxin). 
In three pregnancies in women with moderate AS, the observed worsening of NYHA 
class persisted more than 1 year postpartum. Deterioration of aortic valve function 
could be an explanation in two cases. There was an increase in aortic jet velocity 
from 3.7 to 4.7 m/s in one woman, and an increase in regurgitation from moderate to 
severe in the other woman. In the third woman, no specific cause could be identified. 
All three women underwent valve replacement (Ross-procedure) at 6 months, 1.5, 
and 2 years after pregnancy, with improvement of NYHA class thereafter.  
Clinically significant arrhythmias were documented in three pregnancies. A 
woman with subvalvular AS required electrical cardioversion and oral anticoagulation 
for drug-refractory atrial fibrillation. This same woman experienced a transient 
ischemic attack at 34 weeks’ gestation, with complaints of dysartria and diplopia, 
shortly after switching for subcutaneous heparin in contemplation of cesarean 
delivery. The episodes of atrial arrhythmias in two other women were successfully 
treated with digoxin and beta-blockers. Syncope occurred in one other woman during 
the delivery, however, according to the attending physician the event was probably 
related to pain (i.e. vasovagal reaction) rather than her cardiac condition. No 
episodes of aortic dissection or endocarditis were recorded. 
 
Obstetric complications/ interventions  
Six pregnancies (11.3%) were complicated by hypertension-related disorders, which 
included PIH (n=4), pre-eclampsia (n=1), and eclampsia (n=1). The woman with 
eclampsia was comatose for three days. Two women with placental abruptions had 
no hypertensive disorders during pregnancy, and it must be noted that one of them 
was known with protein S deficiency. Other important obstetric complications 
including premature labour (7.5%), post-partum haemorrhage (1,9%), and premature 
rupture of membranes (1,9%) were not more prevalent compared to the general 
population (7%, 2% and 8%, respectively). Reasons to induce labour were: perceived 
maternal risk (n=9), hypertensive-related disorder (n=3), post-maturity (n=3), foetal 
indication (n=3), and premature rupture of membranes (n=1). No episodes of HELPP 
syndrome were documented. 
Seven elective cesarean deliveries were performed for: hypertensive related 
disorders (n=3), breech presentation (n=2), placenta previa (n=1), and perceived 
maternal cardiovascular risk (n=1). All seven emergency caesarean deliveries were 
performed for obstetric indications: foetal distress (n=4, decelerations on 
cardiotocography), vacuum-assisted delivery failure (n=2), and failure to progress 
during second stage of labour (n=1). During 43 deliveries (81.1%), antibiotic 
prophylaxis against bacterial endocarditis was administered. 
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Table 2. Baseline characteristics, hospitalizations, and mode of delivery during 53 completed 
pregnancies in 35 women with congenital AS 
 Congenital AS 
 Mild/moderate AS Severe AS Total 
Number of completed pregnancies 41 12 53 
Maternal age at pregnancy (yrs), mean±SD 26.4 ± 4.6 26.5 ± 5.4 26.4 ± 4.7 
Aortic jet velocity (m/s), mean ± SD 3.0 ± 0.7 4.5 ± 0.4 3.3 ± 0.9 
Medical history    
• Valvular AS 29 (70.7) 7 (58.3) 36 (67.9) 
• Subvalvular AS 9 (22.0) 5 (41.7) 14 (26.4) 
• Supravalvular AS 3 (7.3) 0 3 (5.7) 
• Repair before pregnancy 20 (48.8) 4 (33.3) 24 (45.3) 
• Aortic valvotomy 10 (24.4) 2 (16.7) 12 (22.6) 
• Subaortic shelf resection 9 (22.0) 2 (16.7) 11 (20.8) 
• Surgical correction supravalvular AS 3 (7.3) 0 3 (5.6) 
• Smoking before pregnancy 9 (22.0) 3 (25.0) 12 (22.6) 
• Smoking during pregnancy 4 (15.3) 3 (25.0) 7 (18.4) 
Parity status    
• Primiparous 29 (70.7) 6 (50.0) 35 (66.0) 
• Multiparous 12 (29.3) 6 (50.0) 18 (34.0) 
NYHA class before pregnancy*    
• Class I 38 (92.7) 6 (50.0) 44 (83.0) 
• Class II 3 (7.3) 6 (50.0) 9 (17.0) 
All-cause hospitalization 9 (22.0) 2 (16.7) 11 (20.8) 
• Hypertensive disorders 4 (44.4) 0 4 (36.4) 
• Dyspnea 1 (11.1) 2 (100.0) 2 (18.2) 
• Other  4 (44.4) 0 4 (36.4) 
Mode of delivery    
• Elective cesarean delivery 6 (14.6) 1 (8.3) 7 (13.2) 
• Vaginal planned 35 (85.4) 11 (91.7) 46 (86.8) 
•     Induction 15 (36.6) 4 (33.3) 19 (35.8) 
•     Artificial rupture of membranes 18 (43.9) 2 (16.7) 20 (37.7) 
•     Epidural analgesia 11 (31.4) 3 (27.3) 14 (30.4) 
•     Episiotomy 14 (34.1) 4 (33.3) 18 (34.0) 
•     Instrumental-assisted deliveries 10 (24.4) 3 (25.0) 13 (24.5) 
•     Emergency cesarean delivery 7 (17.1) 0 7 (13.2) 
Data are presented as n (%), unless indicated otherwise.  
* P <0.05 
 
Perinatal complications  
There were 53 live births (100%) after a mean pregnancy duration of 38.6 ± 2.5 
weeks (Table 3). A perinatal event occurred in 13 of the 53 pregnancies (24.5%). 
Seven children (13.2%) were born premature (4 due to preterm labour), and there 
were 7 small-for-gestational-age births (13.2%). Of the 53 births, two children (3%)  
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Table 3. Maternal and perinatal outcome during 53 completed pregnancies in 35 women with AS 
 Congenital AS 
 Mild/moderate 
AS 
Severe AS Total 
Number of completed pregnancies 41 12 53 
Cardiac complications    
• Arrhythmias 3 (7.3) 0 3 (5.7) 
• Postpartum persistent NYHA ↓ 3 (7.3) 0 3 (5.7) 
• Heart failure 0 2 (16.7)* 2 (3.8) 
• Transient ischemic attack 1 (2.4) 0 1 (1.9) 
• Syncope 1 (2.4) 0 1 (1.9) 
Obstetric complications    
• Hypertension-related disorders 5 (12.2) 1 (8.3) 6 (11.3) 
• Pregnancy-induced hypertension 3 (7.3) 1 (8.3) 4 (7.5) 
• Pre-eclampsia 1 (2.4) 0 1 (1.9) 
• Eclampsia 1 (2.4) 0 1 (1.9) 
• Premature labour 1 (2.4) 3 (25.0)* 4 (7.5) 
• Placental abruption 1 (2.4) 1 (8.3) 2 (3.8) 
• Post-partum haemorrhage 1 (2.4) 0 1 (1.9) 
• Premature rupture of membranes 1 (2.4) 0 1 (1.9) 
Perinatal outcome    
• Offspring 41 12 53 
• Pregnancy duration (weeks), mean ± 
SD 
39.1 ± 2.1 37.1 ± 3.3* 38.6 ± 2.5 
• Premature delivery (<37 weeks 
gestation) 
4 (9.8) 3 (25.0) 7 (13.2) 
• Infant weight (kg), mean ± SD 3.08 ± 0.58 2.77 ± 0.73 3.01 ± 0.63 
• Small for gestational age (<10th 
percentile) 
6 (14.6) 1 (8.3) 7 (13.2) 
• Recurrence of congenital heart disease 2 (4.9) 0 2 (3.8) 
Data are presented as n (%), unless indicated otherwise. NYHA ↓ = NYHA functional class 
deterioration.  
* P <0.05 
 
from two mothers with supravalvular AS (not related) had recurrence of congenital 
heart disease. Both children had a familial supravalvular AS including peripheral 
pulmonary stenosis, without dysmorphic features reminiscent of Williams-Beuren 
syndrome. No perinatal mortality was documented.  
 
Predictors of pregnancy outcome 
Predictors of pregnancy outcome are depicted in Table 4. Women older than 30 
years were at increased risk of having perinatal events with an odds ratio of 4.38 
(95% CI 1.02 to 18.81). No other baseline variable, including severe aortic stenosis, 
could predict pregnancy outcome when complications were grouped as cardiac, 
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obstetric, or perinatal complications. However, when individual complications were 
analyzed, women with severe AS had more episodes of heart failure (16.7% versus 
0.0%, P <0.05), premature labours (25.0% versus 2.4%, P <0.05), and shorter 
pregnancy durations (37.1 ± 3.3 versus 39.1 ± 2.1 weeks, P <0.05) (Table 3). 
 
Table 4. Predictors of cardiac, obstetric, or perinatal events in women with congenital AS 
Odds ratio (95% confidence interval Baseline characteristic 
Cardiac events 
(n=5, 9.4%) 
Obstetric events 
(n=12, 22.6%) 
Perinatal events 
(n=13, 24.5%) 
Severe AS 2.53 (0.37 – 17.3) 2.06 (0.50 – 8.60) 1.78 (0.43 – 7.28) 
Prior repair of AS 0.27 (0.03 – 2.61) 0.27 (0.03 – 2.61) 2.40 (0.67 – 8.67) 
Previous completed 
pregnancy 
1.33 (0.20 – 8.80) 0.96 (0.25 – 3.77) 2.00 (0.55 – 7.22) 
Smoking before pregnancy 0.84 (0.09 – 8.32) 0.62 (0.12 – 3.32) 0.55 (0.10 – 2.89) 
Smoking during pregnancy 1.13 (0.11 – 11.95) 1.37 (0.22 – 8.66) 1.15 (0.19 – 7.14) 
Maternal age > 30 years 1.08 (0.11 – 10.9) 0.83 (0.15 – 4.53) 4.38 (1.02 – 18.81)* 
Cardiac events (i.e. heart failure, TIA, arrhythmias), obstetric events (i.e. PIH, preeclampsia, 
eclampsia, premature labour, postpartum haemorrhage; placental abruption, premature rupture of 
membranes), perinatal events (i.e. premature delivery, small for gestational age).  
* P <0.05 
 
 
DISCUSSION 
 
This study reports on 53 completed pregnancies (>20 weeks gestation) in 35 women 
with congenital AS without previous aortic valve replacement, which renders it one of 
the largest series thus far. In general, pregnancy was well tolerated, however, major 
cardiac complications (e.g. heart failure) were recorded in women with severe AS. 
Furthermore, older women experienced more perinatal events.  
Cardiovascular physiology changes profoundly during pregnancy. Cardiac 
output increases 30-50% due to increases in both stroke volume and heart rate.12,13 
During labour, cardiac output increases further due to pain and uterine 
contractions.14,15 
The haemodynamic impact of AS is aggravated by the physiological changes 
during pregnancy. Pregnancy in AS patients has been the focus of some reports 
because of concern for development of heart failure and mortality during 
pregnancy.2,4 The review of Lao et al. published in 1993 demonstrated seven deaths 
among 65 women, resulting in a maternal mortality of 11%.3 Based on these data, 
women with significant AS were considered high-risk patients,8,9 and 22.2% of the 
women in the current study have been counseled and advised against pregnancy. In 
patients with severe AS, the stenosis may result in abnormal elevations of left 
ventricular systolic and filling pressures. This, in turn, could precipitate or exacerbate 
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heart failure or ischemia, requiring prompt treatment. The recent study of Hameed et 
al.6 found new onset of congestive heart failure in 5 of the 12 women with AS 
(41.7%). However, in our study, there was a low incidence of heart failure (3.8%), 
which is in agreement with most other available literature.5,7 These differences in the 
occurrence of heart failure can be explained by reporting bias as the first study 
included more women with worse NYHA functional class compared to the present 
study.6 
Clinically documented atrial arrhythmias occurred in 5.7% of pregnancies, 
warranting close attention as one woman with atrial fibrillation suffered a transient 
ischemic attack despite optimal treatment. Our findings regarding cardiac 
complications are in agreement with the CARPREG study,7 where left heart 
obstructive lesion was identified as an important independent risk factor for maternal 
cardiac complications (e.g. pulmonary oedema, arrhythmia, stroke, or cardiac death). 
Although present, severe cardiac complications were relatively infrequent in 
our study. However, obstetric (22.6%) and perinatal (24.5%) complications were 
observed more often. The rate of premature deliveries and small-for-gestational-age 
births (both 13.2%) in our study was higher than reported by the previous study of 
Silverside et al. (8% and 2%, respectively).5 Preterm delivery is of major importance, 
because it is the leading cause of infant morbidity and mortality. 
Hypertension-related disorders were observed slightly more often than 
reported in the general population (11.3% vs. 8%).16 There was one case of 
eclampsia, which is normally a rare condition with a reported incidence in developed 
countries of 4-5 cases per 10.000 live births, and is associated with substantial 
maternal and neonatal morbidity.17 None of the women with hypertensive disorders 
had chronic hypertension, renal disease, antiphospholipid antibody syndrome, 
connective tissue disease or thrombophilia at the time of pregnancy or inclusion. 
Shime et al. reported pregnancy-induced hypertension in 25% of pregnancies in 
women with congenital AS.18 
The higher incidence of hypertension-related disorders and perinatal 
complications may be related to reduced placental perfusion secondary to left heart 
obstruction. Several mechanisms for a reduced placental perfusion may be 
hypothesized. First, an inadequate increase in cardiac output during pregnancy due 
to left heart obstruction may be responsible for abnormal placental bed vascular 
remodeling and reduced placental perfusion.19 A low cardiac output results in 
reduced placental perfusion which is a known cause for premature deliveries, 
intrauterine growth restriction, and hypertension-related disorders.19,20 Second, 
endothelial dysfunction may be present, which is associated with increased pressor 
sensitivity, activation of the coagulation cascade, and loss of vascular integrity, all are 
responsible for decreased perfusion of the microvasculature.19 Furthermore, our data 
imply an increased risk of perinatal complications in older women. The aetiology is 
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not clear, and it could be merely a consequence of the general relationship between 
maternal age and uterine dysfunction.21 
A high rate of cesarean deliveries (26.4%) was observed in the present study. 
Current guidelines prefer vaginal delivery which, compared to cesarean delivery, 
causes less haemorrhage, smaller shifts in blood volume, fewer clotting 
complications, and fewer infections.9,22 However, prolonged and difficult labour 
should be avoided. Although most cesarean deliveries in our study were for obstetric 
indications, it is remarkable that this number is much higher than that found in the 
general Dutch population (14%), suggesting a low ‘doctors’ threshold for cesarean 
deliveries. To avoid this, labour and delivery must be planned carefully and well in 
advance. Decisions about timing and mode of delivery should be made by a 
multidisciplinary team, including cardiologists, obstetricians, and anaesthesiologists, 
in agreement with the patient.22 
 
Study limitations 
Several potential limitations must be noted. First, the retrospective study design 
necessitated a review of patient’s medical records consequently leading to missing 
values. Nevertheless, all mentioned complications had to be documented in the 
records according to the pre-set definitions before data-entry. Second, the patient 
sample may not be completely representative due to selection bias as only women 
receiving care in the tertiary centres were enrolled in this study. Third, one can argue 
that it would be better to use aortic valve areas instead of aortic jet velocities, to 
correct for low stroke volumes and aortic regurgitation. However, this was not 
available in all cases and for consistency we used jet velocities. Fourth, a major 
limitation is the lack of a control group preventing solid comparisons with a normal 
population. Finally, this study was performed in women who had survived pregnancy 
and were alive at the time of this study, thus no conclusions regarding mortality risk 
can be made.  
 
Conclusions 
Overall, pregnancy is tolerated well in most women with congenital AS. Major 
cardiovascular complications were infrequent, and were only encountered in women 
with severe AS. However, non-cardiac complications are common, including 
hypertension-related disorders, preterm deliveries and small-for-gestational-age 
births. Not only cardiac complications, but also non-cardiac complications merit close 
attention from the cardiologist taking care of these patients, and antenatal 
counselling should be tailored accordingly. A prospective study investigating the 
relationship between cardiac output, placental perfusion, hypertensive disorders, 
neurohormones, and perinatal outcome in pregnant women with AS is mandatory. 
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ABSTRACT 
 
Background and aim of the study 
The pulmonary autograft has been recommended as the valve of choice for aortic 
valve replacement (AVR) in young women contemplating pregnancy. However, 
current information on maternal and perinatal outcome of pregnancy in women with 
pulmonary autograft valve replacement is limited. 
 
Methods 
Using a nationwide Dutch registry (CONCOR) and a local Belgian tertiary care centre 
database, 17 women (age range: 18-45 years) with pulmonary autograft valve 
replacement were enrolled into the study. Twelve pregnancies were observed among 
five different women, including one miscarriage and one elective abortion. 
 
Results 
Clinically significant (non-)cardiac complications were documented in two of 10 
completed pregnancies. Complications included: (I) placental abruption necessitating 
Cesarean delivery at 29 weeks’ gestation, further complicated by postpartum 
hemorrhage; and (II) preterm premature rupture of the membranes resulting in 
premature delivery at 29 weeks’ gestation with postpartum demise of the immature 
born child. Two women reported primary female infertility, but both became pregnant 
after hormonal substitution therapy. Four women reported irregularities of their 
natural menstrual cycle (menorrhagia, dysmenorrhea, polymenorrhea, 
oligomenorrhea, or amenorrhea). 
 
Conclusions 
Successful pregnancy in women with pulmonary autograft valve replacement is 
possible, although serious and clinically significant events occurred during gestation. 
Infertility and menstrual cycle disorders appear to be more prevalent. 
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INTRODUCTION 
 
The decision to perform aortic valve replacement (AVR) in women of childbearing 
age is difficult, because no ideal valve is available. Mechanical valves are associated 
not only with the disadvantage of increased thrombogenicity but also with the 
requisite anticoagulation that promotest the risks associated with pregnancy for both 
mother and child, namely prematurity, birth defects, and neonatal mortality.1,2 On the 
other hand, bioprostheses have a high rate of early structural valve deterioration in 
young adults, earlier studies have suggested an acceleration of valve deterioration 
during pregnancy,3,4 although this is not reflected by current opinion.5-7  
 A pulmonary autograft (Ross) procedure consists of autotransplantation of the 
pulmonary valve to the aortic position. Subsequently, an aortic or pulmonary 
homograft or a heterograft is placed in the pulmonary position.8 The pulmonary 
autograft is not thrombogenic and provides excellent valve hemodynamics;9 hence, 
several groups have suggested the pulmonary autograft procedure as the preferred 
method for AVR in young women contemplating pregnancy.10,11 However, 
information on pregnancy in women after the pulmonary autograft procedure is 
limited.11,12 
 The primary objective of the study was to identify the magnitude of (non-) 
cardiac pregnancy risks in a contemporary cohort of women who had undergone  
pulmonary autograft valve replacement for congenital aortic valve disease. The 
secondary objectives were to assess the occurrence of infertility and menstrual cycle 
disorders in these patients. 
 
 
CLINICAL MATERIAL AND METHODS 
 
Patients 
In 2005, the Dutch CONCOR registry (CONgenital CORvitia; www.concor.net) and a 
local Belgian tertiary centre database were reviewed for all women (age range: 18-45 
years) who had received a pulmonary autograft valve replacement for congenital 
aortic valve disease. All women were regular visitors to the outpatient clinic of one of 
the six participating tertiary academic centers. The study protocol was approved by 
the institutional review board or ethics committee at each of the participating centers. 
Overall, 17 of the 20 identified women (85%) provided their written informed consent 
to participate in the study. The final study population included five women with one or 
more completed pregnancy (> 20 weeks’ gestation) after the pulmonary autograft 
procedure. 
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Data acquisition 
A detailed structured questionnaire was obtained from each patient by telephone. 
The results of the questionnaire were compared with obstetric data from medical 
records, when available. Data were collected on associated congenital 
cardiovascular anomalies, previous surgical/interventional procedures, medical 
history (as recorded by European Pediatric Cardiac Coding), age at inclusion, age at 
menarche, menstruation cycle (duration, regularity without hormonal substitution); 
primary amenorrhea (menarche not established at 16th birthday, in the presence of 
normal growth and secondary sexual development); secondary amenorrhea 
(absence of menstruation for >180 days after menarche in the absence of pregnancy, 
lactation or menopause); oligomenorrhea (menstrual bleeding at intervals >35 days), 
polymenorrhea (menstrual bleeding at interval <24 days); menorrhagia (excessive or 
prolonged (>7 days) menstrual bleeding occurring at regular intervals characterized 
by loss of blood clots or development of anemia); infertility (>2 years of pregnancy 
attempts, investigated and documented by a gynecologist), miscarriages 
(spontaneous fetal loss before 20 weeks’ gestation), and elective abortions. Detailed 
information regarding each completed pregnancy was also recorded according to the 
protocol, as described previously.13,14 
 
Data analysis 
A Clintrial data-entry program (Phase Forward, Waltham, Massachusetts, USA) was 
used to record data, which were then converted to SPSS (version 13.0, SPSS, Inc., 
Chicago, Illinois, USA). Descriptive statistics for nominal data were expressed in 
absolute numbers and percentages. After checking for normality, mean values and 
standard deviations were calculated for normally distributed continuous variables. 
Medians and ranges were computed for continuous variables with non-normal 
distribution. 
 
 
RESULTS 
 
The characteristics of the 17 women with pulmonary autograft valve replacement for 
congenital aortic valve disease enrolled in the study are summarized in Table I.  
  Five women had 12 pregnancies after the Ross procedure, including one 
spontaneous (<12 weeks) miscarriage and one elective abortion. The elective 
abortion was performed at 8 weeks’ gestation and was due to the perceived maternal 
risk associated with the pulmonary autograft. 
The complications encountered during the remaining 10 completed 
pregnancies are detailed in Table II. The mean maternal age at pregnancy was 29.6 
± 4.4 years. The mean interval between the Ross procedure and pregnancy was 5.0 
± 2.8 years (range: 1 to 9 years). Moderate aortic regurgitation was present in three 
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women before pregnancy. Left ventricular systolic function was normal in all women. 
One woman was in New York Heart Association (NYHA) functional class II before 
pregnancy, but all others were in class I. None of the women received anticoagulants 
or other cardiac medication. 
Two women experienced a temporary deterioration of NYHA class (from class 
I to II) during pregnancy, however, no drug therapy was started and both women 
recovered after pregnancy. No episodes of syncope, arrhythmia, angina, 
thromboembolism, or endocarditis occurred during pregnancy.  
Serious obstetric and neonatal complications were observed during two 
pregnancies.  Patient C, who was known to have a protein S deficiency, was 
admitted to the hospital at 26 weeks’ of gestation due to vaginal blood loss during her 
second pregnancy. Placental abruption was suspected and an emergency Cesarean 
delivery at 29 weeks’ gestation was performed. The abruption diagnosis was 
confirmed. The delivery was further complicated by postpartum hemorrhage which 
requirer additional blood transfusion. The baby (a male, body weight 1,400 g) was 
admitted to the neonatal intensive care unit for respiratory distress.  
At 18 weeks into her second pregnancy, patient D’s membranes ruptured 
prematurely, and despite efforts to prolong the pregnancy this led to a premature 
delivery. At 29 weeks a male baby (body weight 700 g) was delivered, but died 
shortly after birth. No post-mortem examination was performed.  
 
Table I. Characteristics at inclusion of women with pulmonary autograft valve replacement (n=17) 
Characteristic No. of patients 
Age at menarche (years)* 13 (10-17) 
Cardiovascular interventions before Ross procedure+ 15 (88%) 
Open aortic valvotomy 6 (35%) 
Balloon aortic valvotomy 6 (35%) 
Aortic valve replacement† 2 (12%) 
Subaortic fibromuscular shelf resection 4 (24%) 
Closure patent arterial duct 3 (18%) 
Closure atrial septum defect 1 (6%) 
Age at pulmonary autograft procedure (years)** 23.6 ± 6.9 
Age at inclusion (years)** 33.8 ± 6.3 
Future child wish 16 (94%) 
Cardiologist disapproval of pregnancy 3 (18%) 
History of infertility 2 (12%) 
Miscarriage 1 (6%) 
Therapeutic abortion 1 (6%) 
Completed pregnancies 18 
Completed pregnancy after pulmonary autograft procedure 10 
* Values are median (range), ** Values are mean ± SD, + Not mutually exclusive, † One mechanical 
valve; one bioprosthesis  
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Additional complications observed included: Cesarean delivery (n=2, for protraction 
of the second stage of labor), vacuum delivery (n=1), pregnancy-induced 
hypertension (n=1), premature labor leading to premature delivery (n=1), and small 
for gestational age (n=2). At a mean follow-up of 5.5 ± 2.6 years all surviving children 
were in general good health. No recurrence of congenital heart disease was 
recorded. 
Eight of 17 women (47%) were childless. Their primary reasons for being 
childless were: age (n=3), expected health risks associated with the maternal cardiac 
status (n=2), socio-economic situation (n=2), and inheritance risk of congenital heart 
disease (n=1). Two of them were discouraged to get pregnant on cardiological 
grounds. Nonetheless, both women were contemplating pregnancy.  
 
Table II. Overview of complications during 10 completed pregnancies in women after pulmonary 
autograft valve replacement 
Complication(s) Patient Pregnancy 
number 
Duration 
of 
gestation 
(weeks) 
Birth 
weight 
(g) 
Cardiac 
 
Obstetric Perinatal 
A 1 37 3280 0 CS 0 
 2 39 3185 0 CS 0 
B 2 38 3530 0 0 0 
 3 38 3340 0 0 0 
 4 37 3150 NYHA 0 0 
C 3 39 2730 0 0 SGA 
 4 29 1400 0 PL, PA, CS, PPH PD 
D 1 35 1700 0 PL, V PD, SGA 
 2 29 700 0 PPROM, PL PD, SGA, PM 
E 1 40 4100 NYHA PIH 0 
CS = Emergency Cesarean delivery, NYHA =NYHA class deterioration during pregnancy, PA = 
Placental abruption, PD = Premature delivery, PIH = Pregnancy induced hypertension, PL = 
Premature labor, PM = Perinatal mortality, PPH = Postpartum hemorrhage, PPROM = Preterm 
premature rupture of membranes, SGA = Small for gestational age, V = Vacuum assisted delivery 
 
The reported median age at menarche was 13 years (range: 10 to 17 years), with 
primary amenorrhea occurring in one woman. Eight women began taking oral 
anticonception at an early age; hence, information on patient’s menstrual cycle was 
gathered for the remaining nine women. The median duration of the natural 
menstruation cycle was 30 days (range: 28-45 days), indicating the presence of 
oligomenorrhea (n=1). Additional reported menstrual cycle disorders were 
dysmenorrhea (n=2), menorrhagia (n=1), and secondary amenorrhea (n=1, for nine 
months) (not mutually exclusive). Two other women reported primary female 
infertility, but both became pregnant after hormonal substitution therapy. Note: It 
must be realized that the above-mentioned menstrual cycle disorders are more 
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related to the underlying congenital aortic valve disease than to the Ross procedure, 
which was performed at an older age. 
 During a mean follow-up of 10.2 ± 3.9 years after the Ross procedure (all 17 
women), two women required a reintervention for structural valve deterioration. One 
woman (no previous pregnancy) developed a severe stenosis of the pulmonary 
autograft and underwent balloon valvotomy 12 years after the Ross procedure. The 
valvotomy was unsuccessful and subsequently a homograft was implanted. Another 
woman developed complications of both the autograft in the aortic position and the 
allograft in the pulmonic position, consisting of moderate aortic regurgitation in 
combination with a severe pulmonary regurgitation. Right atrial and ventricular 
enlargements were also documented. At nine years after the Ross procedure (five 
years after her last pregnancy) the pulmonary autograft was replaced by a composite 
aortic repair (Bentall procedure) and a new allograft was placed in the pulmonic 
position.  
 
 
DISCUSSION 
 
The key finding of the present case series was that women with pulmonary autograft 
valve replacement for aortic valve disease can successfully carry pregnancy to term. 
Nevertheless, serious non-cardiac complications must be taken into account. 
Furthermore, whilst age at menarche and menstrual cycle were relatively normal, a 
few women reported menstrual cycle disorders (possibly related to the underlying 
congenital aortic valve disease, rather than to the Ross procedure). Finally, almost all 
women had or wished to have children in the future, illustrating the importance of 
pregnancy research. 
 Pregnancy in woman with severe congenital aortic stenosis is associated with 
an increased risk of cardiac complications.15,16 Prophylactic valve replacement is 
recommended in young women with severe aortic stenosis contemplating pregnancy, 
in order to avoid future problems.10 The implantation of a mechanical heart valve 
leads to the requirement of oral anticoagulants, which in turn increases the risk of 
embryopathy and stillbirth.2 In contrast, bioprosthetic valves have a significantly 
higher incidence of valve failure than mechanical valves. A natural history study of 
232 young women with prosthetic valves showed that the 10-year rates of valve loss 
with bioprosthetic, mechanical, and homograft valves were 82%, 29%, and 28%, 
respectively.6 Furthermore, earlier studies have suggested an accelerated 
deterioration of bioprosthetic valves during or shortly after pregnancy,3,4 although 
other more recent studies failed to confirm this finding.5-7 The pulmonary autograft 
procedure has been recommended by some groups as an attractive alternative for 
AVR in young women contemplating pregnancy, as it is associated with low 
thrombogenicity and longer valve durability.10,11 A long-term follow-up study 
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investigating the outcome of the Ross procedure showed survival rates of 85% and 
60% at 10 and 20 years, respectively, and freedom from any reoperation of 76% and 
62%, respectively.17 A recent study conducted by Yacoub et al., investigating 264 
Ross patients operated on at Harefield, UK, or at Erasmus MC, The Netherlands, 
demonstrated an even better outcome, with a 10-year survival rate of 95.4% and 
freedom from autograft reoperation of 94.9% at 10-years.18 Unfortunately, only 
limited data are available on the durability of pulmonary autografts in pregnant 
women. No evidence of valve deterioration was indicated in one report of 14 
pregnancies in eight women, amongst whom right-sided obstruction occurred in two 
cases at nine and 15 years after the pulmonary autograft replacement (at 4 and 7 
years after a second pregnancy.11 The remaining patients were free of valve 
deterioration, with a mean follow-up of 16.5 years. In the present study with a mean 
follow-up of 10.2 years after the Ross procedure, two women required reoperation for 
structural valve deterioration at nine and 12 years, respectively, after the Ross 
procedure. 
 A summary of the available literature on pregnancy and pulmonary autograft 
procedure,11 together with data from the present series, is presented in Table III. 
These data were compared to the largest series of pregnancies in patients with 
congential aortic stenosis without pulmonary autograft.16 The five pregnancies in 
women with a pulmonary autograft in the prospective study by Siu et al were not 
included in the summary, as no specific pregnancy data were presented.15 Overall, 
serious cardiac complications were rare, and only one case of heart failure was 
described by Dore and Somerville.11 This woman suffered heart failure, probably due 
to a dilated cardiomyopathy that was unrelated to aortic or pulmonary valve 
dysfunction. These authors conclude that this might have been related to myocardial 
damage after several cardiac operations.11 Most women (88%) in the present series 
had undergone previous cardiovascular surgery, though none had developed 
cardiomyopathy during pregnancy. 
Remarkably, when combining data from both series, perinatal mortality was 
extremely high (two of 24 pregnancies). No perinatal mortality was encountered in 
the series of Silverside et al, who investigated pregnancies in patients with congenital 
aortic stenosis.16 Perinatal mortality in developed countries is an extremely rare 
complication, occurring in <0.8% of the pregnancies in the general population of The 
Netherlands.19 The infant described by Dore and Somerville11 died on the ninth day 
due to spina bifida and hydrocephalus. In the present series, preterm premature 
rupture of the membranes leading to preterm delivery was the main cause of 
perinatal death. 
Premature delivery is a well-known cause of infant morbidity and mortality, 
which was illustrated by this case. In addition, there was an overall increased rate of 
premature deliveries and children born as small-for-gestational age. This may be 
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Table III. Maternal and fetal outcome of pregnancies in women with congenital aortic valve disease 
with (Dore and Somerville and current series) and without (Silverside) pulmonary autograft valve 
replacement   
Complication(s) Series Completed 
pregnancies 
(n) 
Birth 
weight 
(gram) 
Cardiac Obstetric Perinatal 
Dore and 
Somerville11 
14 3200 HF (1) CS (4) PM (1) 
Current series 10 2712 NYHA (2) CS (3), PL (3), PA (1), 
PPROM (1), PIH (1), V 
(1) 
PD (3), SGA 
(3), 
PM (1), 
Total 24 2997 NYHA (2), 
HF (1) 
CS (7), PL (3), PA (1), 
PPROM (1), PIH (1), V 
(1) 
PD (3), SGA 
(3), 
PM (2) 
Silverside et 
al.16* 
49 - HF (2), 
AA (1) 
PPH (1) PD (5), SGA 
(1) 
AA = Atrial arrhythmias, HF = Heart failure. Other abbreviations as Table II.  
* This study did not focuss on obstetric complications; thus, the number of obstetric complications may 
be underestimated. 
 
related to a reduced placental perfusion secondary to endothelial dysfunction in 
women known to have congenital aortic valve disease. Endothelial dysfunction is 
associated with increased pressor sensitivity, activation of the coagulation cascade, 
and a loss of vascular integrity, all of which are responsible for a decreased perfusion 
of the microvasculature.20 
 Among the present patients, menarche occurred at approximately 13 years, 
which was comparable to the period of 12.8 years reported in the general population. 
Delayed menarche (>16 years) with normal secondary sexual development found in 
one woman was suggestive of primary amenorrhea. In the guidelines of the Dutch 
College of General Practitioners (NHG), it is reported that <5% of menarche occurs in 
patients after the age of 16 years. Furthermore, two women who reported infertility 
became pregnant after hormonal substitution therapy. 
 
Study limitations 
Within the present study, it was important to note several potential limitations. First, 
the retrospective study design necessitated a review of patients’ medical records, 
and, consequently missing values were inevitable. Second, a selection bias may 
have been introduced because only survivors were included. Third, the lack of a 
control group limited the possibility to perform solid comparisons. Fourth, only those 
women were included who underwent the Ross procedure for congenital aortic valve 
disease; hence, these data should not be extrapolated to women undergoing such 
surgery for other reasons. Finally, given the small sample size, all conclusions of the 
present study must be regarded with caution. 
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ABSTRACT 
 
The management of multivalvular heart disease during pregnancy is difficult, as no 
guidelines currently exist. Herein is reported the first case of percutaneous triple-
valve balloon valvulotomy guided by intracardiac echocardiography (ICE) in a 
pregnant woman with multivalvular rheumatic heart disease. ICE provided excellent 
imaging and guidance, which resulted in a low radiation exposure to the mother and 
fetus. 
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INTRODUCTION 
 
Valvular heart disease in young women is most commonly due to rheumatic heart 
disease, congenital abnormalities, or previous endocarditis. Although mitral stenosis 
is the most common rheumatic valvular lesion in pregnancy,1 the rheumatic disease 
process also can affect the aortic valve and, less commonly, the tricuspid valve. 
Conventional options for the management of symptomatic patients with valvular 
disease during pregnancy have included therapeutic abortion or valvular surgery. 
Valve surgery with the need for cardiopulmonary bypass (CPB), is associated with a 
fetal mortality of approximately 20%.2 An alternative to valve surgery is percutaneous 
balloon valvulotomy, which has been reported in increasing numbers of pregnant 
patients with mitral stenosis,3-6 and in a few with aortic stenosis.7-13 The long-term 
outcome of percutaneous balloon valvulotomy has been favorable for both mother 
and fetus, though special considerations for conducting the procedure in gravide 
patients include radiation exposure, the risk of urgent surgery and pregnancy 
outcome. Transesophageal echocardiography (TEE) can be used to reduce 
irradiation, and the technique and use of TEE during percutaneous balloon mitral 
valvulotomy have been well described.14,15  
Intracardiac echocardiography (ICE) offers an alternative means for guidance 
during valvulotomy, especially in multi-valve pathology. The technique combines the 
superior imaging resolution of TEE without exposing the patient to risks of sedation 
or esophageal intubation. The AcuNav (Acuson, Mountain View, CA, USA) ICE 
catheter is a 10-Fr ultrasound-tipped catheter capable of 5.5-10-MHz imaging of 
intracardiac structures via the right atrium or ventricle of the heart. Using this 
catheter, visualization of both left- and right-sided intracardiac structures is possible. 
Herein is described the use of ICE during percutaneous triple-valve balloon 
valvulotomy in a pregnant woman. 
 
 
CASE REPORT 
 
A 25-year-old Iraqi primigravida was admitted to the authors’ hospital with a 
diagnosis of congestive heart failure (NYHA functional class III) at 16 weeks’ 
gestation. Her medical history reported rheumatic fever in 1996 that was treated with 
penicillin in Iraq. A physical examination revealed a blood pressure of 100/65 mmHg 
and a regular heart rate of 75 beats per minute. The patient’s height was 165 cm, 
and body weight 65 kg. The jugular venous pressure was slightly elevated, and the 
lungs were clear. On cardiac examination, a parasternal thrill radiating to the carotid 
arteries was felt. There was a loud S1 and a soft S2, a grade 4/6 systolic ejection 
murmur was best heard at the right parasternal border, and a high frequent 
holosystolic murmur and a diastolic rumble was noted at the apex. The liver was 
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palpable 1 cm below the costodiafragmatic border. Electrocardiography revealed a 
normal sinus rhythm, a normal axis, and signs of biatrial enlargement. Chest X-
radiography was deferred. 
Transthoracic echocardiography (TTE) disclosed rheumatic deformity of the 
mitral, tricuspid and aortic valve without calcification. There was doming of the 
anterior mitral leaflet, and the posterior mitral leaflet showed no forward movement in 
diastole. Both mitral leaflets were thickened, and there was biatrial enlargement. An 
echo-Doppler examination showed severe aortic stenosis despite good mobility of 
the slightly thickened tricuspid aortic valve, moderate to severe aortic regurgitation, 
moderate to severe mitral stenosis, mild mitral regurgitation, moderate tricuspid 
stenosis, and severe tricuspid regurgitation (Table 1). There was left ventricular (LV) 
hypertrophy, with the interventricular septum measuring 11 mm and the posterior wall 
12 mm. The LV end-diastolic diameter was 43 mm, and the LV end-systolic diameter 
23 mm (fractional shortening 47%). The aortic annular diameter measured 19 mm in 
the parasternal long-axis view. The patient underwent TEE to further evaluate the 
abnormalities seen by TTE, confirming the results seen at TTE and showing no left 
atrial thrombus. 
During her hospital stay, the patient complained of shortness of breath and 
also experienced chest pain while walking. Diuretic treatment was started. The 
obstetricians determined that fetal development was within normal limits. The 
presence of cardiac symptoms and the expected increasing hemodynamic burden of 
pregnancy aggravating her symptoms were a clear indication for intervention. As the 
patient wished not to terminate the pregnancy, the risks and benefits of 
cardiothoracic surgery versus percutaneous balloon valvulotomy were discussed with 
the patient and her family.The high risk of fetal loss, durability of tissue valves and 
anticoagulation with mechanical valves were adressed with regard to surgery. With 
respect to percutaneous balloon valvulotomy, the potential need for emergency 
operation and temporary solution were addressed. Consequently, the patient agreed 
to undergo a percutaneous triple-valve balloon valvulotomy of the aortic, mitral and 
tricuspid valves. 
 
Cardiac catheterization 
The procedure was performed at 18 weeks’ gestation, without the use of sedatives. 
The total radiation exposure to the fetus was reduced by using ICE and setting the 
frame rate of fluoroscopy at 6.25 frames per second, without using cineruns. 
Fluoroscopic images were stored digitally. A lead apron for the mother was not used 
as this would not reduce the internal radiation scatter. A 12-F sheath was inserted 
into the patient’s left femoral vein to allow for insertion of the 10-F AcuNav ICE 
catheter. The mitral valve was dilated first, to enhance the forward flow of blood with 
venous loading and to prevent hypotension during aortic balloon valvulotomy. The 
interatrial septum was visualized, and transseptal punction performed with a 
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Table 1. Echocardiographic parameters before and after valvulotomy 
 Before 
valvulotomy 
After 
valvulotomy 
Aortic valve:   
- Peak velocity (m/s) 5.5 3.5 
- Peak gradient (mmHg) 121 49 
- Mean gradient (mmHg) 65 28 
- Valve area (cm2) 0.5* 1.3* 
- Regurgitation 3+ 3+ 
Mitral valve:   
- Peak velocity (m/s) 2.4 1.4 
- Peak gradient (mmHg) 23 9 
- Mean gradient (mmHg) 9 4 
- Valve area (cm2) 1.0† 1.9† 
- Regurgitation 1+ 1+ 
Tricuspid valve:   
- Peak velocity (m/s) 1.4 1.1 
- Peak gradient (mmHg) 8 6 
- Mean gradient (mmHg) 7 3 
- Pressure half time (ms) 262 135 
- Regurgitation 4+ 4+ 
* Calculated using the continuity equation. 
† Based on the pressure half-time. 
 
transseptal dilator through an 8-Fr Mullins sheath, and a standard Brockenbrough 
needle. After entry into the left atrium, 7000 U heparin was administered. An Inoue 
balloon (30 mm) (Toray Industries, Tokyo, Japan) was passed through the interatrial 
septum, mitral orifice, and into the left ventricle under continuous ICE guidance, with 
the ICE catheter in the right atrium. The balloon catheter was positioned across the 
mitral valve (Figure 1). Two sequential balloon inflations were successful in 
decreasing the mean gradient across the mitral valve from 10 to 5 mmHg (Table 2). 
After completion of mitral valvulotomy, the aortic valve was crossed retrogradely, 
facilitated by ICE guidance. After crossing with a back-up wire (Boston Scientific 
Corporation, Miami, FL, USA), a balloon catheter (20 mm by 4.0 cm) was positioned 
across the aortic valve and inflated (Figure 2). Two attempts without pacing were 
unsuccessful because the balloon moved into the aorta during balloon inflation. The 
third inflation was made with rapid pacing using a bipolar pacing catheter (Arrow, 
Reading, PA, USA) in the right ventricle, and successfully reduced the peak-to-peak 
gradient from 75 to 35 mmHg. 
Tricuspid valvulotomy was performed last. The Inoue balloon (30 mm) was 
positioned across the tricuspid valve and inflated. Although fluoroscopy showed good 
position of the balloon (Figure 3A), ICE showed the balloon to be positioned under  
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Table 2. Catheterization-derived hemodynamic data at rest and after balloon valvulotomy 
 Resting Post- MV 
valvulotomy 
Post-AoV 
valvulotomy 
Post-TV 
valvulotomy 
Mean LAP (mmHg) 18 9 N/A N/A 
LV (mmHg) 162 / 9 175 / 13 156 / 16 N/A 
Aorta pressure(mmHg) 99 / 51 100 / 66 121 / 78 N/A 
Mean RAP (mmHg) N/A N/A 15 12 
RV pressure (mmHg) N/A N/A 34 / 5 35 / 9 
Mean gradient MV (mmHg) 10 5 N/A N/A 
Mean gradient AoV (mmHg) N/A 55 23 N/A 
Mean gradient TV (mmHg) N/A N/A 5 1 
Heart rate (beats/min) 82 87 79 78 
AoV, aortic valve; LAP, left atrial pressure; LV, left ventricle; MV, mitral valve; N/A, no data available; 
RAP, right atrial pressure; RV, right ventricle; TV, tricuspid valve 
 
 
Figure 1. Inflation of the Inoue balloon across the mitral valve imaged with intracardiac 
echocardiography. The asterisk indicates the Inoue balloon, and the arrowhead the mitral annulus. LA: 
Left atrium; LV = Left ventricle 
 
the tricuspid valve in the right ventricle (Figure 3B). The following inflation (Figure 3C 
and D) with correct balloon positioning was successful, and the mean gradient 
decreased from 5 to 1 mmHg. There were no complications. Using ICE for guidance, 
and fluoroscopy for fine-tuning, the total dose-area product (DAP) was 16.29 Gy·cm2.  
Radiation exposure to the fetus was calculated as 93 µSv, which was much 
lower than the maximal allowable dosis of 1000 µSv or 1 mSv. The total duration of 
the procedure was 200 min. 
Percutaneous triple-valve balloon valvuloplasty in a pregnant woman 
 185
 
 
Figure 2. Inflation of the balloon across the aortic valve imaged with intracardiac echocardiography. 
The asterisk indicates the Inoue balloon. Ao: Aorta; LA; Left atrium. 
 
The mother’s postoperative course was unremarkable while in the cardiac care unit 
and on the hospital ward. TTE performed two days after the intervention confirmed 
the positive results (Table 1). Color Doppler showed the same regurgitant jets across 
the valves as before the procedure. The patient was discharged in good clinical 
condition at one week after the intervention, and remained symptom-free during the 
subsequent pregnancy. A healthy son (weight 2710 g) was delivered vaginally after 
spontaneous labor at 38 weeks of gestation, without maternal and neonatal 
complications. 
 
 
DISCUSSION 
 
Pregnancy and rheumatic heart disease 
Pregnancy is associated with a 30-50% increase in circulating blood volume , and an 
approximate 5% rise in cardiac output. The latter begins to rise around the fifth week 
and increases rapidly until the 24th week, when it levels off or continues to rise 
slightly.16 These hemodynamic changes are usually well tolerated, but valvular heart 
disease may complicate the course of pregnancy and increase the maternal and fetal 
risks associated with pregnancy. 
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Figure 3. Inflation of the Inoue balloon in the right ventricle just below the tricuspid valve (upper) 
imaged with (A) fluoroscopy and (B) intracardiac echocardiography (ICE). Iinflation of the Inoue 
balloon across the tricuspid valve imaged with (C) fluoroscopy and (D) ICE. The asterisk indicates the 
Inoue balloon, and the arrowhead the tricuspid valve. RA: Right atrium; RV: Right ventricle. 
 
Mitral stenosis is the most common valvular lesion during pregnancy, and is 
caused in most cases by rheumatic heart disease.17 Although commonly associated 
with mitral regurgitation, hemodynamic and symptomatic problems are predominantly 
caused by the stenosis. The increased volume load and increased cardiac output 
associated with pregnancy leads to an increase in pressure gradient, which causes 
an increase in left atrial pressure and pulmonary venous filling pressures, and 
worsening of symptoms such as dyspnea, decreased exercise capacity, orthopnea, 
and pulmonary edema. Rheumatic aortic stenosis occurs in approximately 5% of 
pregnant women with rheumatic valvular disease, almost always in combination with 
mitral valve disease. The combination of mitral and aortic stenosis is associated with 
marked increase in maternal morbidity and an unfavourable effect on fetal outcome.18 
 
Management of valvular heart disease during pregnancy 
Pregnant patients with mild rheumatic heart disease can be managed conservatively. 
The cautious use of diuretics, avoidance of excessive salt, and restriction of physical 
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activity reduce cardiovascular load. When pregnant patients do not respond to 
medical treatment, then either therapeutic abortion or an intervention (e.g., surgery or 
percutaneous balloon valvulotomy) should be considered. Repair19 or replacement of 
a dysfunctional valve during pregnancy is possible, the operative risk of cardiac 
surgery being comparable in pregnant and non-pregnant women.20 However, the 
present patient suffered from multiple valvular lesions and required at least double 
valve replacement, the operative risk for which is 70% higher than for single valve 
replacement.19 The use of CPB is associated with a high risk of fetal loss (ca. 20%).21 
Pregnant patients with severe mitral stenosis who develop NYHA class III-IV 
symptoms are recommended to undergo percutaneous balloon valvulotomy.22 
Although reported results with mitral balloon valvulotomy during pregnancy have 
been excellent, with few maternal and/or fetal complications,3-6 very few reports have 
been made with balloon aortic valvulotomy during pregnancy.7-13 The combination of 
multiple valvular lesions adds to the already complex hemodynamic changes 
accompanying pregnancy. As few data exist to guide the management of multiple 
valve disease during pregnancy, each case must be considered individually and 
management based on the potential derangements in hemodynamics and the 
probable risk/ benefit of intervention. The present patient, who had rheumatic 
multivalvular disease, exhibited symptoms of congestive heart failure and chest 
discomfort with mild exercise, caused mainly by the severity of aortic and mitral 
stenoses. In consideration of the valvular lesions, the duration of pregnancy (16 
weeks) and the expected further hemodynamic changes during pregnancy, it was 
considered that the continuation of pregnancy would aggravate any symptoms and 
be associated with high risks for both mother and fetus. Thus, a percutaneous 
balloon valvulotomy of three valves was performed, having taken into account that 
the procedure might aggravate the regurgitation of the treated valves. However, 
mitral and aortic regurgitation is generally tolerated well during pregnancy, due to a 
fall in systemic vascular resistance. 
 
Imaging technique during percutaneous balloon valvulotomy 
When considering percutaneous balloon valvulotomy during pregnancy the radiation 
exposure to the fetus must be kept to a minimum. TEE can be used to guide 
transseptal puncture and positioning of the balloon catheter across the valves, but it 
is uncomfortable for the patient and conscious sedation or even general anesthesia 
may be needed, especially if prolonged intraprocedure imaging is required. In 
patients with severe aortic stenosis, general anesthesia carries an increased risk and 
requires scrupulous anesthetic handling. These problems were avoided using ICE, 
the imaging technique having been shown to be both feasible and safe during 
percutaneous mitral valvulotomy.23 Consequently, ICE has been adopted as the 
standard adjunct for imaging during patent foramen ovale and atrial septal defect 
closure as it minimizes patient risk, reduces radiation exposure and provides 
Chapter 13 
 188
excellent imaging guidance during percutaneous procedures. These advantages 
were clearly demonstrated in the present patient at inflation of the balloon catheter 
across the tricuspid valve, when fluoroscopy showed the Inoue balloon catheter to be 
in the correct position, but ICE proved otherwise (Figure 3). Notably, imaging of the 
tip and length of the Brockenbrough needle with ICE is comparable to that with TEE; 
this is important, as transseptal puncture is a high-risk procedure that could result in 
atrial or aortic perforation. 
Some potential disadvantages with the use of ICE must be mentioned, 
however. First, the cost of the ICE catheter is high for a single use. Second, there is 
an important learning curve associated with the new technology; in contrast to 
standard TEE, the orientations of ICE images are different and require experience for 
their interpretation and the visual identification of important intracardiac landmarks. 
There is also a potential for venous access complications. 
To date, only one report has been made of successful (for both mother and 
fetus) percutaneous triple-valve balloon valvulotomy during pregnancy,9 although 
other less successful cases may not have been reported. Hemodynamic 
measurements in the present patient post-valvulotomy showed significant reductions 
of the gradients across all valves, without worsening of regurgitation. The long-term 
outcome and need for surgery is not yet known.  
In conclusion, the present case report highlights the technical feasibility, safety 
and effectiveness of performing triple-valve balloon valvulotomy by using ICE. In 
addition, percutaneous balloon valvulotomy guided by ICE represents an important 
alternative for women with valvular heart disease during pregnancy.  
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INTRODUCTION – BENIGN DISEASE OR NOT? 
 
Obstruction to left ventricular outflow is localized most commonly at the level of the 
aortic valve. Congenital malformations of the aortic valve may be unicuspid, bicuspid, 
or tricuspid. In this thesis we focused on congenital AS in adults, where usually a 
stenotic bicuspid aortic valve is responsible for the obstruction (chapter 2). For a 
long time, BAV has been regarded a benign disease. However, the abnormal 
architecture induces turbulent flow, which traumatize the leaflets and leads to 
fibrosis, increased rigidity, calcification of the leaflets, resulting in narrowing of the 
aortic orifice in adulthood. AS is responsible for 2.6% of sudden cardiac deaths 
(SCD) in young athletes.1 Even after surgical valvotomy the incidence of SCD is still 
0.4% per year.2 BAV also poses patients at risk of infective endocarditis, sometimes 
with fatal outcome, with an overall mortality of 14% and surgical mortality of 9%.3 
Furthermore, aortic media abnormalities has been described in BAV patients, 
resulting in aotic dilatation, dissection or rupture. Approximately 5% of patients with 
BAV will develop aortic dissection during their lifetime.4 As patients with BAV may be 
asymptomatic and go undetected throughout life despite the presence of severe 
obstruction, it should be seen as a silent danger. The high inheritance risk warrants 
familial screening to detect asymptomatic BAV. 
 
 
NATURAL HISTORY AND PROGNOSIS 
 
Scarce data are available on the natural history of congenital AS in adults. Most 
natural history studies were performed in children, where the disease is considered 
progressive with a high-risk of SCD.5-9 Based on this high risk, the ACC/AHA 
guidelines recommend intervention in children and young adults when the peak aortic 
gradient exceeds 70-80 mmHg even when there are no symptoms.10 In young adults 
the rate of progression of aortic jet velocity, however, is relatively low, being only 
0.09±0.15 m/s per year (chapter 3).11 The observed rate is much lower than the rate 
of progression in older patient groups (mean age 55-75) with degenerative AS, which 
varies from 0.23 to 0.40 m/s per year.12-14 We found that older age was an 
independent predictor of faster progression. Aging leads to calcification of the aortic 
valve and this process is likely to be the cause of faster stenosis progression. 
There is a high rate of aortic valve interventions in young adults with 
congenital AS: 19% had an intervention at 5 years, and 51% at 8 years (chapter 3). 
Severe AS and rapid progression of aortic jet velocity are independent predictors of 
aortic valve intervention, which is not surprising, and reflect common practice to 
intervene in patients with severe AS with rapid increase in severity of stenosis. 
Interestingly, 54% of the patients who underwent an intervention were asymptomatic, 
stressing the fact that a more aggressive approach (i.e. early intervention) is applied 
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in this young patient group as compared to elderly with AS, where usually a wait-for-
symptoms strategy is employed.15 In young adults with AS, there is controversy 
about the optimal timing of aortic valve replacement, especially in asymptomatic 
patients. Potential risk factors that can identify young adult patients with AS who will 
benefit more from early intervention are abnormal exercise testing (e.g. symptoms, 
abnormal blood pressure response), marked LV hypertrophy (chapter 8), LV systolic 
dysfunction and high plasma levels of natriuretic peptides.16,17 
SCD is the leading cause of mortality in adults with CHD, particularly in 
patients with repaired cyanotic defects and left heart obstructive lesions (i.e., 
corrected AS and aortic coarctation).18,19 Implantable cardioverter defibrillators (ICD) 
have emerged as the primary therapeutic option for survivors of SCD and high-risk, 
mainly ischemic heart disease, patients.20 Information on the outcome of ICD therapy 
in adults with CHD is limited.21-24 We present the largest and first multi-centre study 
that analysed the outcome of ICD therapy in adults with CHD describing that this 
therapy is effective in a quarter of the patients (23%) with low early and late 
complication rates during a median follow-up of 3.7 years (chapter 5). The number of 
inappropriate shocks (41%) is relatively high, mainly caused by supraventricular 
tachycardias. 
The majority of our study patients (72%) had tetralogy of Fallot or transposition 
of the great arteries, only 3% had left heart obstructive lesions. As patients with left 
heart obstructive lesions are known to be at high risk of SCD, it is remarkable that 
only a small percentage of them receives an ICD in contrast the patients with 
tetralogy of Fallot. No clear explanation for this discrepancy was found. Perhaps 
patients with left heart obstructive lesions receive ICD therapy at a younger age. This 
is supported by the survey of the Paediatric Electrophysiology Society reporting left 
heart obstructive lesions in 23% of paediatric patients with CHD receiving an ICD.25  
 
 
AORTIC DILATATION 
 
There is a strong association between bicuspid aortic valves and ascending aortic 
aneurysms (chapter 2 and 4). Approximately 50% of young men with normally 
functioning bicuspid aortic valves have an aortic dilatation.26 Once thought to be the 
consequence of post-stenotic dilatation, currently cystic medial degeneration (i.e., 
fragmentation of elastin, abnormal collagen and smooth muscle cell, increased 
ground substance) has been found to be the underlying cause of aortic dilatation.27-29 
Dilatation of the aorta may be the result of the disruption of the extracellular matrix by 
upregulation of matrix metalloproteinase-2 that is triggered by an inherent deficiency 
of fibrillin-1.27,30-32 Interestingly, samples of the pulmonary arteries of BAV patients 
have been shown to have a similar reduction in fibrillin-1 content,30 explaining the 
high degree of neo-aortic dilatation in patients with a pulmonary autograft 
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procedure.33 Furthermore, premature smooth muscle cell apoptosis leads to 
upregulation of matrix metalloproteinase-2.34,35  
Abnormalities in the aortic media not only cause aortic dilatation, but also 
abnormal elastic properties.36-38 BAV patients demonstrate a stiffer aorta, which 
seems to be related to the dimensions of the aorta, but is independent of stenosis 
severity (chapter 7). A possible relationship between aortic size and stiffness could 
be explained by the presence of “cystic medial necrosis”. Elastin fibers normally bear 
aortic stresses, providing the aorta its biological Windkessel function.39 When the 
elastin fibers fragment and degenerate, the aortic wall stretches and the vessel 
dilates. Wall stress is than transferred to the less extensible collagenous elements in 
the aortic wall, leading to increased stiffness. As the aorta becomes stiffer, it opposes 
a higher afterload to left ventricular ejection, it augments systolic and pulse pressure, 
and it reduces coronary blood flow.40 Furthermore, Bonderman et al.34 showed that in 
BAV patients arterial medial remodelling precedes aortic dilatation. It would be 
interesting to know whether an increased aortic stiffness could be used as a risk 
factor for identifying patients at risk of progressive aortic dilatation, and subsequently 
dissection 
The optimal timing of surgical repair of aortic dilatation is determined by the 
natural course of the underlying disease, risk of surgery, and post-surgical outcome 
(chapter 4). Although data on the natural history of thoracic aortic aneurysms are 
limited, it is well established that the risk of rupture or dissection increases with 
aneurysm size.41,42 In general, surgery for ascending thoracic aortic aneurysms is 
indicated at a diameter of 5.5 cm or greater. Earlier surgery (4.5-5.0 cm) is 
recommended for patients who are at increased risk of aortic dissection and rupture, 
including patients with Marfan’s syndrome, familial thoracic aortic aneurysm, BAV, 
family history of Marfan’s syndrome plus aortic dissection, and patients with a rapid 
progressive aortic dilatation (≥0.5 cm/year). As can be appreciated, serial imaging of 
the aorta is mandatory to estimate optimal timing of surgery. 
 
 
PREGNANCY 
 
Pregnancy in AS patients has been the focus of some reports because of concern for 
development of heart failure and mortality during pregnancy.43,44 The review of Lao et 
al. published in 1993 demonstrated seven deaths among 65 women, resulting in a 
maternal mortality of 11%.45 Based on these data, women with significant AS are 
considered high-risk patients,46,47 and 22.2% of the women in our study have been 
counseled and advised against pregnancy (chapter 11). In patients with severe AS, 
the stenosis may result in abnormal elevations of left ventricular systolic and filling 
pressures. This, in turn, could precipitate or exacerbate heart failure or ischemia, 
requiring prompt treatment. 
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Recent pregnancy reports in AS patients (less severe patients compared to 
the older studies) are more encouraging, showing a favorable pregnancy outcome 
with low maternal mortality.48-51 Previous studies focused mainly on cardiac 
complications,43-45,48-50 and only limited information exists on obstetric and perinatal 
complications in women with congenital AS.  
In our study, severe cardiac complications were relatively infrequent (chapter 
11). However, obstetric (22.6%) and perinatal (24.5%) complications were observed 
often. Even in the whole spectrum of pregnancy in patients with CHD, patients with 
congenital AS do experience relatively more events of hypertension related-disorders 
(chapter 10). The higher incidence of hypertension-related disorders and perinatal 
complications may be related to reduced placental perfusion secondary to left heart 
obstruction. Several mechanisms for a reduced placental perfusion may be 
hypothesized. First, an inadequate increase in cardiac output during pregnancy due 
to left heart obstruction may be responsible for abnormal placental bed vascular 
remodeling and reduced placental perfusion.52 A low cardiac output results in 
reduced placental perfusion which is a known cause for premature deliveries, 
intrauterine growth restriction, and hypertension-related disorders.52,53 Second, 
endothelial dysfunction may be present, which is associated with increased pressor 
sensitivity, activation of the coagulation cascade, and loss of vascular integrity, all are 
responsible for decreased perfusion of the microvasculature.52 
According to the ACC/AHA guidelines women with severe AS should be 
counselled against pregnancy until relief of their stenosis.15 The pulmonary autograft 
has been recommended as the valve of choice for aortic valve replacement in young 
women contemplating pregnancy.15,54 However, information on maternal and 
perinatal outcome of pregnancy in women with pulmonary autograft valve 
replacement is limited.54 We report on 12 pregnancies in 5 different women, including 
1 miscarriage and 1 elective abortion (chapter 12). Clinically significant (non-)cardiac 
complications were documented in 2 of 10 completed pregnancies, including 
placental abruption and preterm premature rupture of the membranes resulting in 
postpartum demise of the immature born child. We conclude that successful 
pregnancy in women with pulmonary autograft valve replacement is possible, 
although serious and clinically significant events can occur.  
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FUTURE DIRECTIONS 
 
Medical treatment 
Recent insights into the pathogenesis of calcification of the aortic valve suggest that 
this is an active, rather than a passive process, with features reminiscent of 
atherosclerosis (chapter 2).55 Inflammation, lipid infiltration, dystrophic calcification, 
ossification, and endothelial dysfunction have been observed in both diseases.56-59 
Furthermore, hypercholesterolaemia, raised lipoprotein Lp(a), smoking, hypertension, 
and diabetes have been reported to be common risk factors for both.55  
The similarities between AS and atherosclerosis have been a great stimulus 
for research on drugs that can delay stenosis progression, the most promising agents 
being statins.60 First, statins by virtue of lowering LDL-cholesterol reduce an 
important risk factor for BAV disease progression. Second, statins, through their 
powerful anti-inflammatory actions, may limit the extent of aortic valve calcification, 
critical to the development of BAV stenosis. Third, statins may limit aortic dilatation 
by reducing the production of matrix metalloproteinases, which are critical to the 
aberrant aortic remodelling seen in BAV. Currently, there are four retrospective 
studies that have shown that statins can reduce stenosis progression.12,61-63 
Recently, two landmark trials showed conflicting results.64,65 The SALTIRE study was 
a randomized, double-blind trial (n=134) which showed no effect of 80 mg 
atorvastatin on the progression of calcific AS.64 In a subsequent prospective open-
label study, RAAVE study, treatment with rosuvastatin according to the NCEP-ATPIII 
guidelines did slow the hemodynamic progression of AS.65 As the last trial was not-
randomized it should be regarded as hypothesis-generating. The RAAVE study 
comprised less severe AS patients, and thus suggests that earlier treatment with 
statins is more efficacious than late treatment. Results of larger randomized trials like 
ASTRONOMER (Canada), SEAS (Europe) and STOP-AS (USA) should be awaited. 
Currently, the choice of medical treatment to prevent aortic dilatation and 
reduce the risk of dissection or rupture is limited. In a small randomized study of 
patients with Marfan’s syndrome, treatment with propranolol has shown to slow the 
progression rate of aortic dilatation, and was associated with fewer aortic events and 
lower mortality.66 Whether this treatment is of value for other patients with thoracic 
aortic aneurysms is not known, but seems plausible. The beneficial effects of β-
adrenergic blockers are probably secondary to blunting of the hemodynamic stress 
(reduction of dP/dt) that is imposed on a structurally deficient aortic wall, however, 
lowering blood pressure alone could also explain the beneficial effect. Recently, 
losartan, an angiotensin II type 1 receptor (AT1) blocker, has shown to prevent aortic 
aneurysm in a mouse model of Marfan’s syndrome by antagonizing transforming 
growth factor β (TGF-β) signaling.67 In contrast to propranolol, AT1 blockade by 
losartan appears to achieve full correction of the phenotypic abnormalities (e.g., 
elastic fiber fragmentation) in the aortic wall. This suggests that AT1 antagonism 
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might achieve superior protection over β-adrenergic blocking agents. Prospective, 
randomized, placebo-controlled studies are required to definitely address these 
issues.  
 
Percutaneous aortic valve replacement 
Despite the promising results of medical treatment, most patients with AS will 
eventually require valve replacement. Percutaneous aortic valve replacement 
(PAVR) is a technique where the artificial valve is loaded inside a catheter and self-
expands to fix in position. The first human report of PAVR by Cribier et al. dates back 
to 2002 and describes a single patient who died 17 weeks after the implant of 
complications related to peripheral artery disease.68 In 2006, the same group 
reported their overall clinical experience: in 36 patients with end-stage AS PAVR 
could be performed successfully in 27 patients. Thirty-day major adverse events 
were 26% (pericardial tamponade, stroke, arrhythmia, urosepsis, and one 
unexplained death). Eleven patients were alive with a follow-up ranging from 9 to 26 
months. All patients experienced amelioration of symptoms (>90% NYHA functional 
class I to II). Percutaneous heart valve function remained unchanged during follow-
up, and no deaths were device-related.69 More recently, Grube et al. reported their 
experience with the self-expanding CoreValve aortic valve prosthesis in 25 elderly 
patients with multiple high-risk comorbid conditions.70 Device success and procedural 
success were achieved in 88% and 84% of patients, respectively. Major in-hospital 
cardiovascular and cerebral events occurred in 32%, including mortality in 5 patients 
(20%). 
Despite these disappointing results, the technique has the potential to become 
the treatment option of choice as many patients in the future will prefer a 
percutaneous intervention rather than an open-heart surgery. However, several 
issues remain to be solved before widespread implementation of the technique will 
take place. Undoubtly, the technical challenges, reliability, and ability to achieve 
consistent results (not to mention appropriate patient selection) will be an area of 
active research and development in the near future. Optimal positioning of the stent 
to avoid coronary ostial impairment and paravalvular leakage is still a challenge. The 
durability of the tissue valve within a metal stent is unknown. Future will tell whether 
these challenges may be overcome. 
 
Genetic inheritance 
Recent findings support the suggestion that all anomalies of the left ventricular 
outflow tract obstruction spectrum are developmentally related and multiple genes 
have been implicated. Endothelium-derived nitric oxide synthase (eNOS) has been 
implicated because mice deficient in this gene frequently develop BAV.71,72 Mutations 
in the signaling and transcriptional regulator NOTCH1 gene result in developmental 
aortic valve abnormalities and severe valve calcification in affected families.73 
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Ubiquitin fusion degradation 1-like gene is another potential candidate, which is 
highly expressed in the cardiac outflow tract during embryogenesis and is 
downregulated in patients with BAV.74  
BAVs appear to be genetically inherited in an autosomal dominant fashion with 
reduced penetrance at least in some families.75,76 With the use of echocardiography 
to screen the family members of patients with a BAV, 36.7% of the screened families 
had more than one first-degree relative with a BAV,76 suggesting that 
echocardiographic screening of first-degree relatives may be valuable especially in 
families with more than one affected family members. Furthermore, familial clustering 
of BAV and other left ventricular outflow tract obstructions has been described.77 
Identification of the genes responsible for the development of BAV may enable better 
genetic counseling. 
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Een aangeboren aortastenose is een vernauwing ter hoogte van de aortaklep. De 
vernauwing kan zich ook onder of boven de klep bevinden, ook wel de subvalvulaire 
en supravalvulaire vorm genoemd. De normale aortaklep bestaat uit 3 even grote 
klepbladen. Een aangeboren aortastenose op klepniveau is het resultaat van een 
abnormale aanleg van de aortaklep, waardoor er 1 tot 4 klepbladen ontstaan. De 
meest voorkomende klepafwijking is een tweekleppige of bicuspide aortaklep (figuur 
1), welke verantwoordelijk is voor >95% van alle gevallen van aangeboren 
aortastenose. Een bicuspide aortaklep komt bij 1% van de bevolking voor, driemaal 
vaker bij mannen dan bij vrouwen. Door zijn afwijkende morfologie kan een bicuspide 
aortaklep leiden tot een klepvernauwing of –lekkage. Bovendien is de klep extra 
vatbaar voor infecties. Verder gaat een bicuspide aortaklep samen met een 
verwijding van het opstijgende deel van de grote lichaamsslagader (aorta 
ascendens), wat vermoedelijk secundair is aan afwijkingen in de aortawand. Een 
verwijde aorta ascendens kan leiden tot levensbedreigende complicaties zoals een 
beschadiging van de binnenwand van de aorta waardoor er bloed tussen de binnen- 
en buitenwand van de aorta ophoopt (dissectie) of een totale scheur van de aorta 
(ruptuur). De meeste patiënten met aangeboren aortastenose hebben geen klachten, 
maar op het moment dat er klachten optreden is er sprake van een ernstige situatie. 
Dit proefschrift beschrijft verschillende klinische aspecten van een aangeboren 
aortastenose bij volwassenen. Het eerste deel van dit proefschrift beschrijft de 
huidige inzichten in de ontstaansmechanismen en het natuurlijk beloop van de 
ziekte. Het tweede deel richt zich op nieuwe diagnostische technieken welke van 
additionele waarde kunnen zijn voor de follow-up van patiënten met een aangeboren 
aortastenose. Het laatste deel beschrijft de zwangerschapsuitkomsten bij vrouwen 
met een aangeboren aortastenose.  
 
 
Figuur 1. Een bicuspide aortaklep 
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KLINISCHE INZICHTEN 
 
Hoofdstuk 1 geeft een algemene inleiding over aangeboren aortastenose en geeft 
een overzicht van de onderwerpen die in dit proefschrift worden besproken. 
Hoofdstuk 2 geeft een overzicht van de meest recente studies met betrekking tot 
aangeboren aortastenose bij volwassenen. De huidige richtlijnen worden besproken 
welke betrekking hebben op het tijdstip van percutane (ingreep via de lies) en 
chirurgische interventie, zwangerschap en sport. De meeste patiënten met een 
aangeboren aortastenose zijn klachtenvrij. Zodra zich klachten voordoen zoals pijn 
op de borst, benauwdheid of flauwvallen, dan heeft dit een negatief effect op de 
gemiddelde overlevingsduur. Het optreden van klachten is een harde indicatie voor 
een behandeling zoals een aortaklepvervanging. Een andere mogelijkheid is een 
percutane interventie waarbij de aortaklep wordt verwijd middels een ballon die is 
ingebracht via de lies, maar dit is een tijdelijke oplossing (het effect blijft gemiddeld 4 
jaar) doordat de klep vaak op termijn weer vernauwd. Plotse hartdood, vooral bij 
inspanning, is een beruchte complicatie van een aangeboren aortastenose. Er wordt 
geadviseerd piekinspanningen te vermijden. Dit heeft consequenties ten aanzien van 
sportbeoefening bij deze jongvolwassenen. Tot slot worden enkele veelbelovende 
medicijnen (statines en ACE-remmers) besproken die wellicht een positief effect 
zouden kunnen hebben op het natuurlijk beloop van de ziekte. Statines hebben naast 
hun cholesterolverlagende, tevens ontstekingsremmende effecten en deze werking 
kan verkalking van de klep afremmen. Deze gunstige resultaten moeten nog 
aangetoond worden in gerandomiseerde studies. 
In hoofdstuk 3 wordt het natuurlijk beloop van een aangeboren aortastenose 
beschreven. De gegevens zijn gebaseerd op een populatie van 84 patiënten die 
tussen 1992 en 2005 in het Erasmus MC gedurende gemiddeld 8 jaar werden 
gevolgd. De jaarlijkse toename van de ernst van de vernauwing was relatief laag. Uit 
deze studie bleek verder dat een oudere leeftijd geassocieerd was met een snellere 
toename van de vernauwing. Dit is waarschijnlijk het gevolg van verkalking van de 
aortaklep. Tijdens deze studie had 42% van de patiënten een aortaklepvervanging 
nodig. Patiënten met een ernstige aortastenose en degenen waarbij sprake was van 
een snellere toename van de vernauwing hadden de grootste kans om een 
aortaklepvervanging te moeten ondergaan.  
In hoofdstuk 4 wordt besproken wat het optimale tijdstip is voor chirurgische 
vervanging van een verwijde aorta. Zoals eerder aangegeven is een verwijde aorta 
een veel voorkomende afwijking bij patiënten met een aangeboren aortastenose 
welke kan leiden tot levensbedreigende complicaties zoals een dissectie of ruptuur. 
Het optimale tijdstip van vervanging wordt bepaald door het natuurlijk beloop van de 
ziekte, operatierisico’s en lange-termijn uitkomsten na operatie. Vervanging van de 
aorta is geïndiceerd als de aorta ascendens een diameter groter dan 5.5 cm bereikt. 
Voor patiënten die een verhoogd risico hebben op aorta dissectie en ruptuur wordt 
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eerder vervangen van de aorta (bij een diameter van 4.5-5.0 cm) aanbevolen. Dit 
betreft onder andere patiënten met de ziekte van Marfan, familiaire thoracale aorta 
aneurysma, een bicuspide aortaklep, een snelle toename van de aorta dimensies en 
patiënten met een positieve familie anamnese voor de ziekte van Marfan plus 
aortadissectie.  
In hoofdstuk 5 worden de uitkomsten van een implanteerbare cardioverter-
defibrillator (ICD) bij volwassenen met een aangeboren hartafwijking besproken. 
Patiënten met een aangeboren aortastenose hebben een verhoogd risico op plotse 
hartdood. Een ICD is een soort pacemaker dat levensbedreigende 
hartritmestoornissen kan herkennen en vervolgens beëindigen door middel van een 
elektroschok. Een ICD kan een plotse hartdood voorkomen. Meerdere 
gerandomiseerde onderzoeken bij ouderen met ischemische hartziekten hebben 
aangetoond dat behandeling met een ICD leidt tot een lagere sterfte in vergelijking 
met medicamenteuze therapie. Deze resultaten zijn nog niet aangetoond voor 
jongvolwassenen met een aangeboren hartafwijking. Het in dit hoofdstuk beschreven 
multi-center onderzoek is gebaseerd op 64 patiënten met een aangeboren 
hartafwijking en een ICD. De meeste patiënten hadden tetralogie van Fallot en 
slechts 3% van de patiënten bleek een linkszijdige obstructieve (bijvoorbeeld 
aortastenose) hartaandoening te hebben. Tijdens een follow-up van bijna 4 jaar 
leidde een ICD bij een kwart van de patiënten tot een terechte schok na een 
levensbedreigende ventrikelritmestoornis. Alarmerend is het hoge aantal “onterechte” 
schokken dat plaats vond bij niet levensbedreigende ritmestoornissen of een normale 
maar snelle hartslag (41%).  
 
 
DIAGNOSTIEK 
 
In het tweede deel van dit proefschrift worden nieuwe diagnostische methoden 
besproken die van belang kunnen zijn voor de follow-up van patiënten met een 
aangeboren aortastenose. In hoofdstuk 6 onderzochten wij de aortaseptale hoek bij 
patiënten met een discrete subvalvulaire aortastenose door middel van 
echocardiografie. Bij een discrete subvalvulaire aortastenose is er sprake van een 
vernauwing onder de aortaklep bestaande uit een membraan. Het wordt 
tegenwoordig beschouwd als een verworven hartaandoening, secundair aan 
abnormale bloedstromen als gevolg van morfologische afwijkingen in de 
linkerventrikeluitstroombaan. Een morfologische afwijking is bijvoorbeeld een 
scherpere aortaseptale hoek, dit is de hoek tussen het linker ventrikel en de aorta 
ascendens. Uit ons onderzoek bleek dat volwassenen met een subvalvulaire 
aortastenose een scherpere aortaseptale hoek hadden in vergelijking tot gezonde 
vrijwilligers. Deze bevinding versterkt de hypothese dat veranderde ‘shear stress’ ten 
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gevolge van een scherpere aortaseptale hoek een lokale prikkel geeft tot 
celproliferatie, leidend tot de ontwikkeling van een membraan.  
In hoofdstuk 7 wordt een studie beschreven waarin de elastische 
eigenschappen van de aortawortel worden onderzocht in patiënten met een 
aangeboren aortastenose ten gevolge van een bicuspide aortaklep. Het is al lange 
tijd bekend dat een bicuspide aortaklep samengaat met een verwijde aorta. Deze 
huidige studie toont aan dat patiënten met een aangeboren aortastenose een minder 
elastische aorta (lees: stijvere aorta) hebben ten opzichte van gezonde vrijwilligers. 
Er was een negatieve correlatie tussen de diameter van de aortawortel en 
parameters van aorta elasticiteit. Een interessante bevinding was tevens dat er geen 
correlatie werd gevonden tussen de ernst van aortastenose en aorta elasticiteit. De 
abnormale elasticiteit van de aorta is dus onafhankelijk van de ernst van 
aortastenose en waarschijnlijk het gevolg van intrinsieke aortawand afwijkingen die 
ook leiden tot een verwijding van de aorta.  
In hoofdstuk 8 wordt de rol van 3-dimensionale (3D) echocardiografie ter 
bepaling van de mate van verdikking van de hartspier (linkerventrikelhypertrofie) 
beschreven bij patiënten met aangeboren aortastenose. Diverse studies hebben 
aangetoond dat linkerventrikelhypertrofie gepaard gaat met een slechtere prognose. 
Echocardiografie is de meest gebruikte diagnostische modaliteit ter bepaling van de 
hypertrofie vanwege de praktische en economische voordelen ten opzichte van een 
MRI-scan (Magnetic Resonance Imaging). Uit onze studie blijkt dat 3D-
echocardiografie waarin slechts 2 langeasdoorsneden worden gebruikt, een 
nauwkeurige schatting geeft van de linkerventrikelhypertrofie. De nauwkeurigheid 
wordt niet verbeterd door 3D-echocardiografie waarin 8 langeasdoorsneden worden 
gebruikt. Voor de dagelijkse praktijk is 3D-echocardiografie een simpele en 
aantrekkelijke methode om de mate van linkerventrikelhypertrofie te bepalen.  
In hoofdstuk 9 wordt een studie beschreven waarin de rol van MRI ter 
bepaling van de aortaklepoppervlakte werd onderzocht bij patiënten met een 
aangeboren aortastenose. Eerdere MRI studies bepaalden de aortaklepoppervlakte 
direct. De oppervlakte kan echter ook worden berekend met behulp van de wet van 
massabehoud, de zogenaamde continuïteitsvergelijking. Hierbij wordt het gemeten 
slagvolume gedeeld door de maximale tijdsnelheidsintegraal in de aorta. Er was een 
goede correlatie (R2 = 0.83) tussen MRI en echocardiografie (standaard techniek) 
voor de bepaling van de aortaklepoppervlakte. MRI is een aantrekkelijk niet-
invasieve diagnostische methode om de ernst van aortastenose te bepalen. 
 
 
ZWANGERSCHAP 
 
In het laatste deel van dit proefschrift worden de uitkomsten besproken van 
zwangerschap voor vrouwen met een aangeboren aortastenose. In hoofdstuk 10 
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wordt een literatuurstudie gepresenteerd betreffende zwangerschapscomplicaties bij 
vrouwen met een structurele aangeboren hartafwijking (n=2491). Cardiovasculaire 
complicaties in het bijzonder hartritmestoornissen en NYHA klasse achteruitgang, 
traden vaker op tijdens een zwangerschap bij vrouwen met een aangeboren 
hartafwijking. Vrouwen met een complexe aangeboren hartafwijking hadden een 
hogere kans op vroegtijdige weëenactiviteit, vroeggeboorten en kinderen met een 
abnormaal laag geboortegewicht. Deze bevindingen suggereren dat het te kort 
schieten van het utero-placentaire (moederkoek) vaatbed een belangrijke 
etiologische factor is. Alarmerend is de hoge perinatale sterfte, welke gerelateerd 
was aan een relatief hoog aantal vroeggeboorten en aangeboren hartafwijkingen bij 
de kinderen.  
In hoofdstuk 11 worden de specifieke zwangerschapsuitkomsten in vrouwen 
met een aangeboren aortastenose besproken. De huidige richtlijnen beschouwen 
vrouwen met een ernstige aortastenose als hoogrisico patiënten voor een 
zwangerschap. Tijdens de zwangerschap neemt het hartminuutvolume met 50% toe 
waarbij een gefixeerde vernauwing kan leiden tot een forse belasting voor het hart. 
Vijfendertig vrouwen met aortastenose hadden 58 zwangerschappen. Drie eindigden 
in een miskraam en 2 in een electieve abortus. De meest voorkomende cardiale 
complicaties waren hartfalen (3.8%) en boezemritmestoornissen (5.7%). Ook 
obstetrische (22.6%) en perinatale (24.5%) complicaties werden frequent 
geobserveerd. Een hypertensieve stoornis werd in 6 zwangerschappen (11.3%) 
vastgesteld. Bij vrouwen met een ernstige aortastenose werd een hoger aantal 
episoden van hartfalen, vroegtijdige weëenactiviteit en vroeggeboortes gevonden. 
Oudere vrouwen (>30 jaar) hadden een viermaal verhoogd risico op perinatale 
complicaties. Over het algemeen werd een zwangerschap goed verdragen in 
vrouwen met een aangeboren aortastenose.  
In hoofdstuk 12 worden de zwangerschapsuitkomsten bij vrouwen met een 
Ross procedure besproken. Jonge vrouwen met matig tot ernstige aortastenose, die 
ooit zwanger willen worden, wordt aanbevolen een aortaklepvervanging te 
ondergaan vóór de zwangerschap. Één van de mogelijkheden is het ondergaan  van 
een pulmonale autograft procedure (Ross procedure), waarbij de eigen 
longslagaderklep op de plaats van de aortaklep wordt geplaatst, in de opening van 
de longslagaderklep wordt dan een bioprothese geplaatst. Dit voorkomt de noodzaak 
voor coumarinederivaten (bloedverdunners noodzakelijk bij mechanische kleppen) 
die teratogeen zijn. Klinisch significante complicaties kwamen voor in 2 van de 10 
complete zwangerschappen. Dit onderzoek toont dat een succesvolle zwangerschap 
bij vrouwen met een Ross procedure mogelijk was, hoewel ernstige en klinisch 
significante complicaties optraden zoals placentaloslating, voortijdig breken van de 
vliezen en neonatale sterfte. Tevens lijken vruchtbaarheidproblemen en 
cyclusstoornissen vaker voor te komen.  
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In hoofdstuk 13 beschrijven we een zwangere 25-jarige vrouw (16 weken) 
met hartfalen bij vernauwingen van meerdere hartkleppen door acuut reuma. De 
behandeling van meervoudige klepproblematiek gedurende de zwangerschap is 
moeilijk. Dit is de eerst beschreven casus van een percutane balloondilatatie van drie 
kleppen gedurende een zwangerschap, waarbij gebruik wordt gemaakt van 
intracardiale echocardiografie. Bij intracardiale echocardiografie wordt er een 
catheter naar het hart gebracht via de lies en middels geluidsgolven wordt een beeld 
gecreëerd. Deze methode reduceert de blootstelling aan röntgenstraling voor zowel 
moeder als foetus. Er was sprake van een succesvolle procedure met verlaging van 
de drukgradiënten over de kleppen en verbetering van de klachten van hartfalen. Bij 
een zwangerschapsduur van 38 weken werd een gezonde zoon geboren. 
Tot slot wordt in hoofdstuk 14 een algemene discussie gegeven over 
aangeboren aortastenose bij volwassenen. Daarnaast worden aanbevelingen 
gedaan voor toekomstige studies. 
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